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Type 1 diabetes mellitus is caused by autoimmune destruction of insulin-producing 
beta cells in the islets of Langerhans of the pancreas. In patients with type 1 diabetes, 
insulin treatment is the only life-saving therapy. Long-term prognosis and quality 
of life of these patients is largely determined by the occurrence and severity of 
secondary diabetic complications. However, even when insulin treatment is well 
tolerated and carried out in a diligent way, metabolic derangements and long-
term complications still occur, resulting in reduced patient survival (1, 2). Beta cell 
replacement, by transplantation of whole pancreas or isolated islets of Langerhans to 
restore endogenous insulin secretion, has emerged as a logical alternative to insulin 
injections. However, there is a shortage of donor pancreata relative to the needs of 
potential transplant recipients (3). Therefore, optimal use of the available donor organs 
is vital. In contribution to optimize the use of available organs, the focus of this thesis 
was on the improvement of pancreas graft survival in pancreas transplantation and to 
optimize islet isolation outcomes in islet of Langerhans transplantation. Furthermore, 
since porcine islet transplantation is an alternative to compensate for the shortage of 
human donor organs, we focused on optimizing porcine islet isolation outcome as 
well. 
Pancreas transplantation
Transplantation of the whole pancreas is a complex procedure that can lead to good long 
term metabolic control and prolong survival of both nephropathic and neuropathic 
diabetic patients (4-7). The first clinical pancreas transplantation was performed 
in 1966, simultaneous with a kidney transplant in an uremic diabetic patient at the 
University of Minnesota (8). The success rate (long-term insulin independence) of 
pancreas transplantation was initially low, but increased dramatically in the 1980’s. 
Pancreas graft and patient survival have further improved in recent years due to 
improved procurement and transplantation techniques, immunosuppression regimes 
and more emphasis on donor management and careful recipient selection (9-12).
The majority of pancreas transplantations are performed simultaneously with a kidney 
transplantation (simultaneous pancreas kidney transplantation: SPK), in patients with 
type 1 diabetes with end-stage or pre-emptive renal disease. Other possibilities are: 
pancreas after kidney transplantation (PAK), in which a pancreas from a deceased 
donor is transplanted in an insulin-dependent diabetic patient with a good functioning 
kidney transplant, and pancreas transplantation alone (PTA), in a type 1 diabetic patient 
with frequent and severe episodes of hypoglycemia, hyperglycemia or ketoacidosis but 
with preserved renal function. SPK transplants are performed more frequently than 
solitary pancreas transplants (211 SPK vs. 92 solitary pancreas transplants, in 2010 
in the Eurotransplant region (3)). However, there is an increase in solitary pancreas 
transplantations, particularly PAK, reflecting an emphasis on living donor kidney 
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transplants in uremic diabetic patients to preempt the need for dialysis (13). This is 
also seen in the Netherlands where in 2005 a single solitary pancreas transplantation 
was performed, with an increase to 11 in 2010, as reported by Eurotransplant (3). 
The International Pancreas Transplant Registry (IPTR) maintains a database of all 
reported pancreas transplants worldwide. In their annual report of 2004, they reported 
1 year pancreas graft survival rates of 80-85% and patient survival rates 95% for both 
SPK and PAK and 98% for PTA (13). In the Leiden University Medical Center, where 
85% of all pancreas transplantations in the Netherlands are performed, even better 
graft survival rates are obtained, in particular with primary bladder-drainage followed 
by elective enteric conversion 6-12 months later, used in most of the patients. In these 
patients 1 year pancreas graft survival rate was 88% (14). 
Pancreas graft and patient survival rates are influenced by several factors, e.g. 
procurement, transplantation technique, immunosuppression regimes and donor and 
recipient related factors. Many donor and recipient characteristics have been reported 
to influence pancreas graft survival (11, 12, 14-30). This raises the question on how the 
impact of donor characteristics relate to that of the recipient. In order to further improve 
pancreas graft and patient survival, do we have to focus on donor selection, optimize 
recipient condition or donor-recipient matching? No studies so far have examined the 
contribution of donor and recipient factors to graft survival. We therefore aimed in 
chapter 2 to identify donor and recipient factors influencing pancreas graft survival, 
to evaluate the impact of donor and recipient factors on pancreas graft survival, and to 
compare their contribution in explaining graft survival differences between pancreas 
recipients. 
The procurement technique of a pancreas graft has also been shown to influence 
pancreas graft and patient survival. Surgical injuries that occur during pancreas 
procurement may lead to complications after transplantation, impaired function of 
the allograft, graft loss or even death of the patient. These injuries may be so severe 
that the pancreas is not transplanted in order to protect the recipient. Liposis of the 
graft and critical vessel injuries have been reported as reasons for pancreas refusal 
after procurement (31). However, only few studies have addressed this issue. We 
therefore assessed how often pancreata were refused for transplantation during back-
table inspection in our center and which type of problems were responsible for the 
decision not to transplant the pancreas (chapter 3). A better understanding of the type 
of problems that occur could lead to a higher awareness for injuries. In combination 
with training this could potentially lead to avoidance of these injuries. This would 
result in the use of more donor pancreata that would otherwise have been discarded 
because of the injuries. Furthermore the quality of the transplanted pancreata with 
minor injuries would improve when these are avoided. This would eventually result in 
better pancreas graft and patient survival.
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Islet transplantation
Whole pancreas transplantation, however, is not devoid of complications, mainly 
secondary to surgery and immunosuppressive therapy (24). The alternative to 
transplantation of the pancreas is transplantation of isolated islets as a free graft. Islet 
transplantation is minimally invasive and has low morbidity because the islets are 
infused percutaneously into the hepatic portal vein. Furthermore, a pancreas graft 
can still be used for islet isolation and transplantation when rejected for pancreas 
transplantation. The first clinical islet allograft was performed in 1974 in a diabetic 
recipient who previous to the islet transplant received a kidney transplant (32). Since 
the late 1980s, the feasibility of isolating and purifying human islets from pancreatic 
organs of deceased donors raised hope that purified pancreatic islet cells, rather 
than an entire gland, could cure diabetes (33). However, a limiting factor in islet 
transplantation is the islet isolation yield that can be obtained from donor pancreata. 
In some cases, sufficient islet numbers can be obtained from a single donor, but even 
in the most successful studies, multiple transplantations are necessary to obtain 
(temporary) normalization of hyperglycemia in the recipients (34-39). Therefore, the 
supply of human donor pancreata as source of islets is insufficient.
In order to potentially enable the use of a single organ, several strategies were developed 
to maximize islet yield, e.g. by choosing better culture conditions, and improving donor 
and recipient selection. Many donor and recipient factors have been reported to have 
an influence on islet isolation yield (40-72). However, no uniformity is to be found in 
factors that are reported. Because of the scattered information, valuable information 
is potentially missed because there is insufficient power to determine the independent 
effect of the donor factors on islet isolation outcome in a single study. Chapter 4 offers 
a review of the literature; identifying donor and recipient factors influencing islet 
isolation yield and provides recommendations for standardized reports of donor and 
recipient factors in order to provide better comparisons in the future and to improve 
the power by providing enough data to perform a meta-analysis.
Despite significant efforts to improve the yield of isolated islets by optimizing donor 
and recipient factors, isolation protocols and culture conditions, islet isolation yields 
in human pancreata remain unpredictable and variable. Histomorphological aspects 
(e.g. collagen and other matrix elements) of the pancreas are thought to play a role in 
these variations (73-79). When studying histological characteristics of human donor 
pancreata, a remarkably high number of hyperemic islets (HIs) was encountered. 
Similar islets have only been reported anecdotally in the literature but no mechanisms 
were described regarding their origin and no relevance has been determined from 
the perspective of islets isolation for transplantation (80-84). We therefore aimed to 
determine the relevance of the presence of HIs in human donor pancreata for isolation 
outcome and to identify donor and procurement factors associated with the occurrence 
of HIs (chapter 5). 
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Xenotransplantation
Xenotransplantation of porcine islets of Langerhans is another way to overcome the 
shortage of human donor pancreata. For various reasons, the pig is considered to be the 
preferred source of pancreatic xeno-islets. Pig insulin, which differs from the human 
type by only one amino acid, is active and well tolerated in humans. For years prior 
to the production of human recombinant insulin, patients were successfully treated 
with insulin injections extracted from swines. Transplantation of porcine islets has 
been proven to be successful in non-human primates as well as in humans (85-88). 
Moreover, pig islets can be successfully isolated and purified from adult pigs with a 
method that is similar to the one used for human islets (89). Advantages of using pigs 
as a source of islets for transplantation are, at least in theory, numerous. Besides the 
benefit of unlimited tissue supply, a higher quality of donor organs could be expected 
by planned elective organ harvesting, therefore minimizing cold ischemia and 
consequently improving islet yields. However, porcine islet isolation procedures have 
been shown to be notoriously difficult and provide unpredictable and variable islet 
isolation yields, even more so than in human pancreata (90-92). Because pancreata 
from adult pigs have resulted in large yields, a possible explanation could be related 
to donor age and to the relative fragility of the islets of juvenile pigs islet isolation 
procedures (90-94).
Furthermore, the amount of endocrine tissue present in a specific pancreas is 
undoubtedly an important factor in determining the islet isolation outcome. However, 
a high endocrine content does not ensure a high isolation yield. Despite improvement 
of isolation procedures, islet isolation is still associated with a considerable loss of 
endocrine tissue. This indicates that collagenase digestion of the pancreas is not limited 
to the exocrine pancreas but affects the islets as well. Because collagen is the major 
target in the enzymatic dissociation of the pancreas, the collagen substrate within 
the pancreas is one of the variables that could account for the unpredictable, highly 
variable islet yields. Also other matrix elements are thought to play a role (77-79, 92, 
95). We have assessed the total amount and distribution of collagen within a large 
study population of adult and juvenile porcine pancreata and assessed the relation of 
these determinants to the outcome of islet isolation in adult pigs in chapter 7. 
Another explanation for the unpredictable islet isolation outcomes could lie in 
morphological characteristics of porcine islets. Similar to human pancreata, we found 
a high number of hyperemic islets (HIs) when studying histological characteristics of 
porcine pancreata. We assessed the frequency of HIs in porcine pancreata compared 
to human pancreata. Furthermore, we studied the occurrence of HIs in relation to 
the outcome of islet isolation similar to the study in human pancreata (chapter 6). 
Besides the presence of HIs, we have observed morphological changes of islets after 
infusing the pancreas with collagenase during the isolation process. Previous studies 
have shown collagenase located within the islets after standard intraductal infusion 
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of collagenase in human and also at lower perfusion pressures in porcine pancreata 
(96, 97). The observed morphological changes could therefore be a result of either 
volume expansion of collagenase entering in the islet, leading to disruption of cell-cell 
contacts or be the result of the digestive effect of collagenase, subsequently leading 
to islet fragmentation. Both scenarios would eventually lead to lower islet isolation 
outcomes. In chapter 8 we aimed to discriminate between these two hypotheses.
Finding answers to these questions will contribute to further optimization of pancreas 
graft survival in pancreas transplantation and improved islet isolation outcomes in 
islet of Langerhans transplantation, eventually leading to better use of available organs.
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Many donor and recipient factors are known to affect pancreas graft survival. However, 
their relative importance in explaining differences in graft survival is unknown. 
Purpose of this study was to retrospectively evaluate the impact of donor and recipient 
factors on pancreas graft survival, and compare their contribution in explaining graft 
survival differences.
Methods and Materials
Patient records of all 170 pancreas transplantations (158 Simultaneous Pancreas-
Kidney; 12 Pancreas-after-kidney) in the period 1997-2008 were reviewed 
retrospectively to assess recipient factors before/during transplantation, and to assess 
graft survival. Eurotransplant reports were reviewed to assess donor factors.
results
Death-censored 1-year graft survival was 88.4% and 82.3% at 3 years. Several factors 
significantly influenced graft survival: female recipient gender (Hazard Ratio (HR) 
2.81[1.10-7.14]), enteric graft drainage (HR 2.85[1.15-7.05]), and donor-recipient 
match on BMI (HR 2.46[1.01-6.02]). None of the donor factors significantly affected 
survival. Similar results were found for 1-year survival, except for enteric graft 
drainage and donor-recipient BMI matching. In total, donor factors explained 3.6% 
and recipient factors 10.0% of the variance in graft survival. Donor factors were more 
important for 1-year survival (3.1%), but still less important than recipient factors 
which explained 6.4%.
Conclusion
Recipient factors are more important in explaining differences in pancreas graft 
survival than donor factors. 
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bACkgrounD
Pancreas transplantation is able to correct metabolic abnormalities in patients with 
type 1 diabetes mellitus, prevent or delay secondary complications, and in simultaneous 
pancreas kidney (SPK) transplants is also a treatment for diabetic nephropathy (1-
3). Outcomes have improved in recent years due to improved procurement and 
transplantation techniques, immunosuppression regimes and more emphasis on 
donor management and careful recipient selection (4-7). 
Many donor characteristics have been reported to influence pancreas graft 
survival (8-14). This led the Eurotransplant Pancreas Advisory Committee to define a 
pancreas donor quality score, (comparable to the SOFT score in liver transplantation 
(15)) based on nine clinical parameters: the “Preprocurement Pancreas Allocation 
Suitability Score” (P-PASS) (16). They reported that pancreata from suboptimal donors 
(P-PASS > 17) had a significantly higher graft failure rate within the 1st year after 
transplantation (17). However, this effect may be partly explained by differences in 
recipient factors that affect survival, which were not taken into account. Other studies 
have shown that recipient characteristics, surgical techniques and other transplantation 
features such as ischemia times have an influence on graft survival (2,4,10,18,19). 
This raises the question on how the impact of donor characteristics relates to that of 
the recipient: are both equally important? To our knowledge, no studies so far have 
examined the contribution of donor and recipient factors to graft survival.
Another issue that may affect survival is whether donor and recipient are 
properly matched. ABO blood group matching and to a lesser extent HLA matching 
are known to improve pancreas graft survival and have become part of routine practice 
(10,20-22). However, donor-recipient matching on other factors (e.g. age) could also 
influence pancreas graft survival, as it is shown that kidneys of older donors give better 
outcomes in older than in younger recipients (23). This could also be true for pancreas 
graft survival, but has not been examined.
The purpose of the present study was to retrospectively evaluate the impact 
of donor and recipient factors on 1-year and overall pancreas graft survival, and to 
compare their contribution in explaining graft survival differences between pancreas 
recipients.
MEtHoDs AnD MAtErIALs 
Patients
Between January 1997 and September 2008 a total of 170 pancreas transplantations (158 
SPK and 12 Pancreas After Kidney (PAK) transplantations) were performed at the Leiden 
University Medical Center in the Netherlands, with the number of transplantations 
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increasing from 9 per year in 1997 to 22 per year in 2007. All patients were insulin 
dependent diabetes mellitus type I. Patients undergoing SPK transplantation also 
had kidney insufficiency due to end-stage diabetic nephropathy. PAK recipients had 
previously received a kidney transplant (1 patient) or lost the pancreas graft after a 
previous SPK transplantation (11 patients). Pancreas Transplantation Alone was not 
performed in this period.
Donors
All donor pancreata were procured from multi-organ donations after brain death 
(DBD). Abdominal organs were mobilised and flushed “in situ” via the abdominal 
aorta with either cold University of Wisconsin (UW) or Histidine Tryptophane 
Ketoglutarate (HTK) organ preservation solution. Subsequently, the pancreata were 
procured “en bloc” with the spleen and stapled loop of the duodenum. In case of 
SPK transplantation, the kidney was procured with the ureter, renal vein and renal 
artery. Directly after procurement, the pancreata were packed and stored according to 
Eurotransplant guidelines and transported to our center (24,25). 
technical aspects
The procedure of SPK transplantation has been described previously (26,27). In short: 
a midline incision was made with both organs placed intraperitoneally. The kidney 
was placed in the left iliac fossa, with the renal vessels anastomosed end-to-side to 
the common or external iliac vessels. The pancreas was placed in the right iliac fossa, 
and the portal vein of the pancreas allograft was anastomosed end-to-side to the 
recipient’s inferior vena cava or to the common or external right iliac vein. In most 
cases, the superior mesenteric and splenic arteries were reconstructed using a donor 
iliac artery Y graft. If the iliac artery could not be used (e.g. due to atherosclerosis), 
the brachiocephalic trunk or aortic arch of the donor were used for the arterial 
reconstruction. In some cases, no vascular reconstruction was performed due to 
anatomical abnormalities of the arterial vascularization of the pancreas allograft. 
Therefore, the pancreas graft was procured with the celiac trunk and the superior 
mesenteric artery together on the aorta patch. Arterial anastomosis in all pancreas 
grafts were performed end-to-side with one of the right common or external iliac 
arteries of the recipient. PAK transplantation was performed in a similar fashion. 
Pancreas transplants were either enteric (ED, n = 31) or bladder drained (BD, n = 
139), with BD patients undergoing elective pancreas conversion 6 – 12 months after 
transplantation, as described previously (26,27). 
Perioperative management
Prophylactic intravenous antibiotics were given for 24 hr perioperatively, consisting 
of benzylpenicillin 1x106 U four times per day, gentamycin 1.5 mg/kg once per 
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day, metrodinazol 500 mg three times per day and ceftazolin 1000 mg three times 
per day. Until the end of 2007, the immunosuppression regime consisted of 
prednisone, tacrolimus/cyclosporine and mycophenolate mofetil as maintenance 
immunosuppression and antithymocyt globulin (ATG) or daclizumab as induction 
treatment. Since the end of 2007, patients received a steroid-free regime with 
tacrolimus and mycophenolate mofetil as maintenance therapy and campath (pre-
operatively and the first postoperative day 15 mg subcutaneously) as induction 
treatment. Episodes of acute rejection are treated with solumedrol. Steroid-resistant 
rejections are subsequently treated with ATG. 
Definitions and methods
Eurotransplant donor reports were reviewed retrospectively to assess donor 
characteristics included in the P-PASS score as well as other characteristics known 
to affect survival. Donor P-PASS scores were calculated as described by Vinkers et al. 
(16) from the following characteristics: age, Body Mass Index (BMI), intensive care 
unit (ICU) stay, cardiac arrest, last sodium, last amylase or lipase blood levels before 
procurement, and vasopressor dosage before procurement. Both the P-PASS score and 
the included individual characteristics were assessed. In addition, we collected data on 
the following donor factors known to affect graft survival: gender, ABO blood group, 
Human leukocyte antigen (HLA) type, Cytomegalovirus (CMV) infection, cause of 
death, hypotensive periods before procurement (Systolic Blood Pressure < 90 mm Hg 
and/or Diastolic Blood Pressure < 60 mm Hg) smoking and preservation fluid (7,10-
12,21,22,28-32). Furthermore, patient records were reviewed retrospectively to assess 
graft survival, and the following recipient characteristics given their reported impact 
on graft survival (2,4,10,11,18,19,21,22,26,31-33): 
- Preoperative recipient characteristics: age at transplantation, gender, BMI, ABO 
blood group, HLA type, duration and type of diabetes, duration and modality 
of dialysis, time on waiting list, preoperative anticoagulant therapy, positive anti-
CMV antibody, last systolic and diastolic blood pressure before transplantation 
and last total cholesterol in blood before transplantation.
- Other (operative) factors: type of transplant (SPK or PAK), primary drainage 
(bladder or enteric), warm and cold ischemia time and postoperative anticoagulant 
therapy in addition to fraxiparine (GlaxoSmithKline inc, London, United 
Kingdom) 0.3 ml once per day, which was given to all patients postoperatively as 
prophylaxis.
All of these characteristics were assessed for each transplant, shortly before 
transplantation. In this way, recipient characteristics of patients receiving multiple 
transplants were not counted twice. Follow-up of graft survival was based on the last 
visit of the patient to the hospital or the outpatient clinic (or date of death in case of 
deceased patients). Mean duration of follow-up was 3.1 years, range [0 – 11 years]. 
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Graft loss was defined as removal of the graft or return to exogenous insulin therapy. 
Patients who deceased with a functioning graft were censored at the time of death. 
statistical analysis
We calculated 1-year and overall survival rates for pancreas graft survival using the 
Kaplan-Meier method. Cox proportional hazard analysis was used to assess which 
donor and recipient factors significantly affected 1-year and overall pancreas graft 
survival. First, univariate analysis was performed for each of the following variables:
1. Donor factors: P-PASS score (> 17 versus <17), age, body mass index (BMI), length 
of ICU stay, last sodium blood level before procurement, last amylase blood level 
before procurement, last lipase blood level before procurement, cardiac arrest (yes/
no), vasopressin use before procurement (yes/no), gender, cause of death (CVA or 
other), hypotensive periods (yes/no), smoking (yes/no), and preservation fluid 
(UW versus other)
2. Recipient factors: age at transplantation, gender, BMI, duration of diabetes, 
type of diabetes (type 1 or type 2), duration of dialysis, dialysis modality (hemo 
dialysis versus peritoneal dialysis), time on waiting list, pre- and postoperative 
anticoagulant therapy (yes/no), last systolic and diastolic blood pressure before 
transplantation, last total cholesterol before transplantation, type of drainage 
(bladder or enteric), type of transplant (SPK or PAK), warm and cold ischemia 
time.
3. Donor-recipient matching: age, gender, BMI, ABO blood group (yes/no, no 
meaning ABO compatible but non-identical), HLA type (yes/no), positive anti-
CMV antibody (yes/no). For age and BMI, we assessed whether donor and 
recipient matched (yes/no) for either age group (<30, 30-40, >40 years) or BMI 
group (<20, 20-25, >25). These categories were chosen since these were used in the 
P-PASS score. For HLA, we assessed whether donor and recipient matched (yes/
no) for HLA group (<5, >5 loci).
The adjusted R2 (% variance explained by the model) (34) was calculated for each 
variable and used as a measure of the importance of each variable in explaining the 
variance in graft survival.
Since the effect on graft survival in univariate analysis may be confounded 
by other factors, a multivariate analysis was performed, including only variables 
significantly influencing graft survival in univariate analysis. To assess the relative 
importance of donor factors versus recipient factors versus donor-recipient matching, 
we included the variables in separate blocks of donor factors, versus recipient factors 
versus donor-recipient matching. In case that none of the factors in a particular block 
showed a significant effect on graft survival in univariate analysis, we included the 
factor explaining the highest percentage of variance. The adjusted R2 (% variance 
explained by the model) was calculated for each block and used as a measure of the 
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importance of each block in explaining the variance in graft survival. In this way, we 
were able to compare the contribution of donor factors, relative to recipient factors and 
donor-recipient matching.
A P value of less than 0.05 was considered statistically significant in all analyses.
rEsuLts
Donor and recipient characteristics of the 170 pancreas transplantations performed 
during the period 1997-2008 are listed in Table 1. In accordance with Eurotransplant 








Donor characteristic Mean ± sD or n (%)
P-PASS score
   < 17
   17+











Body mass index (kg/m2) 1
ICU stay (days) a, 1
Last sodium blood level before 
procurement (mEq/l) 1
Last amylase blood level before 
procurement (U/l) b, 1
Last lipase blood level before 
procurement (U/l) c, 1
Cardiac arrest d, 1





























Smoking f 58 (39.5%) 5 (45.5%) 63 (39.9%)
Cytomegalovirus infection
Cause of death
   CVA










Hypotension 2 50 (31.6%) 5 (41.7%) 55 (32.4%)
Hypotension duration (min) d
Preservation fluid
   UW
   Other










Age (years) 41.5 ± 7.4 43.4 ± 4.6 41.6 ± 7.3
Male gender 92 (58.2%) 4 (33.3%) 96 (56.5%)
Body mass index (kg/m2)
Duration of Diabetes (years) f
Dialysis preoperative g
Duration of dialysis (months) g
Modality of dialysis g
   Haemodialysis
   Peritoneal dialysis



























regulations for pancreas allocation, donor age did not exceed 50 years and donor BMI 
did not exceed 30 kg/m2. Most grafts were matched on gender (74.1%) but not so 
much on age (32.9%) and BMI (50.0%). Death censored graft survival was 88.4% at 1 
year, 82.3% at 3 years and 80.9% at 5 years. In total, 31 (18.2%) of the pancreas grafts 
were lost at some point during follow-up. Graft loss was due to thrombosis (n = 17), 
rejection (n = 5) or to an unknown cause (but patient returning to insulin dependence) 
(n = 9), comparable to other studies (35). 71% of the graft loss due to thrombosis were 
lost within 2 weeks, 82% were lost after 1 year and 100% after 2,5 years.  For rejection, 
20% was lost within 2 weeks, the remaining 80% was lost between 1,5 and 7 years after 
transplantation. 56% of the grafts lost due to an unknown cause was lost after 1 year, 
100% was lost after 2,5 years.
Univariate analysis showed that several factors significantly increased the 
probability of graft loss and thus reduced graft survival: female gender, recipient total 
cholesterol, enteric graft drainage, and donor-recipient match on BMI (Table 2). In 
multivariate analysis, only enteric graft drainage and donor-recipient match on BMI 
remained as independent predictors of graft survival (Table 3). Because no donor 
Preoperative anticoagulant therapy 44 (27.8%) 7 (58.3%) 51 (30.0%)
Last Systolic Blood Pressure preoperative 
(mmHg)
150.6 ± 24.9 149.3 ± 12.3 150.5 ± 24.2
Last Diastolic Blood Pressure 
preoperative (mmHg)
84.8 ± 12.2 83.7 ± 8.1 84.8 ± 11.9
Last Total cholesterol blood level 
preoperative (mmol/l) h
4.6 ± 1.2 4.7 ± 1.1 4.6 ± 1.2 
Warm ischemia time pancreas (minutes) j 29.2 ± 7.7 28.9 ± 6.0 29.2 ± 7.6 
Cold ischemia time pancreas (hours) k 12.9 ± 3.3 11.0 ± 2.8 12.8 ± 3.3 
Drainage
   Enteric







Postoperative anticoagulant therapy 3 29 (18.4%) 7 (58.3%) 36 (21.2%)
Donor – recipient matching
Matching on age (<30, 30-40, >40 years) 53 (33.5%) 3 (25.0%) 56 (32.9%)
Matching on gender (male, female) 115 (72.8%) 11 (91.7%) 126 (74.1%)
Matching on BMI (<20, 20-25, >25 kg/
m2)
77 (48.7%) 8 (66.7%) 85 (50.0%)
ABO blood group mismatch (ABO 
compatible, but non-identical ) h, 4








a Data missing for 35 donors (35 SPK), b Data missing for 6 donors (6 SPK), c Data missing for 125 donors (120 
SPK, 5 PAK), d Data missing for 2 donors (2 SPK), e Data missing for 12 donors (11 SPK, 1 PAK), f Data missing 
for 1 donor (1 PAK), g Data missing for 2 donors (1 SPK, 1 PAK), h Data missing for 1 donor (1 SPK), j Data 
missing for 3 donors (3 SPK), k Data missing for 7 donors (6 SPK, 1 PAK)
1 Characteristics of the P-PASS: Preprocurement Pancreas Allocation Suitability Score  
 2 Hypotension: last measured blood pressure before transplantation, Systolic Blood Pressure (SBP) <90 mm Hg 
and/or Diastolic Blood Pressure (DBP) <60 mm Hg 
3 Started independently of preoperative anticoagulant therapy 
4 Mismatches were 5 donor O, recipient B; 1 donor A, recipient AB; 1 donor B, recipient AB
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factors were found to significantly influence graft survival in univariate analysis, the last 
donor serum amylase before procurement was added as a variable in the multivariate 
analysis since this factor explained the highest percentage of variance (Table 4). Similar 
results were then shown, with female gender as an additional variable significantly 
reducing pancreas graft survival. Taken together, this model explained 11.6% of 1-year 
graft survival and 15.5% of overall graft survival.
When we excluded the PAK transplants from our analysis, similar results 
were found, except that enteric graft drainage was no longer a significant predictor 
for pancreas graft survival (even though results were in the same direction). Further 
exploration of the results regarding donor-recipient BMI match showed that pancreas 
graft survival was better in recipients with higher BMI than the donor, compared with 
recipients receiving a graft from a donor with similar BMI (BMI match). Graft survival 
in recipients with lower BMI than the donor was similar as in recipients with matching 
donor-BMI (data not shown). 
The included donor characteristics explained 3.1% of the variance in 1-year 
graft survival and 3.6% of overall survival. Recipient characteristics were more 
important and explained 6.4% of the variance in 1-year survival and 10.0% of overall 
survival. Donor-recipient matching explained 2.6% of the variance in 1-year and 2.6% 
of overall survival. These results suggest that donor characteristics are approximately 
equally important for short-term and long-term graft survival, but that recipient 
factors remain most important in explaining the variance in graft survival.
DIsCussIon
The present study has shown that both donor and recipient characteristics as well as 
donor-recipient matching influence graft survival. Pancreas graft survival was reduced 
in female patients, who receive a graft from a donor with a similar BMI, with enteric 
graft drainage. While donor factors were equally important in explaining differences in 
short- and long-term pancreas graft survival, recipient factors remain most important 
and explain the largest proportion of the variance in both 1-year and overall survival. 
In the Netherlands, the Leiden University Medical Center is the largest center 
performing pancreas transplantations. In 2007, 87% of all pancreas transplantations 
in the Netherlands were performed in our center (36). Even though all pancreas 
transplantations performed in our centre during the period 1997-2008 were included 
in the present study, thereby including all eligible patients, our results might (in 
theory) be influenced by selection. If pancreata from suboptimal donors (P-PASS > 
17) were accepted only for the best, most optimal recipients, this may only slightly 
reduce survival rates, given the importance of recipient factors. Such selection would 
underestimate the effect of the P-PASS score on pancreas graft survival as the reduction 
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and thus also for less optimal recipients. However, given Eurotransplant allocation 
procedures, the surgeon decides whether quality of the graft is acceptable, after which 
it offered to the first patient on the waiting list. It therefore seems unlikely that our 
results were influenced to a great extent by such selection.
The donor and recipient characteristics found to influence pancreas graft survival 
in the present study have also been found in other studies (2,9,17,26). With respect to 
operative factors, it was found that our routinely used two-step approach of primary 
BD followed by elective ED after 6-12 months, with the aim to prevent short-term 
disadvantages of enteric drained grafts and long-term (urological) complications of 
related to bladder drainage, resulted in better graft survival consistent with previously 
shown results (26). 
Matching donor and recipients on age has been shown to influence kidney 
graft survival (23,37). However, we did not find this for pancreas transplantation 
in our study. Donor-recipient matching on BMI on the other hand, was shown to 
increase graft loss, which to our knowledge has not been described before. Pancreas 
graft survival was shown to be better in recipients with higher BMI than the donor, 
compared to patients who received a graft from a donor with a similar BMI. Mean 
recipient BMI was 23.6 and only 6 recipients had a BMI higher than 30. A possible 
explanation may be that both recipients with high BMI and recipients with a very low 
BMI have worse outcomes than recipients with an average BMI, similar to the effects 
of BMI on cardiovascular mortality found in the general population (38-40). Graft 
survival in these patients is reduced particularly if these patients receive a graft from a 
donor with a similarly high or low (matched) BMI. These results should be tested and 
explained in further research.
Our method of quantifying the impact of donor versus recipient factors has not 
been shown before. Recipient factors were shown to be more important for graft survival 
than donor factors. The advantage of this method is that besides the assessment of 
which factors significantly influence pancreas graft survival, their importance in terms 
of their contribution to graft survival can also be established. Optimizing recipient 
factors thus seem more important for long-term survival than optimizing donor 
factors. This seems logical when considering that pancreas donors are highly selected, 
prior to procurement and transplantation. Because of this selection, the variation 
in donor factors (e.g. age) is much smaller than in recipient factors and would thus 
have a smaller effect in explaining differences in pancreas graft survival. Recipients 
on the other hand are selected to a smaller extent, in particular in more recent years 
in which pancreas transplantation is also offered to more high-risk patients (e.g. older 
patients with comorbidity) so that they differ far more in various characteristics that 
may influence survival. Further research may lead to improvement of this model by 
including other factors, which may result in a higher explained variance in survival. 
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In conclusion, even though both donor factors and donor-recipient matching 
explain part of the differences in short-term and long-term pancreas graft survival, 
recipient factors remain most important and explain the largest proportion of the 
variance in both 1-year and overall survival. Hence, emphasis should be placed 
in optimizing these recipient factors to improve graft survival after pancreas 
transplantation. Surgeons may thus choose to first optimize recipients factors, e.g. by 
treating comorbidity or cholesterol levels before transplanting the patient, to obtain 
better graft survival after transplantation. 
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Chapter 3
surgical injuries of pancreatic allografts 
during procurement
P.J. Marang-van de Mheen, D.E. Hilling, M.C. Dirkes, A.G. Baranski




Quality of most procured pancreata is considered acceptable or good by surgeons, 
but remains difficult to ascertain. Little is known on how often pancreata are refused 
for transplantation during back-table inspection. Purpose of this study was to 
determine the frequency and type of problems responsible for refusal during back-
table inspection, and to identify possible risk factors.
Methods and Materials
All 134 pancreata accepted and procured for whole-organ transplantation and 
transported to the Leiden University Medical Center in the period February 2002 until 
May 2008 were included. These were retrospectively analyzed on: donor characteristics, 
procurement characteristics and (non-)critical problems.
results
A total of 111 (82.8%) pancreata were transplanted while 23 (17.2%) were refused for 
transplantation during back-table inspection, regardless of procurement region (c² = 
0.16 p = 0.93). Fourteen pancreata (13.4%) were refused solely due to surgical injuries. 
In refused pancreata, on average 2.7 critical problems per pancreas were found and 
0.6 non-critical problems (versus 0.3 in transplanted pancreata, t = 1.83 p = 0.08). 
Chances of refusal increased in pancreata from older donors (Odds Ratio 1.08 [1.02 – 
1.14]) procured in centers not performing pancreas transplantations (Odds Ratio 7.95 
[2.43 – 25.97]).
Conclusions
We conclude that pancreatic allografts are frequently refused during back-table 
inspection, partly due to surgical injuries suggesting that quality of procurement may 
be improved.
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IntroDuCtIon
Since the first pancreas transplantation in 1966 (1), this procedure has developed into 
an acceptable treatment for diabetes type I. In the period 2002-2008, on average 21 
pancreas transplantations are performed annually in the Netherlands of which 18 
Simultaneous Pancreas Kidney (SPK) transplantations (2). Most (85%) of the pancreas 
transplantations in this period are carried out in the Leiden University Medical Center. 
The surgical procurement technique of this fragile organ is essential for good graft 
outcomes, but may be challenging for local procurement teams.
Pancreas procurement may be cancelled for reasons such as abnormal arterial 
vascularization between the liver and the pancreas making it impossible to successfully 
split and transplant both organs, problems relating to the organ itself (e.g. fibrosis) 
or neoplasms in the donor discovered during the organ donation procedure (3). 
Surgical injuries that occur during pancreas procurement may lead to complications 
after transplantation, impaired function of the allograft, graft loss or even death of the 
patient. These injuries may be so severe that the pancreas is not transplanted in order 
to protect the recipient. Proper procurement and constant training of surgeons are 
therefore very important to maintain high quality of abdominal organ procurement.
In the Netherlands, a pancreas is offered to the first patient on the national 
waiting list. If the pancreas is refused by the first center, then it is refused for all patients 
in that center (so regardless of any recipient risk factors) and is consequently offered 
to the next patient on the waiting list. Once accepted and transported to a center, a 
pancreas is only refused during back-table inspection if it is considered too dangerous 
for the patient to transplant the pancreas given for instance severe injuries that are 
encountered. Other recipient factors do not play a role anymore at this stage.
Little is known on how often pancreata are refused during back-table inspection. 
A recent report from Germany shows that vascular lesions were observed in three of 
the 18 (16.7%) pancreatic grafts, which could be transplanted after back-table repair 
procedures, but also suggests that procurement may be improved by better surgical 
training and standardization in procurement techniques (4). Schultz et al. (5) showed 
that 8% of the pancreatic grafts procured by teams that were not part of the pancreas 
transplant team, were discarded for transplantation during back-table preparation. 
Liposis of the graft and critical vessel situations (e.g. severe atherosclerosis) were 
reported as the main reasons for pancreas refusal. In the Netherlands, information 
on the type of problems encountered during back-table inspection is always returned 
to the procurement center on the standard Pancreas Quality Form for each pancreas 
procurement as feedback to the procurement team. However, this does not give 
procurement teams information on whether this was just a problem for this particular 
case, or that this type of problems occur more in their center than in others, because 
data on the most frequently encountered problems on a national level are not available.
42 Chapter 3
Purpose of the present study therefore was to retrospectively evaluate all accepted 
pancreata transported to our center for transplantation in the period February 2002 
until May 2008, to determine how often pancreata were refused for transplantation 
during back-table inspection and which type of problems were responsible for the 
decision not to transplant the pancreas. Furthermore, we aimed to determine whether 
donor characteristics, injuries or other factors in the procurement process may increase 
or decrease the probability of pancreas refusal. These findings may be used in training 
programs of organ procurement surgeons to avoid injuries and thereby improve the 
quality of procured pancreata.
MAtErIALs AnD MEtHoDs
technical aspects
All pancreata accepted, procured and transported for transplantation to the Leiden 
University Medical Center in the period February 2002 until May 2008 were included. 
Allografts primarily destined for islet transplantation were excluded. All allografts 
were procured in one of the contributing centers within the Eurotransplant zone 
and procured using standard procurement techniques (3, 6). According to the Dutch 
pancreas procurement protocol in that period, all abdominal organs are first mobilized, 
the common bile duct is ligated close to the pancreas head and transected. After organ 
perfusion, the duodenum is sterilized before it is closed with 50-80 ml povidone-
iodine water solution together with Amphotericin B given through the nasogastric 
tube with the aim to decontaminate the duodenum content (3). After closure of the 
duodenum, the stomach, small bowel and colon are completely dissected and placed 
outside the abdomen. Then, liver and pancreas are separated starting with further 
dissection of the hepatoduodenal ligament. The gastroduodenal artery is transected 
and the pancreatic distal stump is tagged with a suture. The length of the portal vein 
and level of transection must be agreed upon by the procurement team, but is usually 
2-3 cm above the pancreas head. Next, the celiac axis with the common hepatic artery 
is dissected along the superior edge of the pancreas head until the celiac trunk. The 
splenic artery is transected close to its origin and tagged with a suture to facilitate later 
identification. The spleen is always procured with the pancreas. To finish the pancreas 
procurement, the superior mesenteric artery (SMA) is transected carefully with a small 
aorta patch (3). As viability of the pancreatic allograft depends on restoration of the 
blood flow through the superior mesenteric and splenic artery, the procured vessels 
(mostly iliac arteries and veins) must have sufficient length to allow this mandatory 
reconstruction. In case of abnormal anatomical arterial vascularization of the pancreas 
(occurring in about 17% of the cases) when the dorsal pancreatic artery arises from 
the celiac trunk or common hepatic artery, the celiac trunk and the SMA on the aorta 
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patch were procured with the pancreas to ensure its best arterial vascularization (3). In 
all other cases, the dorsal pancreatic artery is not seen during organ procurement, so 
that the celiac trunk is procured with the liver. In our series, a simultaneous intestine-
pancreas procurement did not occur. A right aberrant hepatic artery was never 
considered a contraindication for pancreas procurement.
In the Leiden University Medical Center, all organs are inspected by the 
transplant surgeon prior to taken the recipient to the operating room. All problems (or 
none if no problems were encountered) are reported on the Pancreas Quality Form, 
which is routinely used in the Netherlands and always faxed to the procurement center 
as feedback on the procurement. This form distinguishes between arterial problems, 
venous problems, duodenal problems, quality of parenchyma and other problems.
Data and definitions
For all pancreata, donor characteristics (age, gender, Body Mass Index (BMI)), 
preservation solution, pancreas anatomy and quality of procured organ, as assessed by 
the surgeon performing organ procurement, were obtained from the Eurotransplant 
Pancreas report. Furthermore, data were collected on type of problems reported by 
the pancreas transplant surgeon on the Pancreas Quality Form. Procurement centers 
were categorized into 3 regions: Netherlands West (Leiden, Rotterdam, Amsterdam, 
Utrecht), Netherlands East (Maastricht, Nijmegen, Groningen), and International (all 
pancreata procured outside the Netherlands). Furthermore, procurement centers were 
grouped based on whether or not they also performed pancreas transplantations (yes/
no). Centers were categorized as not performing pancreas transplantations if they 
had not performed any pancreas transplantation in the entire period 2002-2008. Data 
on the number of pancreas transplantations per year per procurement center were 
obtained from Eurotransplant.
Problems reported on the Pancreas Quality Form were retrospectively 
categorized into critical and non-critical problems. Problems were considered critical 
if they were so severe that even when encountered alone, this was sufficient reason 
to refuse the pancreas for transplantation. Non-critical problems in itself are not 
responsible for pancreas refusal, but added to other problems may lead to refusal of the 
pancreas for transplantation. With respect to the type of problems, we distinguished 
between arterial injuries (head, neck, body or pancreas tail), venous injuries (portal, 
mesenteric superior or splenic vein), pancreas parenchyma injuries, duodenal 
and other problems, consistent with the categories on the Pancreas Quality Form. 
Atherosclerosis was considered severe if vascular reconstruction between the “tool-
kit” and the pancreas was impossible, thereby increasing the risk on thrombosis.
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statistical analysis
We first estimated the frequency of pancreas refusal by the type of problem. 
Consequently, the frequency of refusal for transplantation was compared between 
procurement regions using chi-square tests, to assess whether some regions could 
improve more than others. Transplanted and refused pancreata were then compared on 
donor characteristics (age, gender, BMI), preservation solution, procurement region, 
procurement center performing pancreas transplantations (yes/no), average number 
of pancreas transplantations per year in procurement center, pancreas quality as 
assessed by the procurement surgeon, as well as on the number and type of critical and 
non-critical problems. Chi-square tests were used for categorical variables and t-tests 
for continuous variables. Variables that significantly differed between transplanted 
and refused pancreata were consequently entered in multivariate logistic regression 
analyses to assess whether these had an independent effect on the probability of refusal 
when adjusted for the other variables.
rEsuLts
Of the 134 pancreata transported to our center, 111 (82.8%) were transplanted while 
23 (17.2%) were refused during back-table inspection, regardless of procurement 
region (c² = 0.16 p = 0.93) (Table 1). The probability of refusal did not depend on 
whether the pancreas was procured in our own region (West of the Netherlands) or in 
another region (respectively 19% versus 16.3%, c² = 0.15 p = 0.70). In the 23 pancreata 
refused for transplantation, 63 critical problems occurred, ranging between one and 
five per pancreas. Fourteen pancreata (13.4%) were refused solely due to critical 
surgical injuries without any other critical problems. An example of a pancreas with 
one critical injury was a pancreas in which the parenchyma of the pancreas tail was 
completely destroyed. Within all regions, pancreata refused for transplantation more 
often were procured in centers not performing pancreas transplantations, or showed a 
trend towards significance (data not shown).
Nearly one-third of the pancreata refused for transplantation had severe 
atherosclerosis as a critical problem thereby increasing the risk on pancreas thrombosis, 
table 1. Pancreatic allografts by region of organ recovery: number of organs transplanted 
and refused for transplantation at back-table inspection (Leiden University Medical 
Center, February 2002 – May 2008)
region of organ recovery transplanted refused total
number (%) number (%) number
Netherlands East 56 (83.6%) 11 (16.4%) 67
Netherlands West 34 (81.0%) 8 (19.0%) 42
International 21 (84.0%) 4 (16.0%) 25
Total 111 (82.8%) 23 (17.2%) 134
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such that reconstruction became impossible (Table 2). Most critical injuries in the 
pancreata refused for transplantation concerned severe injuries of the pancreas 
parenchyma, superior mesenteric or splenic vein, and splenic or dorsal pancreatic 
artery such that reconstruction and transplantation became impossible (Table 2). In 
addition, 14 non-critical problems occurred in these pancreata, ranging from 0 to 3 per 
pancreas. In comparison, 33 non-critical problems occurred in transplanted pancreata, 
which did not differ from the pancreata refused for transplantation (on average 
0.3 versus 0.6 in rejected pancreata, t = 1.83 p = 0.08). Most frequently occurring 
non-critical problems were portal vein injuries (or too short but with possibilities 
for reconstruction) or other problems like an open choledochal duct because of not 
ligating the common bile duct or severe atherosclerosis (which increases the risk on 
pancreas thrombosis) but with possibilities for reconstruction (Table 2).
The procurement surgeon also makes an assessment of the quality of the pancreas 
after procurement, reported in the Eurotransplant Pancreas report, which can be rated 
as poor, acceptable or good. Of the 23 pancreas allografts refused for transplantation, 
table 2. Frequency of critical and non-critical problems encountered in pancreatic 
allografts during back-table inspection (Leiden University Medical Center, February 






Average number per pancreas (SD) - 2.7 ± 1.6
Injuries
Severe injuries pancreas parenchyma - 17 (73.9%)
Arterial  – head, neck, body pancreas





Venous  – Portal vein
 – Splenic vein








Duodenal problems (e.g. open duodenum) - 6 (26.1%)
Severe artherosclerosis, reconstruction impossible - 7 (30.4%)
non-critical problems
Average number per pancreas (SD) 0.3 ± 0.5 0.6 ± 0.8
Injuries
Minor injuries pancreas parenchyma 6 (5.4%) 1 (4.3%)
Arterial  – head, neck, body pancreas





Venous  – Portal vein (e.g. too short)
 – Splenic vein








Duodenal problems (e.g. no povidone iodine) 8 (7.2%) 2 (8.7%)
Other (artherosclerosis but reconstruction 
possible, open ductus choledochus)
9 (8.1%) 9 (39.1%)
Values are mean ± SD
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20 (87.0%) were assessed as a good-quality organ by the procurement surgeon (Table 
3). Quality was not reported for the other three pancreas allografts. Part of the reason 
for the missing quality assessment may be that the procurement surgeon was not sure 
about the quality but thought that the pancreas may be potentially usable and needed 
to be examined on the back-table by someone more experienced. Of the 111 pancreas 
allografts that were transplanted, 31 (27.9%) had missing quality assessment, 2 (1.8%) 
were assessed as acceptable quality and 78 (70.3%) as good quality pancreas by the 
procurement surgeon.
All pancreas allografts were procured from deceased heart-beating donors. 
Pancreata refused for transplantation during back-table inspection on average were 
procured from older donors, with higher BMI, more often procured during office 
hours and by centers with significantly less experience in pancreas transplantation, 
compared with transplanted pancreata (Table 3). However, when looking at donor 
BMI ≥ 25, a risk factor for surgical complications and technical failure in pancreas 
recipients (7), the difference between refused and transplanted pancreas allografts was 
no longer statistically significant (Table 3). A higher percentage of male donors and 
on average more non-critical problems in refused pancreata showed a trend towards 
significance (Table 3). Because part of these differences may be caused by differences 
in some of the other variables, these variables were entered in a multivariate regression 
analysis. Only pancreata from older donors and procurement by centers not performing 
pancreas transplantation, were independent risk factors for pancreas refusal (Table 4). 
The probability of refusal increased by 8% per year increase in age of the donor, and 
was increased 8-fold for procurement teams from centers not performing pancreas 
transplantations.
DIsCussIon
This study has shown that pancreatic allografts are frequently refused during back-
table inspection, partly because of surgical injuries. Most critical problems concerned 
severe injuries of pancreas parenchyma, superior mesenteric or splenic vein, and 
splenic or dorsal pancreatic artery such that reconstruction and transplantation 
became impossible, or severe atherosclerosis. Donor age and procurement by centers 
not performing pancreas transplantations were both found to significantly increase 
the probability of pancreas refusal. Quality of procurement may thus be improved by 
constant (compulsory) training of procurement surgeons by surgeons who perform 
pancreas transplantations, showing which type of injuries occur frequently, how to 
prevent these, and how to procure organs with severe atherosclerosis.
The frequency of refusal (17.2%) is higher than the 8% reported by Schultz et al. 
(5). They reported liposis of the graft and critical vessel situations as the main reasons 
for pancreas refusal, whereas parenchyma injuries and severe atherosclerosis were the 
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most frequent critical problems in our study, besides severe injuries of (pancreatic) 
vessels. One of the explanations may be a more strict selection of pancreatic grafts 
in our center. If this were true, transplanted pancreata from our center may be 
expected to have better graft survival rates. Schultz et al. (5) reported a 83% one-
yr graft survival rate which is comparable to the rates reported by the International 
Pancreas Transplant Registry (IPTR) over the period 2000-2004 (8, 9). We have shown 
previously that pancreata transplanted in our center seem to have better graft survival 
table 3. Differences between pancreatic allografts transplanted and refused for 
transplantation at back-table inspection (Leiden University Medical Center, February 

















Male gender 49.5% 69.6% X²=3.06 p=0.08
Body Mass Index (kg/m²)








            Brain bleeding








UW preservation fluid 94.6% 91.3% X²=1.54 p=0.67
Good organ quality, assessed by 
procurement surgeon
70.3% 87.0% X²=2.80 p=0.25
Procurement time during the daya 27.0% 47.8% X²=3.88 p<0.05
Procurement center performing PTx 66.7% 21.7% X²=15.89 p<0.01
Average number of PTx per year in 
procurement center
4.7 ± 5.9 0.5 ± 1.0 t=-7.06 p<0.01
Number of non-critical problems 0.3 ± 0.5 0.6 ± 0.8 t=1.83 p=0.08
Values are mean ± SD  
a Procurement between 8.00 and 18.00
table 4. Determinants of pancreatic allografts being refused for transplantation 
(Leiden University Medical Center, February 2002 – May 2008)
odds ratio [95% Confidence Interval]
Donor age (years) 1.08 [1.02 – 1.14]
Male donor 2.67 [0.85 – 8.43]
Donor Body Mass Index (kg/m²) 1.07 [0.86 – 1.33]
Procurement time (daya versus night) 2.45 [0.81 – 7.47]
Procurement center performing PTx (no versus yes) 7.95 [2.43 – 25.97]
Number of non-critical problems 2.18 [0.96 – 4.93]
Model fit: Nagelkerke R-square=0.391
Odds Ratio’s in bold indicate significant differences 
a Procurement between 8.00 and 18.00
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rates than the IPTR, in particular with primary bladder-drainage followed by elective 
enteric conversion 6-12 months later, used in most of the patients (10). All pancreas 
recipients in this study were insulin-dependent diabetes mellitus type I with end-stage 
diabetic nephropathy, and the rate of post-operative complications was comparable 
to that in other studies. Complications like enteric or bladder leaks, possibly related 
to procurement techniques, occurred as frequently as reported in other studies (10). 
Selection may thus explain part of the difference with the study by Schultz et al. 
However, given the large number of 63 critical problems found in 23 refused pancreata 
(on average 2.7 per pancreas), this does not seem to be the entire explanation. Another 
explanation may be that the study by Schultz et al concerned an earlier period (1994-
2003) when it may have been customary that pancreata were procured by teams with 
experience in pancreas transplantation, or that solely by chance they were offered 
more organs procured in centers experienced in pancreas transplantation. Another 
option relating to this difference in time period is that the population of donors has 
become more marginal over time (11). Since we did not have more detailed data, this 
could not be further explored.
Donor age was found to increase the chances of pancreas refusal. One of the 
explanations is that it is a true age effect, e.g. reflecting increased atherosclerosis at 
older ages. Another option may be that procurement is more difficult in older donors, 
for because of the fattening of the pancreas. It is known that acceptable outcomes can 
be achieved with pancreatic grafts from older donors but that graft survival is reduced 
on average (11). If it is true that procurement is more difficult in older donors, it is 
likely that experienced procurement surgeons are performing organ procurement in 
older donors. Selection of experienced procurement surgeons may then interact with 
donor age, but would underestimate chances of refusal for pancreata procured from 
older donors rather than that it would increase refusal rates. Another explanation 
would be that transplant surgeons use more stringent criteria to accept an organ from 
an older donor, requiring the organ to be more ‘perfect’ than from a younger donor 
given that they know that graft survival is reduced on average (11). This hypothesis 
seems likely, but is difficult to test.  
Higher chances of refusal were also found for procurement centers without 
experience in pancreas transplantation in the entire period. This makes sense because 
a pancreas transplantation surgeon may be more aware of potential consequences of 
procurement for pancreas transplantation, given that he has faced these problems and 
knows what is possible and what is not. On the other hand, it may seem contrary 
to results from previous studies, which have shown that early outcomes after SPK 
transplantation are not influenced by the surgical team (from the transplant center 
versus another center) (12). However, no information was given on the experience 
of the ‘other center’, which may have performed pancreas transplantations in recent 
years, whereas the reference category in our study concerned procurement centers 
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without any pancreas transplantations in recent years. Furthermore, given that the 
pancreata were transplanted, it may be assumed that the organs were well procured in 
the study by Fellmer et al. (12), whereas our study focused on pancreas refusal due to 
procurement problems. To our knowledge, this is the first study showing that chances 
of refusal are higher when pancreata are procured in centers without experience in 
pancreas transplantation.
Experience of the individual performing the procurement would be an 
important variable in this context, but unfortunately no data were available on the 
level of training of the procurement surgeon. In the Netherlands, as in other countries, 
trainees may be sent to procure pancreas allografts, supervised by a more experienced 
procurement surgeon. However, the latter surgeon may be more experienced but not 
necessarily in pancreas transplantation. It is therefore not clear whether procurement 
surgeons are experienced enough to always perform a well-procured pancreas, even in 
difficult cases. The decision to refuse the pancreas is thus made based on organ quality 
only. Experience or name of the procurement surgeon is not considered since even the 
most experienced surgeon may make a mistake or overlook something, and excellent 
quality procurement may be performed by relatively inexperienced surgeons.
It is important to note in this context that there is a difference between a pancreas 
with unrecognized damage, which is potentially dangerous if the injury goes unnoticed 
and expensive, and a pancreas that is considered potentially usable but needs to be 
examined during back-table inspection by a more experienced pancreas transplant 
surgeon. It seems more appropriate to let a more experienced pancreas transplant 
surgeon examine a graft from, e.g., an older donor, than to accept the opinion of a less 
experienced procurement surgeon that it is not transplantable. A recommendation 
may therefore be to add the option ‘potentially usable, requires further examination’ 
to the Eurotransplant Pancreas report in the assessment of organ quality, along with a 
specification of which part of the pancreas requires further examination.
Pancreata procured during office hours at first seem to be the best procured 
organs with the lowest chances for refusal, because these teams should be fresh. 
However, even though non-significant, our data seem to suggest the contrary. One 
of the explanations may be that procurement surgeons during the day are more 
junior, since the senior surgeons have other daytime commitments, suggesting 
procurement by less-experienced surgeons during the day. No data were available to 
test this hypothesis of seniority of retrieval teams, but it would give support to the 
evidence presented above that less experience – both in pancreas transplantation and 
procurement – results in higher refusal rates. Further research is needed to support or 
refute this hypothesis.
These results have important implications for current practice in pancreas 
procurement. Quality of pancreas procurement may be improved by reducing refusal 
rates, which can be achieved by more extensive and recurrent training of pancreas 
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procurement surgeons. Surgeons with experience in pancreas transplantation may be 
excellent teachers in such a training program. Another possibility to reduce pancreas 
refusal may be to leave pancreas procurement to those centers also performing pancreas 
transplantations, but this seems hard (if not impossible) to implement in practice. It 
seems better to complement training with annual feedback to each center on the extent 
to which procured organs could be transplanted compared to other centers, which 
may lead to further improvement if rates are lower than expected. Given the crucial 
importance and lack of organs, it is vital that all procured organs can be used and do 
not have to be discarded because of injuries inflicted in the procurement.
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Effects of donor, pancreas and isolation-
related variables on human islet isolation 
outcome: a review





Different factors have been reported to influence islet isolation outcome, but vary 
between studies and are hampered by small study samples per study. The purpose of 
this study was to perform a systematic review to assess the impact of donor, pancreas 
and isolation-related variables on successful human islet isolation outcome. 
Methods and Materials
Pubmed, Embase and Web of Science were searched electronically in April 2009. All 
studies reporting on donor, pancreas and isolation-related factors relating to pre-
purification, post-purification islet isolation yield and proportion of successful islet 
isolations were selected. 74 retrospective studies had sufficient data and were included 
in the analyses. 
results
Higher pre-and post-purification islets yields and a higher proportion of successful 
islet isolations were obtained when pancreata were preserved with TLM, rather than 
UW in donors with shorter cold ischemia times (one hour longer cold ischemia 
time resulted in an average decline of pre-purification, post-purification yields and 
proportion of successful isolations of 59IEQ/g, 54 IEQ/g and 21%, respectively). 
Higher pre-purification yields and higher percentage successful islet isolations were 
found in younger donors with higher BMI. Lower yields were found in donation after 
brain death (DBD donors) compared to donation after cardiac death (DCD donors). 
Higher post-purification yields were found for isolation with Serva collagenase.
Conclusion
This review identified donor, pancreas and isolation-related factors that influence islet 
isolation yield. Standardized reports of these factors in all future studies may improve 
the power, identify additional factors and thereby contribute to improving islets 
isolation yield. 
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IntroDuCtIon
Transplantation of islets of Langerhans can improve metabolic control and quality of life 
in patients with longstanding type 1 diabetes. Despite improvement and standardization 
of isolation procedures, the outcome of human islet isolation remains unpredictable 
and highly variable. Furthermore, generally more than one islet preparation is required 
per recipient to achieve insulin independence after transplantation (1-6).
Previous studies have reported donor and other factors associated with higher 
success rates in terms of attaining adequate islet numbers for transplantation (7-
13). However, different factors have been identified and large-scale trials in humans 
demonstrating the influence of a set of donor factors are lacking. Because previous 
studies are relatively small, factors could be missed. Therefore, different factors could 
be identified when studying larger numbers of donors and the question remains which 
factors independently affect islet isolation outcome when corrected for the effect of 
other variables. 
Because there is a shortage of donor pancreata relative to the needs of potential 
transplant recipients, optimal use of the available donor organs is vital. We carried out 
a systematic review of the literature on human studies reporting on donor, pancreas 
and isolation-related factors and their influence on isolation outcome. In this way we 
can identify factors that have an independent effect on islet isolation outcome. 
MEtHoDs AnD MAtErIALs
study selection
PubMed, Embase and Web of Science were searched to retrieve articles in English on 
human islet isolation from 1966 onwards.
The following search string was used:
(“Islets of Langerhans Transplantation”[Mesh] OR ((“Islets of Langerhans”[Mesh] OR 
“islets”[all fields]) AND (“transplantation”[MeSH Terms] OR “transplantation”[All 
Fields]))) 
AND 
(“isolation”[all fields] OR “Cell Separation”[Mesh] OR “Separation”[all fields] OR 
“Tissue and Organ Harvesting”[Mesh] OR “Harvesting”[all fields] OR “Tissue 
and Organ Procurement”[Mesh] OR “Organ Preservation Solutions”[Mesh] OR 
“Solution”[all fields] OR “Solutions”[all fields] OR “tissue donors”[MeSH Terms] OR 
“donor”[All Fields] OR “donors”[All Fields])
AND 
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(yield[All Fields] OR yields[All Fields] OR “isolation outcome”[All Fields] OR 
“isolation outcomes”[All Fields] OR “isolation result”[All Fields] OR “isolation 
results”[All Fields] OR harvest[All Fields] OR profit[All Fields] OR profits[All Fields] 
OR earnings[All Fields] OR earning[All Fields] OR output[All Fields] OR “success 
rate”[All Fields] OR “success rates”[All Fields] OR “recovery”[All Fields])
The search resulted (by April 2009) in 412 Pubmed, 60 Embase and 228 Web of 
Science titles, constituting a total of 702 titles. Two independent reviewers (DEH and 
PJMvdM) examined titles and read relevant abstracts to decide if the full-text articles 
should be obtained. Cases of disagreement were resolved by discussing the title and 
abstract. Full-text articles (n = 141) were examined and selected based on the following 
criteria: (1) Reporting on either donor, pancreas or isolation-related variables and their 
relation to islet isolation outcome, (2) Reporting isolation outcome in IE/g pancreas 
pre- or post-purification (3) sufficient specification of “successful” and “unsuccessful” 
islet isolation outcome as used in that study, (4) sufficient specification of donor organs 
used for islet isolation procedures with respect to selection characteristics.
Exclusion criteria were: (1) Histologically obtained pancreas variables and their 
relation to islet isolation outcome (2) Animal donor, pancreas and isolation-related 
variables and their relation to islet isolation outcome
Literature references were checked to minimize the risk of missing relevant 
studies. For duplicate papers reporting on the same study, we selected the article that 
reported the most complete and detailed data. This resulted in a total of 74 studies, 
eligible for further analysis (7-12, 14-81). 
Data extraction
Data were extracted independently by DEH and PJMvdM by means of a predefined 
form. The following topics were included based on data availability in at least 50% of 
the studies:
General variables: year of index admission, country of study, number of pancreata in 
the study
- Donor pancreas variables: age, body mass index (BMI), last serum glucose before 
procurement, donation after brain death (DBD donors)/donation after cardiac 
death (DCD donors) 
- Pancreas variables: pancreas weight, cold ischemia time (CIT), method of 
preservation
- Isolation variables: method of purification (continuous vs discontinuous and 
Ficoll vs other), brand of collagenase 
- Study results: islet isolation outcomes in terms of pre-purification isolation 
yield, post-purification isolation yield, proportion of successful islet isolations 
(according to the definitions in the particular study).
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statistical analysis 
Since the number of pancreata varied considerably between studies we weighted all 
isolation outcomes by the number of pancreata per study in all analyses. We studied 
the previously listed variables with respect to their relation with 3 outcomes: pre-
purification isolation yield, post-purification isolation yield, and proportion of 
successful islet isolations. 
We first performed univariate analysis, relating each variable to each of the 
3 outcomes. However, since the effect of some factors on isolation outcome may be 
confounded by others, a multivariate analysis was performed, including only the 
variables that had a significant effect on isolation outcome in the univariate analysis. 
In this way, the independent effect of each of the variables on the 3 outcomes was 
assessed. The analysis with the outcome proportion of successful islet isolations was 
adjusted for differences between studies in the criteria used to define successful by 
including the criterium as a variable in the multivariate analysis.  
rEsuLts
A total of 74 studies met our inclusion criteria, all retrospective studies. When studies 
compared different groups in relation to isolation outcome (e.g. TLM vs UW), 
these were included as separate groups, giving a total of 132 groups that were finally 
compared in the analysis.
When studies addressed both pre- and post-purification isolation yield and/
or proportion of successful isolations, we included the studies in the analyses of each 
outcome.
Pre-purification isolation yield
Thirty-nine studies (7, 9-12, 14, 20, 21, 27, 31, 32, 34, 37-45, 48-57, 59, 62-64, 71, 
75, 76, 80), 70 groups in total, reported characteristics influencing pre-purification 
isolation yield. Univariate analysis showed several factors to significantly affect pre-
purification isolation outcome (Table 1):  higher yields were obtained in studies with 
younger donors, with higher BMI, without a last glucose or a low last glucose reported, 
with relatively few DBD donors, short cold ischemia time and preservation with TLM 
rather than UW. These effects remained in multivariate analysis (Table 2), suggesting 
that each of these factors independently influenced pre-purification yield. For example, 
from donors who are one year older, on average a 64IEQ/g lower pre-purification yield 
was obtained. Furthermore, when cold ischemia time was 1 hour longer, on average 
a 59IE/g lower pre-purification yield was obtained, independently from other factors.
Less than 50% of the included studies reported data on pancreas weight and 
isolation specific characteristics so these were excluded from the analysis.
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Post-purification isolation yield
Fifty-nine studies (7, 9-12, 14-20, 23-27, 30, 31, 33-37, 39-47, 50-56, 59-63, 65-70, 
72-79, 81), 106 groups in total, reported characteristics related to post-purification 
isolation yield. Univariate analysis showed several factors to significantly affect post-
purification isolation outcome (Table 1):  higher yields were obtained in studies 
without a last glucose or a low last glucose reported, with relatively few DBD donors, 
short cold ischemia time, preservation with TLM rather than UW, purification with 
Ficoll and isolation with Serva collagenase. In multivariate analysis (Table 2), these 
effects remained as independent significant effects influencing post-purification 
isolation yield, except for last glucose before procurement and purifcation with Ficoll. 
For example, when cold ischemia time was 1 hour longer, on average a 54IEQ/g lower 
post-purification yield was obtained, independently from other factors.
In contrast with pre-purification yield, age, BMI and last glucose before 
procurement are no independent predictors of post-purification yield.
Less than 50% of the included studies reported data on pancreas weight and 
isolation specific characteristics so these were excluded from the analysis.
Proportion of successful isolations
Thirty-one studies (7-12, 22, 23, 28-30, 32, 34, 36, 38, 44, 48, 51, 52, 57, 58, 60, 66, 68, 
69, 73-75, 78-80), 57 groups in total, reported characteristics related to the proportion 
of successful isolations. In univariate analysis (Table 1) higher yields were obtained 
in studies with younger donors, with higher BMI, without a last glucose or a low last 
glucose reported, with relatively few DBD donors, short cold ischemia time, higher 
pancreas weight and preservation with TLM rather than UW. In multivariate analysis 
(Table 2) these effects remained as independent predictors of a high percentage of 
successful isolations, except that higher percentage successful isolations were found 
in studies that did reported the last glucose before procurement. Furthermore, the 
percentage DBD donors had no independent significant influence on the percentage 
of successful islet isolations. 
For example, from donors who are one year older on average a 1% lower 
percentage of successful isolations was obtained. Furthermore, when cold ischemia 
time was 1 hour longer, on average a 21% percentage of successful isolations was 
obtained, independently from other factors.
In contrast with pre-purification yield, percentage DBD donors is not and 
pancreas weight is an independent predictor as well as age, BMI and last glucose before 
procurement in contrast with post-purification yield.
In total, data of 2198, 4122 and 2769 pancreata were available for uni- and multivariate 
analysis of pre- and post-purification yield and proportion of successful islet isolations, 
respectively. However, in univariate analysis, 12.5% to 33.7% of the pancreata were 
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excluded in at least 1 analysis due to missing data. In multivariate analysis this was 
even higher (79.4-89.7%) since studies had to report on all of the variables included in 
the analysis, to have their pancreata included.
DIsCussIon
The present study has shown that donor, pancreas and isolation-related factors have 
an influence on both pre- and post-purification islet isolation outcome, as well as on 
proportion of successful islet isolations. 
Higher islets yields and a higher proportion of successful islet isolations 
were obtained when pancreata were preserved with TLM, compared to UW. This is 
in accordance with Agrawal et al (13). In their meta-analysis, significantly higher 
yields were found in pancreata preserved with TLM compared to UW. However, in 
their study, they found an equal rate of successful islet isolations in both groups. A 
possible explanation for this difference with our study could lie in the fact that in our 
multivariate analysis, the influence of TLM is corrected by other factors that have an 
influence on islet isolation yield. 
Higher BMI and shorter cold ischemia times were also associated with higher 
islet isolation outcome pre- and post-purification as well as with a higher percentage of 
successful isolations when looking at cold ischemia time. Since larger islets are usually 
encountered in patients with higher BMI to obtain the higher insulin demand and 
longer cold ischemia times result in more damage to the islets, these results seem to 
have face validity and have been well reported in previous studies (11, 12, 19, 52, 58, 
60, 82). 
Our study showed lower isolations yields and proportion of successful 
isolations in studies with a higher percentage of DBD donors. This is remarkable since 
in previous studies, generally, higher yields were found in DBD donors compared to 
DCD donors. However, successful islet isolations from DCD donors have also been 
reported previously (3, 48, 81, 83). In our multivariate analysis, studies with a large 
percentage of DBD donors had significantly lower yields in pre-, post-purification 
isolation outcome and also a lower proportion of successful isolations, when adjusted 
for the effects of other variables. Part of the explanation could be that in previous 
studies there was insufficient power to correct for other variables. In the studies that 
did correct for other factors, the results could be prone to the effect of the other, 
potentially underreported, factors in the models. This last explanation could also have 
an effect on our results as well. Furthermore, results of different studies can not be 
easily compared without correcting for certain factors like age, since an age difference 
of 1 year has an influence on pre-purification islet yield of 64IEQ/g.
This study is a first attempt to look at the effect of donor, pancreas and isolation-



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































studies would be standardized we could possibly identify other factors and make 
more accurate estimation of the independent effect of these factors. To illustrate the 
necessity of these standardized reports, we have looked at the missing variables in our 
analysis. In univariate analysis 66.3-87.5% of the available pancreata were analyzed on 
the effect on pre- and post-purfication yield or percentage of successful isolation. In 
multivariate analysis this percentage was only 10.3-20.6%, due to missing data on at 
least 1 of the variables included. This indicates that the studies differ to such a great 
extent in the variables that they report, even when we selected only those variables that 
were reported in most studies. 
Standardized reporting of the factors in all studies in the future on a minimal 
set of variables would also lead to a better fit of the model used in any meta-analysis. 
In the current analysis on post-purification yield 19% of the variance in islet isolation 
outcome could be explained by the included variables. In pre-purification islet yield 
and proportion of successful isolations, this percentage was better, but still only 50% of 
the variance could be explained. This suggests that besides the reported variables other 
factors also influence isolation outcome. 
In conclusion, this study identified donor, pancreas and isolation relating factors 
that influence islet isolation yield. However, standardized reports of these factors are 
lacking, and are needed to get more reliable evidence. To improve the power and 
provide better comparisons in future research, standardized reporting of these factors 
are recommended.  
65Review of factors influencing islet isolation outcome
rEfErEnCEs
1. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using 
cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 
5:2037-46.
2. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation 
in patients with type 1 diabetes. JAMA 2005; 293:830-5.
3. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet 
transplantation and single islet infusions. Ann Surg 2003; 237:741-9; discussion 749-50.
4. Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin 
Organ Transplant 2011; 16:627-31.
5. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 
diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 
343:230-8.
6. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. 
Am J Transplant 2004; 4:295-8.
7. Barbaro B, Salehi P, Wang Y, et al. Improved human pancreatic islet purification with the refined 
UIC-UB density gradient. Transplantation 2007; 84:1200-3.
8. Hanley SC, Paraskevas S, Rosenberg L. Donor and isolation variables predicting human islet 
isolation success. Transplantation 2008; 85:950-5.
9. Jung HS, Choi SH, Kim SJ, et al. A better yield of islet cell mass from living pancreatic donors 
compared with cadaveric donors. Clin Transplant 2007; 21:738-43.
10. Kin T, Zhai X, Murdoch TB, et al. Enhancing the success of human islet isolation through 
optimization and characterization of pancreas dissociation enzyme. Am J Transplant 2007; 
7:1233-41.
11. Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet 
isolation: influence of donor and isolation factors. Cell Transplant 2007; 16:595-607.
12. Sakuma Y, Ricordi C, Miki A, et al. Factors that affect human islet isolation. Transplant Proc 
2008; 40:343-5.
13. Agrawal A, Gurusamy K, Powis S, et al. A meta-analysis of the impact of the two-layer method 
of preservation on human pancreatic islet transplantation. Cell Transplant 2008; 17:1315-22.
14. Al-Abdullah IH, Bentsi-Barnes K, Valiente L, et al. Testing combinations of protease inhibitor 
and preservation solution to improve islet quality and yield. Transplant Proc 2008; 40:390-2.
15. Arita S, Smith CV, Nagai T, et al. Improved human islet isolation by a tube method for 
collagenase infusion. Transplantation 1999; 68:705-7.
16. Balamurugan AN, Chang Y, Fung JJ, et al. Flexible management of enzymatic digestion 
improves human islet isolation outcome from sub-optimal donor pancreata. Am J Transplant 
2003; 3:1135-42.
17. Benhamou PY, Watt PC, Mullen Y, et al. Human islet isolation in 104 consecutive cases. Factors 
affecting isolation success. Transplantation 1994; 57:1804-10.
18. Brandhorst D, Brandhorst H, Hering BJ, et al. Islet isolation from the pancreas of large mammals 
and humans: 10 years of experience. Exp Clin Endocrinol Diabetes 1995; 103 Suppl 2:3-14.
19. Brandhorst H, Brandhorst D, Hering BJ, et al. Body mass index of pancreatic donors: a decisive 
factor for human islet isolation. Exp Clin Endocrinol Diabetes 1995; 103 Suppl 2:23-26.
20. Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing 
recombinant collagenase. Diabetes 2003; 52:1143-6.
21. Brandhorst H, Friberg A, Andersson HH, et al. The importance of tryptic-like activity in 
purified enzyme blends for efficient islet isolation. Transplantation 2009; 87:370-5.
22. Briones RM, Miranda JM, Mellado-Gil JM, et al. Differential analysis of donor characteristics 
for pancreas and islet transplantation. Transplant Proc 2006; 38:2579-81.
23. Bucher P, Mathe Z, Morel P, et al. Assessment of a novel two-component enzyme preparation 
for human islet isolation and transplantation. Transplantation 2005; 79:91-7.
24. Caballero-Corbalan J, Eich T, Lundgren T, et al. No beneficial effect of two-layer storage 
compared with UW-storage on human islet isolation and transplantation. Transplantation 
2007; 84:864-9.
66 Chapter 4
25. Close NC, Hering BJ, Anand R, et al. Collaborative iIslet Transplant Registry. Clin Transpl 
2003:109-18.
26. Close NC, Hering BJ, Eggerman TL. Results from the inaugural year of the Collaborative Islet 
Transplant Registry. Transplant Proc 2005; 37:1305-8.
27. Dufrane D, Goebbels RM, Guiot Y, et al. A simple method using a polymethylpenten chamber 
for isolation of human pancreatic islets. Pancreas 2005; 30:e51-9.
28. Fiedor P, Goodman ER, Sung RS, et al. The effect of clinical and biochemical donor parameters 
on pancreatic islet isolation yield from cadaveric organ donors. Ann Transplant 1996; 1:59-62.
29. Frutos MA, Ruiz P, Mansilla JJ. Pancreas donation for islet transplantation. Transplant Proc 
2005; 37:1560-1.
30. Goto M, Eich TM, Felldin M, et al. Refinement of the automated method for human islet 
isolation and presentation of a closed system for in vitro islet culture. Transplantation 2004; 
78:1367-75.
31. Hubert T, Gmyr V, Arnalsteen L, et al. Influence of preservation solution on human islet 
isolation outcome. Transplantation 2007; 83:270-6.
32. Hubert T, Strecker G, Gmyr V, et al. Acute insulin response to arginine in deceased donors 
predicts the outcome of human islet isolation. Am J Transplant 2008; 8:872-6.
33. Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet 
preparations for transplantation. Am J Transplant 2005; 5:21-30.
34. Ichii H, Wang X, Messinger S, et al. Improved human islet isolation using nicotinamide. Am J 
Transplant 2006; 6:2060-8.
35. Kenmochi T, Miyamoto M, Une S, et al. Improved quality and yield of islets isolated from 
human pancreata using a two-step digestion method. Pancreas 2000; 20:184-90.
36. Kim SC, Han DJ, Kang CH, et al. Analysis on donor and isolation-related factors of successful 
isolation of human islet of Langerhans from human cadaveric donors. Transplant Proc 2005; 
37:3402-3.
37. Kin T, Mirbolooki M, Salehi P, et al. Islet isolation and transplantation outcomes of pancreas 
preserved with University of Wisconsin solution versus two-layer method using preoxygenated 
perfluorocarbon. Transplantation 2006; 82:1286-90.
38. Kin T, Shapiro AM, Lakey JR. Pancreas divisum: a study of the cadaveric donor pancreas for 
islet isolation. Pancreas 2005; 30:325-7.
39. Kin T, Zhai X, O’Gorman D, et al. Detrimental effect of excessive collagenase class II on human 
islet isolation outcome. Transplant international : official journal of the European Society for 
Organ Transplantation 2008; 21:1059-65.
40. Kneteman NM, de Groot TJ, Warnock GL, et al. The evaluation of solutions for pancreas 
preservation prior to islet isolation. Horm Metab Res Suppl 1990; 25:409.
41. Kneteman NM, Lakey JR, Kizilisik TA, et al. Cadaver pancreas recovery technique. Impact on 
islet recovery and in vitro function. Transplantation 1994; 58:1114-9.
42. Kneteman NM, Lakey JR, Warnock GL, et al. Human islet isolation after prolonged cold 
storage. Diab Nutr Metab 1992; 5:33-37.
43. Lakey JR, Helms LM, Kin T, et al. Serine-protease inhibition during islet isolation increases islet 
yield from human pancreases with prolonged ischemia. Transplantation 2001; 72:565-70.
44. Lakey JR, Rajotte RV, Warnock GL, et al. Human pancreas preservation prior to islet isolation. 
Cold ischemic tolerance. Transplantation 1995; 59:689-94.
45. Lakey JR, Warnock GL, Shapiro AM, et al. Intraductal collagenase delivery into the human 
pancreas using syringe loading or controlled perfusion. Cell Transplant 1999; 8:285-92.
46. Leeser DB, Bingaman AW, Poliakova L, et al. Pulsatile pump perfusion of pancreata before 
human islet cell isolation. Transplant Proc 2004; 36:1050-1.
47. Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme 
blend, liberase. Diabetes 1997; 46:1120-3.
48. Liu X, Matsumoto S, Okitsu T, et al. Analysis of donor- and isolation-related variables from 
non-heart-beating donors (NHBDs) using the Kyoto islet isolation method. Cell Transplant 
2008; 17:649-56.
49. Lu S, Jaeger C, Wolff-Vorbeck G, et al. Increase of islet yields obtained from human pancreas 
donor following change of pH value in collagenase digestion medium. Transplant Proc 1995; 
27:3202-4.
67Review of factors influencing islet isolation outcome
50. Markmann JF, Deng S, Desai NM, et al. The use of non-heart-beating donors for isolated 
pancreatic islet transplantation. Transplantation 2003; 75:1423-9.
51. Matsumoto I, Sawada T, Nakano M, et al. Significant impact of two layer (Perfluorochemical/
University of Wisconsin solution (PFC/UW)) method on islet yield and function for short-
term preservation of human donor pancreata prior to islet isolation and transplantation. 
Transplantation 2003; 76:S58.
52. Matsumoto I, Sawada T, Nakano M, et al. Improvement in islet yield from obese donors for 
human islet transplants. Transplantation 2004; 78:880-5.
53. Matsumoto S, Noguchi H, Naziruddin B, et al. Improvement of pancreatic islet cell isolation for 
transplantation. Proceedings 2007; 20:357-62.
54. Matsumoto S, Qualley SA, Goel S, et al. Effect of the two-layer (University of Wisconsin 
solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, 
as assessed by the Edmonton Isolation Protocol. Transplantation 2002; 74:1414-9.
55. Matsumoto S, Rigley TH, Qualley SA, et al. Efficacy of the oxygen-charged static two-layer 
method for short-term pancreas preservation and islet isolation from nonhuman primate and 
human pancreata. Cell Transplant 2002; 11:769-77.
56. Matsumoto S, Rigley TH, Reems JA, et al. Improved islet yields from Macaca nemestrina and 
marginal human pancreata after two-layer method preservation and endogenous trypsin 
inhibition. Am J Transplant 2003; 3:53-63.
57. Matsumoto S, Zhang G, Qualley S, et al. The effect of two-layer (University of Wisconsin 
solution/perfluorochemical) preservation method on clinical grade pancreata prior to islet 
isolation and transplantation. Transplant Proc 2004; 36:1037-9.
58. Matsumoto S, Zhang G, Qualley S, et al. Analysis of donor factors affecting human islet isolation 
with current isolation protocol. Transplant Proc 2004; 36:1034-6.
59. Nagata H, Matsumoto S, Okitsu T, et al. Procurement of the human pancreas for pancreatic 
islet transplantation from marginal cadaver donors. Transplantation 2006; 82:327-31.
60. Nano R, Clissi B, Melzi R, et al. Islet isolation for allotransplantation: variables associated with 
successful islet yield and graft function. Diabetologia 2005; 48:906-12.
61. Olack BJ, Swanson CJ, Howard TK, et al. Improved method for the isolation and purification of 
human islets of langerhans using Liberase enzyme blend. Hum Immunol 1999; 60:1303-9.
62. Ramachandran S, Desai NM, Goers TA, et al. Improved islet yields from pancreas preserved 
in perflurocarbon is via inhibition of apoptosis mediated by mitochondrial pathway. Am J 
Transplant 2006; 6:1696-703.
63. Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal 
donors following addition of oxygenated perfluorocarbon to the cold-storage solution. 
Transplantation 2003; 75:1524-7.
64. Robertson GS, Chadwick D, Thirdborough S, et al. Human islet isolation--a prospective 
randomized comparison of pancreatic vascular perfusion with hyperosmolar citrate or 
University of Wisconsin solution. Transplantation 1993; 56:550-3.
65. Rose NL, Palcic MM, Helms LM, et al. Evaluation of Pefabloc as a serine protease inhibitor 
during human-islet isolation. Transplantation 2003; 75:462-6.
66. Rose NL, Palcic MM, Shapiro AM, et al. Endogenous pancreatic enzyme activity levels show no 
significant effect on human islet isolation yield. Cell Transplant 2004; 13:153-60.
67. Sabek OM, Cowan P, Fraga DW, et al. The effect of isolation methods and the use of different 
enzymes on islet yield and in vivo function. Cell Transplant 2008; 17:785-92.
68. Salehi P, Hansen MA, Avila JG, et al. Human islet isolation outcomes from pancreata 
preserved with Histidine-Tryptophan Ketoglutarate versus University of Wisconsin solution. 
Transplantation 2006; 82:983-5.
69. Socci C, Davalli AM, Vignali A, et al. A significant increase of islet yield by early injection of 
collagenase into the pancreatic duct of young donors. Transplantation 1993; 55:661-3.
70. Takei S, Teruya M, Grunewald A, et al. Isolation and function of human and pig islets. Pancreas 
1994; 9:150-6.
71. Tons HA, Baranski AG, Terpstra OT, et al. Isolation of the islets of Langerhans from the human 
pancreas with magnetic retraction. Transplant Proc 2008; 40:413-4.
72. Toso C, Oberholzer J, Ris F, et al. Factors affecting human islet of Langerhans isolation yields. 
Transplant Proc 2002; 34:826-7.
68 Chapter 4
73. Tsujimura T, Kuroda Y, Avila JG, et al. Influence of pancreas preservation on human islet 
isolation outcomes: impact of the two-layer method. Transplantation 2004; 78:96-100.
74. Tsujimura T, Kuroda Y, Churchill TA, et al. Short-term storage of the ischemically damaged 
human pancreas by the two-layer method prior to islet isolation. Cell Transplant 2004; 13:67-
73.
75. Tsujimura T, Kuroda Y, Kin T, et al. Human islet transplantation from pancreases with prolonged 
cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) 
cold-storage method. Transplantation 2002; 74:1687-91.
76. Vargas F, Vives-Pi M, Somoza N, et al. Advantages of using a cell separator and metrizamide 
gradients for human islet purification. Transplantation 1996; 61:1562-6.
77. Warnock GL, Meloche RM, Thompson D, et al. Improved human pancreatic islet isolation for 
a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes 
mellitus. Arch Surg 2005; 140:735-44.
78. Witkowski P, Liu Z, Guo Q, et al. Two-layer method in short-term pancreas preservation for 
successful islet isolation. Transplant Proc 2005; 37:3398-401.
79. Wojtusciszyn A, Bosco D, Morel P, et al. A comparison of cold storage solutions for pancreas 
preservation prior to islet isolation. Transplant Proc 2005; 37:3396-7.
80. Zhang G, Matsumoto S, Newman H, et al. Improve islet yields and quality when clinical grade 
pancreata are preserved by the two-layer method. Cell Tissue Bank 2006; 7:195-201.
81. Zhao M, Muiesan P, Amiel SA, et al. Human islets derived from donors after cardiac death are 
fully biofunctional. Am J Transplant 2007; 7:2318-25.
82. Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of 
human islets of Langerhans. Transplantation 1996; 61:1047-53.
83. Matsumoto S, Okitsu T, Iwanaga Y, et al. Successful islet transplantation from nonheartbeating 
donor pancreata using modified Ricordi islet isolation method. Transplantation 2006; 82:460-5.
Chapter 5
Presence of hyperemic islets in human 
donor-pancreata results in reduced islet 
isolation yield
D.E. Hilling, H.A.M. Töns, P.J. Marang-van de Mheen, A.G. Baranski, 
E.K. van den Akker, O.T. Terpstra, E. Bouwman




When studying histological characteristics of human donor-pancreata, a remarkably 
high number of hyperemic islets (HIs) was encountered. The abnormalities in these 
HIs ranged from single/multiple dilated vessels to hemorrhages extending into the 
exocrine tissue. We aimed to determine the relevance of the presence of HIs in human 
donor-pancreata for isolation outcome and to identify donor and procurement factors 
associated with the occurrence of HIs. 
Methods and Materials
The presence of HIs was scored semi-quantitatively (HI-,HI+) in 102 human donor-
pancreata. Islet isolation was performed in 40 cases. Donor and procurement factors 
were retrospectively analyzed in 94 donors.
results
HIs were found in 54.6% of all donor-pancreata. However, only 4.5% of all islets in 
the affected pancreata was hyperemic. The affected pancreata contained slightly more 
endocrine tissue, but produced significantly lower yields. When corrected for other 
factors known to influence isolation outcome, the presence of HIs and endocrine 
content were the only factors significantly influencing isolation outcome. Prolonged 
ICU stay and pre-procurement hypertension were associated with the presence of HIs. 
Conclusions
This study is a first indication that the presence of HIs in human donor-pancreata are 
associated with reduced isolation outcomes and suggest an impact of the procurement 
procedure and pre-procurement hemodynamic status of the donor on the islet quality. 
It is tempting to speculate that this contributes to the generally experienced difficulties 
in obtaining sufficient amounts of human islets.
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IntroDuCtIon
Transplantation of islets of Langerhans can improve metabolic control and quality of 
life in patients with longstanding type 1 diabetes (1-4). Sufficient islet numbers can 
be obtained from a single donor, but generally more than one islet preparation per 
recipient is required to obtain insulin independence (1, 3, 5-7). An important factor in 
determining the islet isolation outcome is the amount of endocrine tissue present in a 
specific pancreas. However, a high endocrine content does not ensure a high isolation 
yield. Other factors, such as collagen and other matrix elements are thought to play 
a role (8-15). When studying histological characteristics of the human pancreas in 
relation to islet isolation, a remarkably high number of hyperemic islets (HIs) was 
encountered, a phenomenon that, besides our previous report in pigs (16), has not 
been described in detail before. The abnormalities observed in these HIs ranged from a 
single dilated vessel through multiple widely dilated vessels to hemorrhages extending 
into the surrounding exocrine tissue. In some cases, the endocrine tissue was reduced 
to a small rim of cells, with only a few scattered cells left, which may consequently 
affect isolation yield.
The aim of the present study was to assess the frequency and different types 
of HIs in human donor-pancreata. Furthermore, we studied the occurrence of HIs 
in relation to the amount of endocrine tissue in situ and the relation to islet isolation 
outcome. In addition we assessed donor and procurement factors to identify possible 
factors associated with the presence of hyperemic islets.
MAtErIALs AnD MEtHoDs
organ Procurement and Pancreatic sampling
A total of 102 human pancreata were obtained through Eurotransplant. The organs 
were obtained from 66 multi-organ donations after brain death (DBD) and 36 multi-
organ donations after cardiac death (DCD), for which consent for islet isolation and 
transplantation related research was given by relatives. The majority of the obtained 
organs was unsuitable for whole organ transplantation. However, all organs were 
procured and handled in the same way as the organs that were procured for whole 
organ transplantation. Organs were flushed in situ via the abdominal aorta with either 
cold University of Wisconsin (UW) or Histidine Tryptophane Ketoglutarate (HTK) 
organ preservation solution and removed “en bloc” with the spleen and stapled loop 
of the duodenum.
After dissection, the pancreata were stored in cold (4°C) UW or HTK (with 
the exception of 2 pancreata which were stored in another preservation solution) 
and transported according to Eurotransplant regulations, on ice, to the laboratory for 
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further processing. Mean (± SD) cold ischemia time (CIT, the interval between the 
aortic cross-clamp and initiation of the digestion procedure in the laboratory) was 
8.0 ± 3.2 h. The pancreata were dissected free of spleen, duodenum, surrounding fat 
and vessels in the laboratory. Before the isolation procedure, biopsies of head, neck 
and body of the pancreas were taken, immersed in Formalin (Klinipath, Duiven, The 
Netherlands) fixative for 24-48 h and subsequently cleared and stored in ethanol 70%. 
Histology
From each pancreas, paraffin-embedded sections of 5 mm were stained using the 
Aldehyde Fuchsine-Halmi (AF) technique: Rehydration, 90 s 2.5% potassium 
permanganate, 2' distilled water, 2' 1% oxalic acid, 10' running water, 1' distilled water, 
15' AF, 3' 90% ethanol (2 times), 1' 70% ethanol, 1' 50% ethanol, 5' aquadest, 10-60 
s Halmi, 10 seconds 0.2% acetic acid, 2' 100% ethanol (2 times), 5' xylene (2 times). 
Sections were embedded in malinol (Chroma-Gesellschaft, Köngen, Norway).
Microscopic evaluation
Islet sizes were determined in each pancreas using a calibrated grid and grouped into 8 
categories: >50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400 and >400 
mm diameter. As is generally practiced in the endocrine quantification in islet isolation 
procedures, islets smaller than 50 mm were not included because of their neglectable 
contribution to the total endocrine content. For determination of the endocrine 
content and the islet numbers, all islets in a tissue area of 1 cm2 per slide were assessed. 
The endocrine area density was determined by summation of all calculated (πr2) islet 
areas and expressed as percentage of the total area. According to the principle of 
Delesse (area density = volume density) and the assumption that islets are spherical, 
the determined endocrine area represents the endocrine content. 
Islets described as hyperemic in this study ranged from islets showing only a 
single slightly dilated vessel to hemorrhages extending into the surrounding exocrine 
tissue (Fig.1). The presence of HIs was scored semi-quantitatively (HI-, HI+). HI- 
pancreata contained none and HI+ pancreata at least one hyperemic islet. 
To assess the influence of the severity of the hyperemia, the HI+ pancreata 
were subdivided into HI+ and HI++ pancreata, also on a semi-quantitative basis. 
HI++ pancreata were more severely affected than the HI+ pancreata. Because of the 
enormous diversity in the occurrence of hyperemic islets both the amount of affected 
islets and the severity of hyperemia in the tissue sample were considered. For example, 
a tissue sample with 2 severely affected islets (with only a rim of islet cells left, as shown 
in Fig 1F) was scored as ++, while another tissue sample with 3 only slightly affected 
islets (with 1 dilated vessel, as shown in Fig 1B) was scored as +.
The pancreata were independently allocated to the different categories by 
2 observers. The observers were blinded for the isolation outcome when allocating 
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the pancreata to the different categories. Any differences between observers in the 
allocation of the pancreata, were resolved by discussion.
Donor and Procurement factors
To identify donor and procurement factors associated with the presence of HIs, we 
compared donor and procurement factors in HI+ and HI- pancreata. From the 102 
figure 1: Histology of pancreata (Af staining) showing different stages of hyperemic islets.
(A) Normal islet. (B) Islet with a single dilated vessel. (C) Islet with multiple dilated vessels. (D) Islet with multiple, 
more severely dilated vessels. (E,F) Swollen islet with vastly dilated vessels and only a rim of islet cells left. 
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pancreata, 8 (5 HI+ and 3 HI-) were excluded due to incomplete data, leaving 94 
pancreata (52 HI+ and 42 HI-) for analysis. 
Variables of interest were identified based on the literature (17-21). Donor 
variables included: age, sex, height, weight, body mass index (BMI = weight / height2), 
ABO blood group, vascular co-morbidity (cardiac, cerebral and/or peripheral vascular 
event or disease), DBD/DCD donors, presence and duration of cardiac arrest and 
hypotensive periods, length of stay on the intensive care unit (ICU), cause of death, use 
of vasopressors and steroids, as well as routine biochemical blood screen (levels before 
organ removal) and pre-procurement hemodynamic measurements. Procurement 
variables included: CIT, procurement team and preservation solution.
Average beta cell/endocrine content ratio per islet 
To assess possible swelling of the islets, the average beta cell/endocrine content ratio 
per islet was compared in HI+ and HI- pancreata. This was done in a smaller sample 
of 40 randomly selected pancreata (20 HI+ and 20 HI-).
In paraffin-embedded sections of 5 µm, beta cells were stained with a 
polyclonal peroxidase-labeled rabbit anti-human insulin antibody (Santa Cruz 
Biotechnology, Heidelberg, Germany) at a dilution of 1:100 overnight and visualised 
with 3,3’-diaminobenzidine (DAB) dissolved in Tris/HCl (0.05 M) with 15 µl H2O2. 
An average of 75 islets per tissue sample was assessed. To quantify the beta cell content 
(Fig. 2A), the brown stained area was quantified using the Zeiss KS400 image analysis 
system (Zeiss-Vision, Germany). Only islets larger than 50 mm in diameter were 
included. To quantify the endocrine content, every islet used in the assessment of the 
beta cell content was surrounded by a drawn line, manually delineated with a pen 
tablet using ImageJ (freeware image processing tool) (Fig. 2B). In human islets, beta 
cells represent 50-60% of the endocrine content. Because alpha, beta and delta cells 
have been shown to appear scattered throughout the islet (22, 23), the area inside the 
surrounding line was considered to represent the endocrine content (Fig 2C). This 
area was also quantified using the Zeiss KS400 image analysis system. To quantify a 
possible swelling of the islets, the ratio between the beta cell and endocrine content 
was calculated. The greater the swelling of the islets due to vasodilatation or edema, the 
lower the beta cell/endocrine content ratio would be.  
Islet isolation 
Islet isolation was performed in a smaller sample of 40 pancreata. These were different 
pancreata than those used in the determination of the beta cell/endocrine content 
ratio. Islet isolations were performed by a modification of the automated method 
previously described by Ricordi et al. (24). In short: the body and tail of the pancreas 
were used in the islet isolation procedure. The main pancreatic duct was identified, 
cannulated and perfused for 10 min (5 min at 80 mmHg and 5 min at 180 mmHg) with 
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a chilled solution of Collagenase NP (Serva Electrophoresis, Heidelberg, Germany), 
Neutral Protease NP (25U, Serva Electrophoresis, Heidelberg, Germany) and 
(Aminoethyl)-benzene sulfonyl fluoride hydrochloride (AEBSF-HCl, 20 mg/ml, Serva 
Electrophoresis, Heidelberg, Germany) in Hanks Balanced Salt Solution (HBSS). The 
distended tissue was cut into 5 or 6 pieces and placed in the Ricordi chamber, in a 
closed recirculating system and heated to 37°C to activate the enzyme blend. During 
the course of enzymatic and mechanical dissociation of the gland, samples were taken 
and evaluated in real-time using Dithizone (DTZ, diphenylthiocarbazone, 13 mM 
DTZ dissolved in 91.2% ethanol supplemented with 1.2% NH4OH, Sigma, Steinheim, 
Germany). After the appearance of islets unembedded in acinar tissue, the circulation 
circuit was cooled and the digest collected. The digested tissue was placed in a beaker 
on ice and islet samples of 50 ml were stained with an equal volume of DTZ solution, 
figure 2: Calculation of the beta cell/endocrine 
content ratio
The brown stained (beta cell) area was quantified 
using an image analysis system (A). To quantify the 
endocrine content, every islet used in the assessment 
of the beta cell content, was surrounded by a manually 
drawn line (B). The area inside the surrounding line 
was considered to represent the endocrine content (C). 
To quantify the swelling of the islets, the ratio between 
the beta cell and endocrine content was calculated: 
area A / area C.
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freshly prepared by the addition of 5% DTZ to HBSS. Islet numbers, expressed as islet 
equivalents (IE, representing islets of 150 mm diameter), were determined in duplicate.
Data analysis
Statistical analysis was performed using SPSS 16.0 statistical software. HI- and HI+ 
pancreata were compared on endocrine content, number of islets, isolation outcome 
and the average beta cell/endocrine content ratio per islet using student t-tests. 
HI-, HI+ and HI++ pancreata were compared to assess the influence of the severity 
of hyperemia on the above outcomes using one-way analysis of variance. Post hoc 
Bonferroni’s multiple comparisons tests were performed to determine which groups 
differed from each other. 
To assess whether the relation between the presence of HIs and isolation 
outcome was confounded by other factors known to influence isolation outcome (17-
21, 25), multivariate analyses was performed using linear regression with isolation 
outcome as dependent variable. Independent variables included: the presence of HIs, 
endocrine content, donor age, sex, BMI, cause of death, DBD/DCD donors, ICU stay, 
cardiac arrest, use of vasopressors, hypotensive periods (last measured blood pressure 
before procurement, SBP < 90 mm Hg and/or DPB < 60 mm Hg), pre-procurement 
hypertension, local/distant procurement, CIT and preservation solution.
To identify possible relevant variables in the occurrence of HIs, HI+ and HI- 
pancreata were compared on differences in donor and procurement factors using 
student t-tests for continuous variables and χ2 analyses for categorical variables. 
In case of expected count less than 5, the Fisher exact test was used. Multivariate 
analysis was consequently performed using binary logistic regression with presence 
of HIs as the dependent variable. As independent variables were included: age, sex, 
BMI, cause of death, vascular co-morbidity, ICU stay, use of vasopressors, use of 
steroids, hypotensive periods, blood creatinine, amylase, glucose and sodium levels, 
pre-procurement hypertension, duration of cardiac arrest, DBD/DCD donors, local/
distant procurement team, CIT and preservation solution. 
All p-values < 0.05 were considered to be statistically significant.
rEsuLts
Presence of HIs
Histological analysis showed that 57 of the 102 pancreata (54.6%) contained at least 
one hyperemic islet and were scored as HI+. However, only an average of 4.5% of 
all assessed islets in the HI+ pancreata was hyperemic. Hence, 45 pancreata (45.4%) 
contained no HIs and were scored as HI-.  
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We assessed the presence of HIs in different parts of the pancreata. There were 
no differences in the occurrence of HIs in the head, neck or body of the pancreata 
(results not shown).
Donor and Procurement factors in relation to HIs
Differences in donor and procurement factors between the HI- and HI + groups are 
listed in Table 1, 2. ICU stay was significantly longer in the HI+ group compared to 
the HI- group. Furthermore, pre-procurement hypertension (last measured blood 
pressure before procurement, Systolic Blood Pressure (SBP) > 140 mmHg and/or 
Diastolic Blood Pressure (DBP) > 90 mm Hg) was more frequently found in the HI+ 
than in the HI- group. We also found a trend (p = 0.07) towards longer cold ischemia 
times in the HI+ group.
Multivariate analyses confirmed that length of ICU stay (Odds ratio (OR) 1.32, 
95% Confidence Interval (CI) [1.02 – 1.71]) and the presence of pre-procurement 
hypertension (OR 3.43 [1.07 – 11.03]) significantly increased the probability of HIs. 
Last sodium level before organ procurement was found to significantly reduce the 
probability of HIs (OR 0.85 [0.76 – 0.95]). 
Endocrine content in relation to HIs
The mean endocrine content in the HI+ pancreata was 0.66%. This was significantly 
higher than in the HI- group where this was 0.55% (p = 0.04) (Fig. 3A). 
To assess the influence of the severity of the hyperemia on the endocrine 
content, the HI+ pancreata (n = 57) were subdivided into 31 HI+ and 26 HI++ 
pancreata (Fig. 3B). The mean endocrine content was 0.55% in the HI-, 0.58% in the 
HI+ and 0.75% in the HI++ group. One way analysis of variance showed that the mean 
endocrine content differed between the groups (p = 0.004). Bonferroni’s test revealed 
that endocrine content was significantly higher in the HI++ group compared to the 
HI- (p = 0.004) and the HI+ group (p = 0.03).
The mean number of islets (in 1 cm2 tissue) was 72 in the HI- and 78 in the HI+ 
group. We found no significant differences in numbers of islets between these groups 
(p = 0.19).
These results suggest that the higher endocrine content in the affected pancreata 
is a result of swelling of the islets, due to vasodilatation, edema or both. 
In a smaller sample of 20 HI+ and 20 HI- randomly selected pancreata, we 
observed that the mean beta cell/endocrine content ratio in the HI- group was 0.67%, 
which is significantly higher (p = 0.02) than the 0.55% shown for the HI+ pancreata. 
This supports our hypothesis that the higher endocrine content in the most affected 
pancreata is the result of islet expansion. 
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table 1. Differences in donor characteristics between HI+ and HI- pancreata 
Donor characteristic HI + (n = 52) HI - (n = 42) test of difference
Age (y) (± SD) 47.4 ± 13.0 46.9 ± 14.3 t = -0.181, p = 0.86
Sex X² = 0.416, p = 0.52 
   Male 27 (51.9%) 19 (45.2%)
   Female 25 (48.1%) 23 (54.8%)
ABO Blood Group X² = 0.614, p = 0.94
   O 18 (34.6%) 14 (33.3%)
   A 25 (48.1%) 19 (45.2%)
   B 6 (11.5%) 5 (11.9%)
   AB 3 (5.8%) 4 (9.5%)
Body mass index (kg/m2) 25.2 ± 5.3 24.4 ± 4.3 t = -0.823, p = 0.41
Cause of Death X² = 0.314, p = 0.86
   Cerebrovascular accident 30 (57.7%) 26 (61.9%)
   Trauma 11 (21.2%) 9 (21.4%)
   Other 11 (21.2%) 7 (16.7%)
DBD/DCD donors X² = 0.105, p = 0.75
   DBD 33 (63.5%) 28 (66.7%)
   DCD 19 (36.5%) 14 (33.3%)
ICU stay (days) 3.4 ±  3.5 2.2 ± 2.1 t = -2.033, p = 0.05
Cardiac arrest X² = 0.024, p = 0.88
   Yes / No 19 (36.5%) / 33 (63.5%) 16 (38.1%) / 26 (61.9%)
Cardiac arrest duration 
(min) 
5.5 ± 10.7 8.1 ± 13.8 t = 1.004, p = 0.32
Hypotension a X² = 0.001, p = 0.97
   Yes / No 20 (38.5%) / 32 (61.5%) 16 (38.1%) / 26 (61.9%)
Hypotension duration (min) 6.5 ± 13.2 9.0 ± 20.4 t = 0.738, p = 0.46
Hypertension b X² = 3.753, p = 0.05
   Yes / No 29 (55.8%) / 23 (44.2%) 15 (35.7%) / 27 (64.3%)
Vascular comorbidity c X² = 0.171, p = 0.68
   Yes / No 22 (42.3%) / 30 (57.7%) 16 (38.1%) / 26 (61.9%)
Sodium (mmol/l) d 145 ± 7 147 ± 7 t = 1.470, p = 0.15
Creatinine (mg/dl) d 77.9 ± 37.5 72.5 ± 27.0 t = -0.786, p = 0.43
Amylase (U/l) d 240 ± 349 206 ± 161 t = -0.595, p = 0.55
Glucose (mmol/l) d 8.1 ± 2.8 8.5 ± 3.7 t = 0.623, p = 0.54
Hyperglycemia e X² = 0.211, p = 0.65
   Yes / No 26 (50.0%) / 26 (50.0%) 23 (54.8%) / 19 (45.2%)
Vasopressors X² = 0.004, p = 0.95
   Yes / No 35 (67.3%) / 17 (32.7%) 28 (66.7%) / 14 (33.3%)
Vasopressor (µg/kg/min)
   Noradrenaline 1 0.32 ± 0.74 0.27 ± 0.40 t = -0.301, p = 0.77
   Dobutamine 2 5.60 ± 3.15 5.37 ± 4.92 t = -0.083, p = 0.94
   Dopamine 3 7.10 ± 5.42 5.87 ± 2.95 t = -0.612, p = 0.55
Steroids X² = 0.369, p = 0.54
   Yes / No 12 (23.1%) / 40 (76.9%) 12 (28.6%) / 30 (71.4%)
DBD: Donation after brain death, DCD: Donation after cardiac death, ICU: Intensive care unit 
a Hypotension: last measured blood pressure before procurement, SBP < 90 mm Hg and/or DPB < 60 mm Hg 
b Hypertension: last measured blood pressure before procurement, SBP > 140 mm Hg and/or DBP > 90 mm Hg 
c Vascular co-morbidity: cerebral, cardiac and/or peripheral vascular event or disease  
d Levels before organ procurement 
e Hyperglycemia: last serum glucose level before organ procurement > 10.0 mmol/l 
1 Means were calculated for 51 donors who received Noradrenalin before procurement 
2 Means were calculated for 8 donors who received Dobutamine before procurement 
3 Means were calculated for 20 donors who received Dopamine before procurement
79Presence of hyperemic islets result in low yields in humans
Islet isolation yield in relation to HIs 
In a different series of 40 pancreata (20 HI- and 20 HI+), we assessed whether the 
presence of HIs might influence isolation outcome. In spite of their histologically 
assessed higher endocrine content, the mean isolation yield was significantly lower in 
the HI+ pancreata compared to the HI- group (2634 IE/g and 4069 IE/g, respectively 
p = 0.05). 
However, the HI+ pancreata contained significantly higher endocrine content. 
When this higher endocrine content was taken into account and the isolation results 
were expressed as the ratio of yield and content, the results were even more pronounced 
and illustrated a severely compromised endocrine quality (p = 0.003) (Fig.4A).
We also assessed the influence of the severity of hyperemia on isolation 
outcome and subdivided the HI+ group (n = 20) into 13 HI+ and 7 HI++ pancreata 
(Fig. 4B). One way analysis of variance showed that the mean yield/endocrine content 
ratio differed between the groups (p = 0.008). Bonferroni’s test revealed that the yield/
endocrine content ratio was significantly lower in the HI++ group compared to the 
HI- group (p = 0.02). Furthermore, a trend towards a lower yield/endocrine content 
ratio was found in the HI++ group compared to the HI+ group (p = 0.06).
Furthermore, we assessed whether the reduced isolation outcome in the HI+ 
groups was confounded by other factors know to influence isolation outcome. We 
corrected for endocrine content, donor age, sex, BMI, cause of death, DBD/DCD 
donors, ICU stay, cardiac arrest, use of vasopressors, use of steroids, hypotensive 
periods, local/distant procurement, CIT, preservation solution. The presence of HIs 
(B -1648.9, p = 0.01) and the endocrine content (B 6809.4, p < 0.001) were the only 
factors significantly influencing isolation outcome.
Etiology of HIs
To gain more insight in the etiology of HIs and validate whether other differences 
existed between HI groups, an experienced pathologist assessed a random selection of 
10 HI+ and HI- pancreata. The exocrine tissue and the nonhyperemic islets appeared 
to be visually normal in both groups. The pathologist found no macrophages or iron 
table 2. Differences in pancreas characteristics between HI+ and HI- pancreata
HI + (n = 52) HI - (n = 42) test of difference
Pancreas characteristic
Cold ischemia time (h) (± SD) 8.5 ± 3.4 7.3 ± 2.5 t = -1.871, p = 0.07
Procurement team X² = 1.098, p = 0.30
   Local 18 (34.6%) 19 (45.2%)
   Distant 34 (65.4%) 23 (54.8%)
Preservation solution 1 X² = 0.128, p = 0.72
   UW 34 (66.7%) 26 (70.3%)
   HTK 17 (33.3%) 11 (29.7%)
UW: University of Wisconsin Solution, HTK: Histidine Tryptophane Ketoglutarate 
1 Data missing for 1 HI+ and 5 HI- donors. Percentages calculated for 51 and 37 donors, respectively.
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figure 3: The endocrine content in relation to hyperemic islets.
The bars represent the mean endocrine content per hyperemic islet category. The error bars represent the standard 
deviation.
(A) The mean endocrine content in 45 HI- and 57 HI+ pancreata was 0.55, and 0.66%, respectively. Significantly 
higher endocrine content was found in the HI+ group, * p = 0.04 
(B) The influence of the severity of the hyperemia, by subdividing 57 HI+ pancreata into 31 HI+ and 26 HI++ 
pancreata, in relation to the endocrine content. Significant higher endocrine content was found in the HI++ 
group compared to the HI- and HI+ group, * p = 0.004, ** p = 0.03.
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figure 4: Yield/endocrine content ratio in relation to hyperemic islets.
The bars represent the mean yield/endocrine content ratio per hyperemic islet category. The error bars represent 
the standard deviation. 
(A) The mean yield/endocrine content ratio in 20 HI- and 20 HI+ pancreata. A significantly lower ratio was found 
in the HI+ group, * p = 0.003. 
(B) The influence of the severity of the hyperemia, by subdividing 20 HI+ pancreata into 13 HI+ and 7 HI++ 
pancreata, in relation to the yield/endocrine content ratio. A significantly lower yield / endocrine content ratio 
was found in the HI++ group compared to the HI- group, * p = 0.02. 
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deposits and no evidence for an ongoing chronic process in the affected pancreata. 
Beside the presence of HIs, no differences were seen between the HI- and HI+ 
pancreata.
To assess whether HIs also occurred in normal pancreatic tissue, we examined a 
series of 30 “normal” pancreatic tissue samples excised at elective surgical procedures 
(e.g. after pancreatoduodenectomy for pancreatic carcinoma) at the Academic 
Medical Centre, Amsterdam, The Netherlands. Areas with pancreatic pathology were 
identified by an experienced pathologist and were left out of the assessment. Only areas 
with “normal” pancreatic tissue were used in our assessment. At least 1 HI was found 
in 43.3% of these pancreata. Apparently, the presence of HIs is not limited to donor 
organs, but they can also be found in pancreatic tissue excised in elective surgery, 
suggesting that besides the pre-procurement hemodynamic status, the handling of the 
pancreas during surgery could also be a contributing factor in the development of HIs. 
DIsCussIon
Human islet isolations produce unpredictable, highly variable islet yields. We 
previously reported HIs as a possible explanatory factor in the varying porcine islet 
yields (16). When we studied histological characteristics of the human pancreas in 
relation to islet isolation, we found a similar remarkably high number of HIs. Similar 
islets have only been reported anecdotally in the literature but no mechanisms were 
described regarding their origin and no relevance has been determined from the 
perspective of the isolation of islets for transplantation (26-30). Slight hyperemia in 
islets has been reported in normal metabolic situations when higher insulin release 
is demanded (30, 31). However, like in our pig study, the phenomena encountered in 
the present study are far more dramatic and are most likely not related to the normal 
glucose metabolism. 
In the present study, HIs were found in more than half of the pancreata. However, 
the HI+ category consisted of pancreata with at least 1 HI. This could potentially 
lead to an overestimation of the HI- group, when a hyperemic islet was missed by 
an observer or when an islet appeared just outside the sectioning plane. However, 
because 2 observers independently assessed the tissue samples and since we have 
found no differences in the presence of HIs between different parts of the pancreata, 
it is unlikely that our results were influenced by this. Because no macrophages or lytic 
erythrocytes were seen and no evidence for an ongoing chronic process was found, 
it is most likely that the HIs arose shortly before or during the procurement of the 
pancreas. Since length of ICU stay and pre-procurement hypertension were shown to 
increase the probability of HIs, it can be speculated that a rise of blood pressure just 
before procurement and hemodynamic instability associated with prolonged ICU stay, 
are responsible for the formation of HIs. This in line with our porcine study where we 
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reported a rise in blood pressure, induced by the slaughtering process, as a possible 
causative moment for the presence of hyperemic islets in pigs. It is not clear how our 
findings with respect to the last sodium level fit in this explanation. Hence, since the 
mean sodium level of both the HI positive and HI negative groups are around the 
upper limit of normal values and the mean values only differed by 2 points, this finding 
might not be of clinical relevance. However, HIs were also found in 43.3% of “normal” 
pancreatic tissue samples obtained from elective surgical procedures. Since we have 
very little donor specifications of these tissue samples, we cannot make any statement 
about whether these influenced the presence of HIs, but apparently the presence of HIs 
is not limited to donor organs. However, these “elective patients” were most likely not 
admitted to the ICU before undergoing surgery and were probably hemodynamically 
more stable than the pancreas donors, especially when compared to DBD donors. 
Therefore, it seems likely that, besides the pre-procurement hemodynamic status, the 
handling of the pancreas during surgery could also be a contributing factor in the 
development of HIs. 
We found no microscopic hemorrhages in the exocrine pancreas, which makes 
up 98-99% of the organ, indicating that the islet vasculature is probably very sensitive 
for blood pressure rises and hemodynamic instability. This vulnerability may be 
reflected in its unique structure: blood vessels from the surrounding exocrine tissue 
abruptly increase in diameter upon entering the islet, have a thinner wall and are 
extensively fenestrated inside the islet, as reported in a rat study (32). 
We have also investigated the possible relevance of the presence of HIs from the 
perspective of islet isolation. A higher presence and severity of HIs was accompanied 
by a small increase in the endocrine content. This increase, however, is not paralleled 
by a similar increase in islet numbers, and could therefore be caused by expansion 
of the individual islets. Additionally, we found a lower beta cell/endocrine content 
ratio in the most affected pancreata, indicating that islets in these pancreata are more 
swollen, probably through vasodilatation, edema or both. In spite of the slightly higher 
endocrine content of the HI+ pancreata, substantial lower yields were found. When 
we corrected for the amount of endocrine tissue, even more pronounced lower yields 
were found in the affected groups. Furthermore, when corrected for other factors that 
are known to influence isolation outcome, the presence of HIs and endocrine content 
were the only factors significantly influencing isolation outcome. This is remarkable 
since even in the affected pancreata only a few percent of all islets were histologically 
abnormal. Most likely, the substantial increase in islet volume, or the reduced isolation 
outcome is not caused by this small fraction itself. A possible explanation could be 
that the entire islet population is compromised and that the abnormal islets are just an 
indicator of the actual damage of the islets. It can be speculated that besides the reduced 
isolation outcome, this phenomenon could also provide a possible explanation for the 
variable, unexplained loss of islets during culture and after transplantation. When 
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islets are obtained from donor-pancreata containing HIs, these islets would appear 
to be “normal” when in fact, the entire islet population of these pancreata is affected. 
Therefore, these islets are more likely to fail in culture or have impaired function 
when transplanted. In whole organ transplantation this would probably be less of a 
problem because of the intact integrity of the exocrine pancreas, providing external 
support for the islets and a possibility for recovery and angiogenesis. However, further 
research would be necessary to support this hypothesis, Furthermore, in this study, we 
have assessed the relation between the presence of HIs and pre-purification yield. To 
establish the importance of HIs for islet transplantation, further research, involving 
post-purification yield, purity, viability etc. would be necessary.  
In conclusion, these data are a first indication that the presence of hyperemic 
islets negatively influence isolation outcome and suggest an impact of the procurement 
procedure and pre-procurement hemodynamic status of the donor on the islet quality. 
It is tempting to speculate that this contributes to the generally experienced difficulties 
in obtaining sufficient amounts of human islets.
ACknowLEDgMEnts
The authors would like to thank Dr. I.M. Bajema MD, PhD for the histological 
assessment of the differences between most and not affected tissue samples, Dr. V. 
Terpstra MD, PhD (Academic Medical Center, Amsterdam, the Netherlands) for the 
pancreatic tissue samples of elective surgical procedures and K.G. van der Ham for the 
images of the hyperemic islets.
85Presence of hyperemic islets result in low yields in humans
rEfErEnCEs
1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 
diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 
343:230-238.
2. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. 
Diabetes 2005; 54:2060-2069.
3. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using 
cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 
5:2037-2046.
4. Ricordi C, Inverardi L, Kenyon NS, et al. Requirements for success in clinical islet transplantation. 
Transplantation 2005; 79:1298-1300.
5. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. 
Am J Transplant 2004; 4:295-298.
6. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation 
in patients with type 1 diabetes. JAMA 2005; 293:830-835.
7. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet 
transplantation and single islet infusions. Ann Surg 2003; 237:741-749.
8. van Deijnen JH, Hulstaert CE, Wolters GH, et al. Significance of the peri-insular extracellular 
matrix for islet isolation from the pancreas of rat, dog, pig, and man. Cell Tissue Res 1992; 
267:139-146.
9. van Deijnen JH, van Suylichem PT, Wolters GH, et al. Distribution of collagens type I, type III 
and type V in the pancreas of rat, dog, pig and man. Cell Tissue Res 1994; 277:115-121.
10. van Suylichem PT, van Deijnen JE, Wolters GH, et al. Amount and distribution of collagen 
in pancreatic tissue of different species in the perspective of islet isolation procedures. Cell 
Transplant 1995; 4:609-614.
11. Hughes SJ, McShane P, Contractor HH, et al. Comparison of the collagen VI content within the 
islet-exocrine interface of the head, body, and tail regions of the human pancreas. Transplant 
Proc 2005; 37:3444-3445.
12. Hughes SJ, Clark A, McShane P, et al. Characterisation of collagen VI within the islet-exocrine 
interface of the human pancreas: implications for clinical islet isolation? Transplantation 2006; 
81:423-426.
13. Uscanga L, Kennedy RH, Stocker S, et al. Immunolocalization of collagen types, laminin and 
fibronectin in the normal human pancreas. Digestion 1984; 30:158-164.
14. Töns HA, Terpstra OT, Bouwman E. Heterogeneity of human pancreata in perspective of the 
isolation of the islets of langerhans. Transplant Proc 2008; 40:367-369.
15. Cross SE, Hughes SJ, Partridge CJ, et al. Collagenase penetrates human pancreatic islets 
following standard intraductal administration. Transplantation 2008; 86:907-911.
16. Hilling DE, Rijkelijkhuizen JK, Töns HA, et al. Hyperemic islets, a possible explanation for poor 
yields in human and porcine islet isolation. Transplant Proc 2009; 41:316-318.
17. Hanley SC, Paraskevas S, Rosenberg L. Donor and isolation variables predicting human islet 
isolation success. Transplantation 2008; 85:950-955.
18. Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of 
human islets of Langerhans. Transplantation 1996; 61:1047-1053.
19. Mahler R, Franke FE, Hering BJ, et al. Evidence for a significant correlation of donor pancreas 
morphology and the yield of isolated purified human islets. J Mol Med 1999; 77:87-89.
20. Matsumoto I, Sawada T, Nakano M, et al. Improvement in islet yield from obese donors for 
human islet transplants. Transplantation 2004; 78:880-885.
21. Nano R, Clissi B, Melzi R, et al. Islet isolation for allotransplantation: variables associated with 
successful islet yield and graft function. Diabetologia 2005; 48:906-912.
22. Cabrera O, Berman DM, Kenyon NS, et al. The unique cytoarchitecture of human pancreatic 
islets has implications for islet cell function. Proc Natl Acad Sci U S A 2006; 103:2334-2339.
23. Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of human pancreatic islet architecture 
and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005; 53:1087-
1097.
86 Chapter 5
24. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. 
Diabetes 1988; 37:413-420.
25. Stewart ZA, Cameron AM, Singer AL, et al. Histidine-tryptophan-ketoglutarate (HTK) is 
associated with reduced graft survival in pancreas transplantation. Am J Transplant 2009; 
9:217-221.
26. Basta G, Falorni A, Osticioli L, et al. Method for mass retrieval, morphologic, and functional 
characterization of adult porcine islets of Langerhans: a potential nonhuman pancreatic tissue 
resource for xenotransplantation in insulin-dependent diabetes mellitus. J Investig Med 1995; 
43:555-566.
27. Coleman R, Silbermann M. Erythrocytes within pancreatic B-cells of corticosteroid-treated 
mice. Experientia 1978; 34:1049-1050.
28. Imaoka M, Satoh H, Furuhama K. Age- and sex-related differences in spontaneous hemorrhage 
and fibrosis of the pancreatic islets in Sprague-Dawley rats. Toxicol Pathol 2007; 35:388-394.
29. Kaduk B, Husslein EM, Siegfried A. Morphology of the chronic toxicity of busulfan on the islets 
of Langerhans in the rat. Hepatogastroenterology 1987; 34:108-112.
30. Lucocq JM, Findlay JA. Islet organ, blood glucose and glucose tolerance of lean and obese 
Mongolian gerbils. A quantitative study. Cell Tissue Res 1981; 220:623-636.
31. Moldovan S, Livingston E, Livingston E, et al. Glucose-induced islet hyperemia is mediated by 
nitric oxide. Am J Surg 1996; 171:16-20.
32. Henderson JR, Moss MC. A morphometric study of the endocrine and exocrine capillaries of 





reduced porcine islet isolation yield in the 
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When studying histological characteristics of porcine pancreata in relation to islet 
isolation, a remarkably high number of hyperemic islets (HIs) was encountered. The 
abnormalities observed in these HIs ranged from a single dilated vessel to hemorrhages 
extending into the surrounding exocrine tissue. The aim of the present study was to 
compare pancreata with and without HIs on islet isolation outcomes.
Methods and Materials 
This study involved a histological examination of 143 purebred (74 juvenile and 69 
adult) and 47 crossbred (only juvenile) porcine pancreata. Islet isolation was performed 
in 48 purebred adult pigs and in 25 crossbred pigs. Tissue samples were stained with 
Aldehyde Fuchsine. The presence of HIs was scored semi-quantitatively (HI-, HI+).
results
We observed HIs in 48% of the purebred and in 68% of the crossbred pigs. However, 
only 3.3 ± 3.1% and 3.1 ± 4.7% of all assessed islets was hyperemic in HI+ pancreata 
in purebred and crossbred pigs, respectively. In both groups, significantly higher 
endocrine cell mass was found in the HI+ pancreata (p < 0.01). When the higher 
endocrine cell mass was taken into account, we found significantly lower yields in the 
HI+ pancreata in both purebred and crossbred pigs (p = 0.03 in both groups). 
Conclusions
The presence of HIs occurs frequently in porcine donor-pancreata and is associated 
with reduced isolation outcomes. 
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IntroDuCtIon
Much research has been conducted to optimize the outcome of porcine islet isolation. 
The amount of endocrine tissue present in a specific pancreas is undoubtedly an 
important factor in determining the islet isolation outcome. However, a high endocrine 
cell mass does not ensure a high isolation yield. Other factors, such as collagen and 
other matrix elements are thought to play a role (1-6). It is presently unclear to what 
extent such factors are dependent on breed, sex and age.
When studying histological characteristics of the porcine pancreas in relation to 
islet isolation, a remarkably high number of hyperemic islets (HIs) was encountered, a 
phenomenon that has been described only anecdotally, but not been studied in detail 
before (7-11). The abnormalities observed in these HIs ranged from a single dilated 
vessel through multiple widely dilated vessels to hemorrhages extending into the 
surrounding exocrine tissue. We have previously reported our study of human donor-
pancreata where we found that the presence of HIs is associated with reduced isolation 
outcomes (12).
The aim of the present study was to assess whether this is a general phenomenon 
also present in porcine pancreata, and to determine the frequency of HIs in porcine 
pancreata compared to human pancreata. Furthermore, we studied the occurrence 
of HIs in relation to the amount of endocrine tissue in situ and in relation to the 
outcome of islet isolation to assess whether a similar relation was found as in human 
pancreata. Because external factors (e.g. breed, nutrition, age and transportation) 
could potentially have a confounding effect on islet isolation outcome, we assessed 2 
distinctly different groups: purebred and crossbred pigs. 
MAtErIALs AnD MEtHoDs
organ Procurement and Pancreatic sampling
A total of 143 purebred and 47 crossbred porcine pancreata were harvested in different 
commercial slaughterhouses. The purebred population consisted of a juvenile group 
(6 – 12 months) of 74 animals and involved 8 different breeds (Great Yorkshire n = 18, 
Dutch Landrace n = 25, Norwegian Landrace n = 3, Large White n = 11, Hampshire n 
= 2, Finnish Landrace n = 7, Duroc n = 8) The adult purebred group (12 – 78 months) 
consisted of 69 animals and involved 8 different breeds (Great Yorkshire n = 14, Dutch 
Landrace n = 17, Norwegian Landrace n = 6, Large White n = 7, Hampshire n = 3, 
Finnish Landrace n = 10, Duroc n = 10). The crossbred group consisted of only juvenile 
animals (6 – 12 months) and were a cross of 2 or 3 different breeds. 
All animals were killed by electric stunning and exsanguination. Warm ischemia 
times were between 20 – 30 min. After dissection, the pancreata were stored in cold 
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(4°C) Hank’s Balanced Salt Solution (HBSS) and transported on ice to the laboratory 
for further processing. Cold ischemia times were between 2 – 5 h. Biopsies were taken 
from the splenic, duodenal and connecting lobes, immersed in Bouin’s fixative, cleared 
and stored in ethanol 70%. 
Histology
From all pancreata, paraffin-embedded sections of 4 mm were stained using the 
Aldehyde Fuchsine-Halmi (AF) technique: Rehydration, 90 seconds 2.5% potassium 
permanganate, 2' distilled water, 2' 1% oxalic acid, 10' running water, 1' distilled water, 
15' AF, 3' 90% ethanol (2 times), 1' 70% ethanol, 1' 50% ethanol, 5' aquadest, 10-60 s 
Halmi, 10 s 0.2% acetic acid, 2' 100% ethanol (2 times), 5' xylene (2 times). Sections 
were embedded in malinol (Chroma-Gesellschaft, Köngen, Norway).
Microscopic evaluation
The same method was used as reported previously for human pancreata [12]. We have 
assessed the relation between the presence of HIs and endocrine cell mass, because 
pancreata with higher endocrine cell mass could produce higher yields simply because 
there is more endocrine cell mass to begin with. This could potentially confound our 
results when assessing the relation between the presence of HIs and isolation outcome.
Islet sizes were determined in each pancreas using a calibrated grid and grouped 
into 8 categories: >50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400 
and >400 mm diameter. As is generally practiced in the endocrine quantification in 
islet isolation procedures, islets smaller than 50 mm were not included because of 
their neglectable contribution to the total endocrine cell mass. For determination of 
the endocrine cell mass and the islet numbers, all islets in a tissue area of 1 cm2 per 
slide were assessed. The endocrine area density was determined by summation of all 
calculated (πr2) islet areas and expressed as percentage of the total area. According 
to the principle of Delesse (area density = volume density) and the assumption that 
islets are spherical, the determined endocrine area represents the endocrine cell mass. 
Assuming that the islet density does not significantly differ throughout the pancreas, 
the endocrine cell mass that is found in 1 cm2 tissue represents the percentage of 
endocrine tissue in the pancreas.
Islets described as hyperemic in this study ranged from islets showing only a 
single slightly dilated vessel to hemorrhages extending into the surrounding exocrine 
tissue (Fig.1). The presence of HIs was scored semi-quantitatively (HI-, HI+) as done in 
our study of human pancreata (12). HI- pancreata contained none and HI+ pancreata 
at least one hyperemic islet. 
To assess the influence of the severity of the hyperemia, the HI+ pancreata 
were subdivided into HI+ and HI++ pancreata, also on a semi-quantitative basis. 
HI++ pancreata were more severely affected than the HI+ pancreata. Because of the 
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enormous diversity in the occurrence of hyperemic islets both the amount of affected 
islets and the severity of hyperemia in the tissue sample were considered. For example, 
a tissue sample with 2 severely affected islets (with hemorrhages extending into the 
surrounding exocrine tissue, as shown in Fig. 1F) was scored as ++, while another 
tissue sample with 3 only slightly affected islets (with 1 dilated vessel, as shown in Fig. 
1B) was scored as +.
figure 1: Histology of porcine pancreata (Af staining) showing different stages of hyperemic islets.
(A) Normal islet. (B) Islet with a single dilated vessel. (C) Islet with multiple dilated vessels. (D) Swollen islet 
with vastly dilated vessels and only a rim of islet cells left. (E) As in picture D, with several small hemorrhages 
breaking through the rim. (F) Grossly enlarged and distorted islet with multiple hemorrhages penetrating 
deeply into the surrounding exocrine tissue.
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The pancreata were independently allocated to the different categories by 
2 observers. The observers were blinded for the isolation outcome when allocating 
the pancreata to the different categories. Any differences between observers in the 
allocation of the pancreata, were resolved by discussion.
Average beta cell/islet area ratio per islet and total number of islets
To assess possible swelling of the islets, the average beta cell/islet area ratio per islet 
was compared in HI+ and HI- pancreata, consistent with the method used previously 
(12). This was done in a smaller sample of 44 randomly selected pancreata (22 HI+ 
and 22 HI-). Furthermore, the total number of islets was assessed by counting all islets, 
including islets < 50 µm, in an area of 1 cm2 tissue in these pancreata. 
In paraffin-embedded sections of 4 µm, beta cells were stained with a 
polyclonal peroxidase-labeled guinea pig anti-porcine insulin antibody (Zymed, 
Invitrogen, Carlsbad, CA, USA) at a dilution of 1:200 overnight and visualized with 
3,3’-diaminobencidine (DAB) dissolved in Tris/HCl (0.05 M) with 15 µl H2O2. 
An average of 75 islets per tissue sample was assessed. To quantify the beta 
cell area, the brown stained area was quantified using the Zeiss KS400 image analysis 
system (Zeiss-Vision, Germany). Only islets larger than 50 mm in diameter were 
included. To quantify the islet area, every islet used in the assessment of the beta cell 
area, was surrounded by a drawn line, manually delineated with a pen tablet using 
ImageJ (freeware image processing tool). In human islets, beta cells represent 50-60% 
of the endocrine cell mass. Because alpha, beta and delta cells have been shown to 
appear scattered throughout the islets and porcine islets have been shown to have 
similar cytoarchitecture as human islets (13,14), the area inside the surrounding line 
was considered to represent the islet area. This area was also quantified using the Zeiss 
KS400 image analysis system. To quantify a possible swelling of the islets, the ratio 
between the beta cell and islet area was calculated. The greater the swelling of the islets 
due to vasodilatation or edema, the lower the beta cell/islet area ratio would be.  
Islet isolation 
In the purebred group, islet isolation was performed in 48 adult animals. In the 
crossbred group, islet isolation was performed in 25 animals. The pancreata were 
cut clean in the laboratory. The arm of the pancreas was intraductally injected with a 
solution of Liberase PI (0.5 mg/ml, Roche Applied Science, Germany) in University of 
Wisconsin solution (UW). The distended tissue was cut into pieces and incubated in 
HBSS at 37°C for 20 – 30 min. The digested tissue was placed in a beaker on ice, which 
was manually shaken to gently dissociate and dilute the tissue. Subsequently, the tissue 
was poured over a filter with 1000 mm mesh and washed in cold HBSS for 3 times. 
Islet samples of 25 ml were stained with an equal volume of Dithizone solution (DTZ, 
diphenylthiocarbazone, Sigma, Steinheim, Germany), freshly prepared by the addition 
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of 5% DTZ stock-solution (13 mM DTZ dissolved in 91.2% ethanol supplemented with 
1.2% NH4OH) to HBSS. Islet numbers, expressed as islet equivalents (IE, representing 
islets of 150 mm diameter), were determined in duplicate.
Data analysis
Statistical analysis was performed using SPSS 16.0 statistical software. HI- and 
HI+ pancreata were compared on endocrine cell mass, number of islets, isolation 
outcome and the average beta cell/islet area ratio per islet using student t-tests. HI-, 
HI+ and HI++ pancreata were compared to assess the influence of the severity of 
hyperemia on the yield/islet area ratio using one-way analysis of variance. Post hoc 
Bonferroni’s multiple comparisons tests were performed to determine which groups 
differed from each other. To assess the influence of the percentage HIs in a pancreas 
on isolation outcome, linear regression analysis was performed with yield/islet area 
ratio as dependent and percentage HIs as independent variable. P values < 0.05 were 
considered to be statistically significant.
rEsuLts
Presence of HIs
Histological analysis showed that 48% of the pancreata in the purebred group contained 
at least one HI and were scored as HI+. HIs were found more frequently in juvenile 
than in adult purebred pigs (64% vs. 32%, p < 0.001). In the crossbred group, HIs were 
found in 68% of the pancreata. In purebred HI+ pancreata, 3.3 ± 3.1% of all assessed 
islets was hyperemic. In crossbred pancreata 3.1 ± 4.7% of all assessed islets in HI+ 
pancreata was histological abnormal. 
We assessed the presence of HIs in different parts of both purebred and 
crossbred pancreata. There were no differences in the occurrence of HIs in either the 
splenic, duodenal or connecting lobes in both groups. We also found no significant 
differences in the occurrence of HIs between the different breeds (results not shown).
An experienced pathologist assessed a random selection of 10 HI+ and HI- 
pancreata. The exocrine tissue and the non-hyperemic islets appeared to be visually 
normal in both groups of pancreata. In the HI+ pancreata no macrophages or iron 
deposits were seen and no evidence for an ongoing chronic process was found. Beside 
the presence of HIs, no differences were seen between the HI+ and HI- pancreata.
Endocrine cell mass in relation to HIs
In both the purebred and crossbred group, significantly higher endocrine cell mass 
was found in the HI+ pancreata (p = 0.006 and p < 0.001, respectively) (Fig. 2A,C). 
HI+ pancreata were also found to contain significantly higher number of islets in 1 
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cm2 tissue (p = 0.009 and p < 0.001, respectively) (Fig. 2B,D). To assess the influence 
of the severity of the hyperemia on the endocrine cell mass and number of islets, the 
HI+ pancreata were subdivided into HI+ and HI++ pancreata. One-way analysis of 
variance showed that the mean endocrine cell mass differed between the groups in 
both purebred and crossbred pigs (p = 0.001 and p < 0.001, respectively). In both 
purebred and crossbred pigs, Bonferroni’s test revealed that the endocrine cell mass 
was significantly higher in the HI++ group compared to the HI- (p < 0.001 and p 
< 0.001, respectively) and HI+ (p = 0.02 and p = 0.001, respectively) groups. One-
way analysis of variance showed that the mean number of islets differed between the 
groups in both purebred and crossbred pigs (p < 0.001 and p < 0.001, respectively). In 
both purebred and crossbred pigs, Bonferroni’s test revealed that the number of islets 
was significantly higher in the HI++ group compared to the HI- (p < 0.001 and p < 
0.001, respectively) and HI+ (p = 0.003 and p = 0.007, respectively) groups.
figure 2: The endocrine cell mass and number of islets in relation to hyperemic islets.
The bars represent the mean endocrine cell mass (A,C) and the mean number of islets per cm2  (B,D). The error 
bars represent the standard deviation. 
(A,B) Pancreata from purebred pigs. (A) Mean endocrine cell mass in HI- pancreata was 0.65 ± 0.32%. In HI+ 
pancreata this was 0.83 ± 0.43% *p = 0.006 (B) Mean number of islets per cm2 was 97.8 ± 41.2 in HI- and 116.0 
± 40.7 in HI+ pancreata *p = 0.009 
(C,D) Pancreata from crossbred pigs. (C) Mean endocrine cell mass in HI- pancreata was 0.50 ± 0.14%. In HI+ 
pancreata this was 0.89 ± 0.33% *p < 0.001 (D) Mean number of islets per cm2 was 78.2 ± 17.5 in HI- and 117.7 
± 37.3 in HI+ pancreata *p < 0.001.   
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When we subdivided the purebred group into juvenile and adult pigs and 
assessed them separately, similar results were observed (data not shown).
These results suggest that the higher endocrine cell mass in the affected 
pancreata is associated with a higher number of the islets. The endocrine cell mass in 
HI+ pancreata was found to be 1.7 and 1.3 times higher compared to HI- pancreata in 
both purebred and crossbred pigs. It is not immediately obvious how this difference 
can be explained. Although the increased endocrine volume is paralleled by an increase 
in islet numbers, a straightforward comparison is confounded by the fact that only 
islets of greater than 50 mm were counted. When the underlying cause of the increased 
endocrine cell mass would be expansion of the individual islets, then a substantial 
number of islets smaller than 50 mm might cross the 50 mm limit and enlarge the total 
pool of countable islets. Alternatively, the most affected pancreata might simply have 
1.7 and 1.3 time greater islet numbers. To elucidate this, we have assessed the average 
beta cell/islet area ratio per islet and furthermore counted all islets, including islets < 
50 mm, in a limited series of 22 HI+ and 22 HI- pancreata. Furthermore, to assess and 
quantify possible swelling of the islets, we determined the average beta cell/islet area 
ratio per islet. The mean beta cell/islet area ratio in the HI- group was 0.57%, which 
was significantly higher (p = 0.004) than in the HI+ pancreata where this was 0.52%. 
No significant difference was found between the numbers of islets/cm2 in HI- and 
HI+ pancreata (785 and 916, respectively, p = 0.169). This suggests that the higher 
endocrine cell mass in HI+ pancreata is the result of islet expansion, (probably through 
vasodilatation, edema or both) rather than to an increase in the number of islets. 
Islet isolation yield in relation to HIs 
In a series of isolations in 48 purebred adult and 25 crossbred porcine donors we 
assessed whether the presence of HIs might influence isolation outcome. Lower 
yields were found in HI+ pancreata compared to HI- pancreata in both purebred and 
crossbred pigs, but these differences were not significant (p = 0.125 and p = 0.190, 
respectively) (Fig. 3A,C). However, these outcomes may be confounded by the higher 
endocrine cell mass in HI+ pancreata given that pancreata with higher endocrine 
cell mass produce higher yields simply because there is more endocrine cell mass to 
begin with. Adjusted for the differences in endocrine cell mass, significantly lower 
yields were found in HI+ pancreata compared to HI- pancreata in both purebred and 
crossbred pigs (p = 0.03 in both groups) (Fig. 3B,D). 
To assess the influence of the severity of the hyperemia on the yield/endocrine 
cell mass ratio, the HI+ pancreata were subdivided into HI+ and HI++ pancreata. 
One-way analysis of variance showed that the mean yield/endocrine cell mass ratio 
differed between the groups in both purebred and crossbred pigs (p = 0.007 and p 
= 0.02, respectively). Bonferroni’s test revealed that the yield/endocrine cell mass 
ratio was significantly higher in the HI++ group compared to the HI- group (p = 
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0.02) in purebred pigs. In crossbred pigs the yield/endocrine cell mass ratio was also 
significantly higher in the HI++ group compared to the HI- group (p = 0.02). No 
significant differences were found between HI- vs HI+ and HI+ vs HI++ pancreata in 
both groups. 
Linear regression analysis showed that the yield/endocrine cell mass ratio after 
was significantly lower in pancreata for every increase in the percentage of HIs in 
both purebred and crossbred pigs (B = -115.90, p = 0.005 and B = -106.25, p = 0.05, 
respectively).
DIsCussIon
Similar to our findings in human donor-pancreata (12), a remarkably high number 
of hyperemic islets was encountered when studying histological characteristics of 
the porcine pancreas in relation to islet isolation. Similar islets have been reported 
figure 3: Islet isolation yield and yield/endocrine cell mass ratio in relation to hyperemic islets. 
The bars represent the mean islet isolation yield (A,C) and the mean yield/endocrine cell mass ratio (B,D). The 
error bars represent the standard deviation. 
(A,B) Pancreata from purebred pigs (A) Mean yield in HI- pancreata was 679.2 ± 697.5 IE/g. In HI+ pancreata 
this was 383.4 ± 408.9 IE/g. (B) Mean yield/endocrine cell mass ratio was significantly lower in HI+ pancreata 
*p = 0.03 
(C,D) Pancreata from crossbred pigs. (C) Mean yield in HI- pancreata was 1960.5 ± 1220.6 IE/g. In HI+ pancreata 
this was 1411.0 ± 733.6 IE/g. (D) Mean yield/endocrine cell mass ratio was significantly lower in HI+ pancreata 
*p = 0.03
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anecdotally in the literature but no mechanisms were described regarding their 
origination (7-11). Also, no relevance has been determined from the perspective of 
the isolation of islets for transplantation. Although a slight hyperemia in islets is seen 
in normal metabolic situations when higher insulin release is demanded (11,15), the 
phenomena encountered in the present study are far more dramatic and are most 
likely not related to the normal glucose metabolism. In the literature only one study 
mentioned the finding of dilated blood vessels in islets, caused by congestion (7). The 
authors excluded the affected porcine pancreata from their study and gave no data on 
incidence and severity of the phenomenon, or on possible consequences for isolation 
outcome.
In the present study, HIs were found in 48% of the pancreata in purebred and 
in 68% of crossbred pigs. However, the HI+ category consisted of pancreata with at 
least 1 HI. This could potentially lead to an overestimation of the HI- group, when 
a hyperemic islet was missed by an observer or when an islet appeared just outside 
the sectioning plane. However, because 2 observers independently assessed the tissue 
samples with good agreement and since we have found no differences in the presence 
of HIs between different parts of the pancreata, it is unlikely that our results were 
influenced by this. Even if such a misclassification would have occurred, it would have 
lead to an underestimation of the relationship between HI and isolation outcome, given 
that HI+ pancreata have lower yields than true HI- pancreata. As a result, the data 
presented here are a conservative estimate of the strength of the relationship between 
HI and isolation outcome. Furthermore, we have found similar results in our study 
of 102 human donor-pancreata (12). In this previous study, HI’s were found in 54.6% 
of all human donor-pancreata, with 4.5% of all islets in the affected pancreata being 
hyperemic. The affected human pancreata contained slightly more endocrine tissue, 
and produced significantly lower yields similar to the findings in porcine pancreata. 
It thus seems to be a general phenomenon occurring in about half of the pancreata.
We have investigated the possible relevance of the presence of HIs from the 
perspective of islet isolation. A higher endocrine cell mass was found in the affected 
pancreata. Although the increased endocrine volume was paralleled by an increase in 
islet numbers, a straightforward comparison is confounded by the fact that only islets 
of greater than 50 mm were counted. To elucidate this, we have assessed the average 
beta cell/islet area ratio per islet and furthermore counted all islets, including islets < 50 
mm, in a limited series of 22 HI+ and 22 HI- pancreata. We found a significantly lower 
beta cell/ islet area ratio in HI+ pancreata, without a difference in the total number 
of islets compared with HI- pancreata. This suggests that islets in these pancreata are 
more swollen, probably through vasodilatation, edema or both. 
When we corrected for the fact that the HI+ pancreata contained significantly 
more endocrine tissue, significantly lower yields in the HI+ pancreata were seen 
compared to the HI- pancreata in both purebred and crossbred pigs. This is remarkable 
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since in HI+ pancreata only a small percentage of all islets was histological abnormal. 
Most likely, the substantial increase in islet volume, or the reduced isolation outcome 
is not caused by this small fraction itself. A possible explanation could be that the 
abnormal islets are just an indicator of the actual damage of the islets. No macrophages 
or iron deposits were seen and no evidence for an ongoing chronic process was found, 
a possible explanation is that the HIs arose shortly before the exsanguination and 
death of the animal and that for instance a sudden rise in blood pressure is responsible 
for the formation of HIs. In veterinarian literature, it is widely recognized that the 
slaughtering process induces a rise of the blood pressure with hemorrhages of different 
extent (16-18). However, further research is needed into the mechanisms by which 
these hyperemic islets arise e.g. by comparing pigs killed by electric stunning to 
pigs killed by another method. In our human study, prolonged ICU stay and pre-
procurement hypertension were associated with the presence of HIs (12). On the other 
hand, HIs were also found in 43.3% of “normal” pancreatic tissue samples obtained 
from elective surgical procedures. So apparently the presence of HIs is not limited 
to donor organs. However, these “elective patients” were most likely not admitted to 
the ICU before undergoing surgery and were probably hemodynamically more stable 
than the pancreas donors. Therefore, it seems likely that, besides the pre-procurement 
hemodynamic status, the handling of the pancreas during surgery could also be a 
contributing factor in the development of HIs. This could also be a contributing factor 
in porcine pancreata. 
We have found a relation between the severity of the hyperemic islets in the 
pancreata in relation to the endocrine cell mass and number of islets, with an increase in 
severity of the hyperemia being paralleled by a higher endocrine cell mass and number 
of islets. On the other hand, an increase in severity of the hyperemia did not seem 
to have a relation with isolation outcome. However, the absence of such a statistical 
difference could have been the result of the numbers in our study being too small, 
since there is a statistically lower isolation outcome in HI+ pancreata when compared 
to HI- pancreata. Furthermore, linear regression analysis showed significantly lower 
isolation outcome in pancreata containing a higher percentage of HIs. We have found 
similar results in human donor-pancreata (12). To establish the importance of HIs 
for islet transplantation, further research, involving post-purification yield, purity, 
viability etc. would be necessary.  
Taken together, we hypothesize that hyperemic islets in porcine pancreata are 
just an indicator of the actual damage of the islets in the pancreas. These damaged 
islets could be more prone to fragmentation during the isolation procedure, and thus 
have more chance to become smaller than 50 mm, thereby resulting in lower isolation 
yields given the common practice of not including islets smaller than 50 mm when 
determining the isolation yield. This hypothesis should be tested in future research.
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In conclusion, these data confirm that the presence of hyperemic islets may 
negatively influence isolation outcome in porcine pancreata as they were shown to do 
in human pancreata and possibly affect the islet quality in the procurement procedure. 
It is tempting to speculate that this eventually may explain part of the generally 
experienced difficulties in obtaining sufficient amounts of porcine islets. 
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Chapter 7
Porcine islet isolation outcome is not 
affected by the amount and distribution of 
collagen in the pancreas





Variable islet yields in porcine islet isolation may be caused by the collagen substrate 
within the pancreas. The aim of the present study was to determine the total amount 
and distribution of collagen within porcine pancreata and their relationship to islet 
isolation outcome. 
Method and Materials
A total of 64 juvenile and 76 adult porcine pancreata of eight purebred breeds were 
histologically examined. The amount of collagen was quantitatively assessed in 
tissue samples stained with Sirius Red. Collagen distribution was semi-quantitatively 
determined by assessing the presence of collagen in the endocrine-exocrine interface 
and within the islet, in tissue samples stained with Sirius Red and anti-insulin. Islet 
isolation was performed in 58 pancreata of the adult group.
results
Total collagen content and islet encapsulation ranged widely in both adult and juvenile 
pigs. However, the majority of islets in adult and juvenile pigs had no or only a limited 
collagen capsule. The difference in collagen content between adult and juvenile pigs 
could not be explained by age. Furthermore, no differences between adult and juvenile 
pigs were found in islet encapsulation or the amount of intra-islet collagen. In adult 
pigs, no significant relationships were found between obtained islet yield and total 
collagen content, islet encapsulation or amount of collagen within the islet.
Conclusions
Considering the limitations in experimental design (staining method) and study 
material, isolation outcome does not seem to be affected by the total collagen content 
or collagen distribution. The influence of other matrix elements and collagen subtypes 
should be investigated.
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IntroDuCtIon
The pig is considered to be a potentially alternative for human donors of islets of 
Langerhans (1-5). However, porcine islet isolation procedures have been shown to be 
notoriously difficult. A possible explanation could be related to donor age and to the 
relative fragility of the islets of juvenile pigs (4,6,7). Collagenase digestion of the young 
porcine pancreas usually results in a complete dissociation of both the exocrine and 
endocrine tissue (7). On the other hand, islet isolation procedures using pancreata 
from adult pigs have resulted in large islet yields (8-10). 
Furthermore, despite improvement of isolation procedures, islet isolation is still 
associated with a considerable loss of endocrine tissue. This indicates that collagenase 
digestion of the pancreas is not limited to the exocrine pancreas but affects the islets 
as well. Because collagen is the major target in the enzymatic dissociation of the 
pancreas, the collagen substrate within the pancreas is one of the variables that could 
account for the unpredictable, highly variable islet yields (7,10-12). As successful islet 
isolation depends upon effective separation of islets from exocrine tissue, a more 
detailed knowledge of the composition of the connective tissue of the pancreas on 
which collagenase is acting is necessary. 
Previous studies reporting on the collagen content of porcine pancreata have 
based their conclusions on a small number of animals and furthermore, did not 
correlate their results to the actual isolation outcome of the pancreata used in their 
collagen assessment (10-14). 
The aim of the present study was to determine the total amount and distribution 
of collagen within a large study population of adult and juvenile porcine pancreata and 
assess the relationship of these determinants to the outcome of islet isolation in adult 
pigs. 
MAtErIALs AnD MEtHoDs
organ Procurement and Pancreatic sampling
A total of 140 purebred porcine pancreata were harvested in different slaughterhouses. 
The population consisted of a juvenile group (6 to 12 months) of 64 animals and 
involved five different breeds (Great Yorkshire n = 21, Dutch Landrace n = 25, 
Norwegian Landrace n = 2, Large White n = 9, Finnish Landrace n = 7). The adult 
group (12 to 78 months) consisted of 76 animals and involved eight different breeds 
(Piétrain n = 8, Great Yorkshire n = 10, Dutch Landrace n = 15, Norwegian Landrace 
n = 7, Large White n = 7, Hampshire n = 5, Finnish Landrace n = 14, Duroc n = 
10). All animals were killed by electric stunning and exsanguination. Warm ischemia 
times were between 20 and 30 minutes. After dissection on ice, the pancreata were 
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stored in cold (4°C) Hank’s Balanced Salt Solution (HBSS) and transported on ice to 
the laboratory for further processing. Cold ischemia times were between 2 and 5 h. 
Biopsies were taken, immersed in Bouin’s fixative, cleared and stored in ethanol 70%. 
Amount of collagen
To detect collagen, paraffin-embedded tissue samples of 4µm were stained with 0.1% 
Sirius Red F3B (Klinipath, Duiven, The Netherlands) in a saturated solution of picric 
acid for 90 minutes, washed with a saturated solution of picric acid, dehydrated and 
cleared with xylenes. Sirius Red, when dissolved in a saturated solution of picric acid, 
stains both structural as well as basement membrane collagen and consequently stains 
all types of collagen without differentiating between collagen subtypes (15-17). 
Quantitative measurements were made using the Zeiss KS-400 image analysis system 
(Carl Zeiss Ltd, Welwyn Garden City, Herts, UK). The collagen stained area was 
quantified by the assessment of 30 random fields in each tissue sample (Fig. 1 A, B). The 
KS-400 image analysis system quantified the red stained area per field, by calculating 
the percentage of red staining in each field. The average percentage of red staining in 
these 30 fields was considered to be a valid representation of the amount (percentage) 
of collagen in the whole pancreas.  
Distribution of Collagen
Distribution of collagen was evaluated in 4-µm sections of the same paraffin-embedded 
tissue samples as used in the determination of the amount of collagen. Collagen was 
stained with 0.1% Sirius Red F3B (Klinipath, Duiven, The Netherlands) and the 
identification of islets was facilitated by staining the beta cells with a polyclonal guinea-
pig anti-porcine insulin antibody (Zymed, Invitrogen, Carlsbad, USA) at a dilution 
of 1:200 overnight. To visualize the immunoreactions, sections were incubated with 
3,3’-diaminobencidine (DAB) dissolved in Tris/HCl (0.05 M) with 15 µl H2O2. 
Distribution of collagen was determined by assessing the presence of collagen 
within the islet and in the endocrine-exocrine interface (the “islet-capsule”), in an 
average of 100 islets per tissue sample. The presence of collagen in the islet-capsule 
(prior to isolation) of each assessed islet was scored in four categories: 0% to 25%, 25% 
to 50%, 50% to 75%, 75% to 100% collagen encapsulation (Fig. 1 C,D). The average 
score of all islets in a tissue sample was taken to represent the islet encapsulation with 
collagen in the whole pancreas. The amount of collagen within the islets was scored 
semi-quantitatively: 0 (absent), 1 (intra-islet collagen present in < 25% of islet area), 2 
(intra-islet collagen present in >25% of islet area) (Fig. 1 E,F). The average score of all 
islets in a tissue sample was considered to be a valid representation of the amount of 
collagen within the islets in the whole pancreas. 
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figure 1: total amount of collagen and collagen distribution 
A,b) The total amount of collagen (red) was determined in tissue samples stained with Sirius Red in a saturated 
solution of picric acid. The collagen stained area was quantified by the assessment of 30 random fields in each 
tissue sample 
A) 1 of the 30 fields of a pancreas with an average amount of collagen of 3.0%. This field displays part of the 
exocrine tissue of the pancreas neck B) 1 of the 30 fields of a pancreas with an average amount of collagen of 
10.2%. This field displays part of the exocrine tissue of the pancreas neck.
C,D) Collagen encapsulation (red) was assessed in tissue samples double stained with Sirius Red and anti-
insulin (brown) 
C) Islet with 0-25% collagen encapsulation D) Islet with 75-100% collagen encapsulation
E,f) Intra-islet collagen (arrows) was assessed in tissue samples double stained with Sirius Red and anti-insulin 
(brown) 




Islet isolation was performed in 58 porcine pancreata of the adult group. The isolations 
in this study were performed after obtaining sufficient experience with porcine 
islet isolations to achieve consistent results. The pancreata were cut clean in the 
laboratory. The arm of the pancreas (20 to 40 g in weight) was intraductally injected 
with a solution of Liberase PI (0.5 mg/ml, Roche, Basel, Switzerland) in University of 
Wisconsin solution. The distended tissue was cut into pieces and incubated in HBSS 
at 37°C for 20 to 30 min. The digested tissue was placed in a beaker on ice, which was 
manually shaken to dissociate gently and dilute the tissue. Subsequently, the tissue was 
poured over a filter with 1000-mm mesh and washed in cold HBSS for three times. 
Islet samples of 25 ml were stained with an equal volume of Dithizone solution (DTZ, 
diphenylthiocarbazone, Sigma, Steinheim, Germany), freshly prepared by the addition 
of 5% DTZ stock-solution (13 mM DTZ dissolved in 91.2% ethanol supplemented with 
1.2% NH4OH) to HBSS. Islet numbers, expressed as islet equivalents (IE, representing 
islets of 150 mm diameter), were determined in duplicate.
statistical Analysis
Statistical analysis was performed using SPSS 16.0 statistical software (SPSS Inc., 
Chicago, IL, USA). After visual inspection of the data, these were found to be normally 
distributed so that parametric tests were used. Juvenile and adult pigs were compared 
by the parametric student t-test. To determine the effect of age on collagen content 
and islet encapsulation, multiple linear regression was performed with either collagen 
content or islet encapsulation as dependent factors and groups of pigs (juvenile vs. 
adult) and age in months as independent variables. One way analysis of variance 
was used to compare isolation outcomes between different breeds. Multiple linear 
regression was performed with yield as dependent factor. Independent factors were 
either total amount of collagen, islet encapsulation or intra-islet yield, breed and age in 
months. P values < 0.05 were considered to be statistically significant.
rEsuLts
Amount of Collagen
The mean collagen content (± SD) in the adult group was 5.5 ± 2.0%, this was 
significantly higher (p < 0.001) than in the juvenile group where this was 3.7 ± 1.3% 
(Fig. 2A). The collagen content ranged in adult pigs from 1.7 to 11.0% and in juvenile 
pigs from 1.1 to 7.1%, showing a widespread range in collagen content between 
pancreata. 
When we corrected for age in months, a difference in collagen content in 
juvenile vs. adult groups still remained (B = -2.08, p < 0.001). However, this difference 
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could not be explained by the age in months (B = -0.01, p = 0.40), and must therefore 
be explained by another (unknown) difference between these groups. 
In a limited series of 15 (randomly selected) pancreata, the collagen content was 
assessed in tissue samples from two different parts of the pancreas. No clear differences 
in collagen content were observed between the different parts of the pancreas (results 
not shown). 
Collagen distribution
In adult pancreata, the mean degree of encapsulation of the islet with collagen was 38.9 
± 12.8%. In juvenile pancreata, the mean percentage was 35.2 ± 8.7% (p = 0.04) (Fig. 
2B). This percentage ranged in adult pigs from 14 to 78% and in juvenile pigs from 19 
to 64%, showing a widespread range in islet encapsulation between pancreata. 
However, when adjusted for age in months, no difference in islet encapsulation 
between adult and juvenile groups was found (B = -4.76, p = 0.09). 
The majority of the assessed islets was 0% to 25% encapsulated with collagen. 
Moreover, 82% of the assessed islets in adult and 88% in juvenile pigs was encapsulated 
< 50% (Table 1). 
We found no significant difference between juvenile and adult pigs with regard 
to the presence of collagen within the islet (p = 0.69) (Fig. 2C). In all instances, collagen 
was exclusively located around the capillaries.
In a limited series of 15 (randomly selected) pancreata, the islet encapsulation 
and intra-islet collagen were assessed in tissue samples from two different parts of 
the pancreas. No clear differences in islet encapsulation or intra-islet collagen were 
observed between the different parts of the pancreas (results not shown). 
Amount of collagen and collagen distribution vs. islet yield
After isolation, the average obtained islet yield in 58 adult pigs was 545.4 ± 601.2 
IE/g pancreas (range 18 to 3849). One way analysis of variance showed that the mean 
obtained yield did not differ between the different breeds (p = 0.28)
When corrected for breed and age in months, no significant relations were found 
between isolation outcome and collagen content, islet encapsulation and intra-islet 
collagen (B = -33.28 p = 0.52, B = -1.51 p = 0.81 and B = 103.02 p = 0.85, respectively).
table 1. Percentage collagen encapsulation in adult and juvenile pancreata
Percentage collagen encapsulation, mean ± sD
0-25% 25-50% 50-75% 75-100%
Adult pigs (n = 76) 59.6 ± 21.3 22.6 ± 8.8 10.6 ± 8.9 7.3 ± 7.7
Juvenile pigs (n = 64) 68.7 ± 16.8 19.7 ± 8.8 7.1 ± 6.2 4.6 ± 4.2
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figure 2: total amount of collagen and collagen distribution
The bars represent A) the mean percentage of collagen B) the mean percentage of the circumference of the islets 
that is encapsulated with collagen C) the mean score for intra-islet collagen. The error bars represent the standard 
deviation. 
A) The mean percentage of collagen in adult pigs was significantly higher than in juvenile pigs, * p<0.001 
B) The mean islet encapsulation with collagen was significantly higher in adult than in juvenile pigs * p=0.04 
C) No significant differences (p=0.94) in intra-islet collagen were found between adult and juvenile pigs
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DIsCussIon
Variable yields in porcine islet isolation may be caused by the collagen substrate within 
the pancreas. If this were true, we would be able to select eligible pigs in advance, to 
achieve higher isolation yields. However, considering the limitations in experimental 
design (staining method) and study material, in our study of 58 adult pigs we failed to 
observe a relationship between isolation outcome and total amount of collagen, islet 
encapsulation and intra-islet collagen. Juvenile pigs are generally shown to produce 
lower islet yields than adult pigs and collagenase digestion usually results in complete 
dissociation of the pancreas (7-10). These contrasting results may also be caused 
by differences in the collagen substrate between adult and juvenile pigs. However, 
because we found no relationship in adult pigs and the variance of total amount of 
collagen, islet encapsulation and intra-islet collagen was even smaller in juvenile pigs, 
it is unlikely that these would have an effect on isolation outcome in juvenile pigs.
The total amount of collagen in porcine pancreata has been considered to 
be an important factor in determining the isolation result (11). Yet our results do 
not support this., the difference in collagen between adult and juvenile pigs in our 
study could not be explained by the age-difference, but may be explained by another 
(unknown) difference between those groups. A collagen capsule surrounding the islet 
could potentially provide protection against enzymatic disintegration of islets and 
consequently their fragmentation, it has been suggested that a factor in the differing 
results is a more extensive capsule surrounding the islets of the adult pig pancreas 
as compared to the young pig pancreas (7,10). However, in our study, we found no 
difference in islet encapsulation between adult and juvenile pigs. Both adult and 
juvenile pancreata had no or only a very limited collagen capsule. This is in accordance 
with van Suylichem et al. (11) and van Deijnen et al. (13) who found that in pigs, the 
adhesion between islets and exocrine tissue almost exclusively depends on cell-to-cell 
adhesion. 
Our isolation results could have been influenced by (i) the isolation method and 
(ii) the procurement method and pancreas sampling. The isolation method we used 
is an accepted method of islet isolation, which is performed in many centers in every 
day practice and provides consistent results. Even though other methods may result in 
higher yields, it is unlikely that the observed relationship between isolation outcome 
and collagen was influenced by the isolation method. Ideally, pancreas samples should 
be taken before any manipulation takes place and warm ischemia times should be as 
short as possible. However, as the same procedure was used for all the pancreata in our 
study, it is unlikely that it will explain any relationship between collagen and isolation 
outcome.
In the present study, Sirius Red was used to stain collagen. Hence, our 
observations concern the amount and distribution of collagen in general, without 
differentiating between subtypes. Previous studies have shown that collagen types I, 
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III, IV and VI are present in the peri-islet capsule of the porcine pancreas (12,18). 
Compared with rat, human, and canine tissues, expression of most collagen types and 
laminin in the porcine pancreas seems to be rather weak (11). It can be speculated that 
the composition of the islet capsule, and the relative concentration of the components, 
could influence islet isolation outcome and possibly confound the observed relation 
between islet isolation outcome and the complete islet capsule. However, as we found 
no or only a very limited collagen capsule in our study population when we stained 
tissue samples for all types of collagen, we expect that collagen subtypes play no or 
only a minor role. 
In conclusion, although collagen is the major target in the enzymatic 
dissociation of porcine pancreata and although total collagen content and collagen 
distribution show high variability, we found no relationship between islet isolation 
outcome and these determinants in adult pigs. However, other matrix elements and 
collagen subtypes could play a role and should be further investigated.
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A remarkable change in porcine islet morphology was observed after infusion of 
the pancreas with collagenase. The aim of the present study was to quantify these 
morphological changes and to assess whether these changes were due to the volume 
expansion caused by the collagenase entering the islet or the result of its digestive 
effects.
Methods and Materials
This study was performed in pancreata of 28 crossbred pigs. First, eight pancreata were 
intraductally injected with collagenase by a continuous controlled pressure of 180 
mmHg. Pancreas samples before collagenase infusion were used as controls. All tissue 
samples, both before and after infusion, were stained with anti-insulin. To quantify 
the morphological change of the islets, the mean beta cell/endocrine content ratio of 
the infused and not-infused tissue samples was compared. In a second experiment, 20 
pancreata were similarly assessed after intraductal injection with Hank’s Balanced Salt 
Solution (HBSS).
results
In both the collagenase- and HBSS-infused groups, mean beta cell/endocrine content 
ratio was lower than in the control samples. The observed decline in the beta cell/
endocrine content ratio was not significantly different between collagenase- and 
HBSS-infused pancreata. This suggests that the lower beta cell/endocrine content ratio 
and thus the morphological change in the infused tissue samples is caused by volume 
expansion of the fluid entering the islet and that the digestive effect of collagenase 
plays no or only a minor role. 
Conclusions
Morphological changes of islets are observed after infusion of pancreata with 
collagenase and HBSS, most likely caused by volume expansion due to fluid entering 
the islets. 
117Morphological changes of porcine islets during isolation
IntroDuCtIon 
The pig is considered to be a potential alternative for human donors of islets of 
Langerhans. However, porcine islet isolation procedures have been shown to be 
notoriously difficult (1-4). Although procedures have been improved, porcine islet 
isolation is still associated with considerable loss of endocrine tissue. This indicates that 
not only the exocrine pancreas is affected by collagenase digestion, but that collagenase 
affects the islets as well. If we can find explanations for the loss of endocrine tissue, this 
may be a first step into finding a solution for this problem so that isolation procedures 
can be improved. 
When studying histological characteristics of porcine pancreata in relation to 
islet isolation, a remarkable change in morphology of the islets was observed after 
infusion of the pancreas with collagenase. Previous studies have shown collagenase 
located within the islets after standard intraductal infusion (at a perfusion pressure 
of 180 mmHg) of collagenase in human and also at lower perfusion pressures (as low 
as 50 mmHg) in porcine pancreata (5,6). The observed morphological changes could 
therefore be a result of either volume expansion of collagenase entering in the islet, 
leading to disruption of cell-cell contacts or be the result of the digestive effect of 
collagenase, subsequently leading to islet fragmentation. 
Other studies have reported on islet morphology after isolation (7,8). However, 
both studies have assessed the shape and size of islets after isolation, but did not perform 
a quantitative study of morphologic changes in islets after collagenase distension. 
Furthermore, it is not known whether the morphological changes are specific for 
collagenase or might also be observed for other fluids. If these are also shown for other 
fluids, this would suggest that the morphological changes are the result of volume 
expansion caused by fluid entering the islets. 
The aim of the present study was to quantify the observed morphological 
changes after collagenase infusion. Furthermore, we aimed to discriminate whether 
these morphological changes are the result of volume expansion of collagenase 
entering in the islet or the result of the digestive effect of collagenase. To distinguish 
between these two hypotheses, a second series of experiments was performed in which 
pancreata distended with HBSS.
MEtHoDs AnD MAtErIALs
organ procurement and pancreatic sampling
A total sample of 28 pancreata of crossbred pigs (6-12 months) was harvested in 
a commercial slaughterhouse. All animals were killed by electric stunning and 
exsanguination. Warm ischemia times were between 20 to 30 min. After dissection 
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on ice, the pancreata were stored in cold (4ºC) HBSS and transported on ice to the 
laboratory for further processing. Cold ischemia times were between 2 to 5 h, with 
most pancreata having a cold ischemia time around 3 h. Per pancreas, 1-cm biopsies of 
the duodenal part, splenic part and arm of the pancreas were taken directly before and 
some time after collagenase and HBSS infusion, immersed in Bouin’s fixative, cleared 
and stored in ethanol 70%.
Collagenase and Hbss distension
Eight pancreata were distended with Liberase PI (Roche Applied Science, Manheim, 
Germany). Liberase PI was stored at a temperature of -20 ºC and defrosted directly 
before injection. The pancreata were dissected free of surrounding fat and vessels in 
the laboratory. The main pancreatic duct was cannulated at the arm of the pancreas and 
intraductally injected with a solution of Liberase PI (0.5 mg/ml, solution temperature 4 
ºC at the start of infusion) in University of Wisconsin Solution (UW) by a continuously 
controlled pressure of 180 mmHg for 10 min. We have chosen 180 mmHg as perfusion 
pressure because it is used in standard infusion protocols. The syringe was removed 
before taking the biopsies. In a second experiment, 20 pancreata were intraductally 
injected with HBSS in the same way.
Histology
In paraffin-embedded sections of 4 µm, beta cells were stained with a polyclonal 
peroxidase-labeled guinea pig anti-porcine insulin antibody (Zymed, Invitrogen, 
Carlsbad, CA, USA) at a dilution of 1:200 overnight and visualized (brown colored 
staining) with 3,3’-diaminobencidine (DAB) dissolved in Tris/HCl (0.05 M) with 15 
µl H2O2. The specificity of the antibody was confirmed by a negative control. Infused 
and not-infused tissue samples were stained in the same way. 
Microscopic evaluation
An average of 75, randomly selected, islets per tissue sample were assessed. As is 
generally practiced, islets smaller than 50 mm were not included. To quantify the beta 
cell content (Fig. 1A,D), the brown stained area was quantified using the Zeiss KS400 
image analysis system (Zeiss-Vision, Germany). The Zeiss KS-400 image analysis 
system quantified the brown-stained area per field, by calculating the percentage of 
brown staining in each field. Image J (freeware image processing tool) was used to 
manually delineate every islet used in the assessment of the beta cell content (Fig. 
1B,E). The islets were independently delineated by two observers. The observers were 
blinded for the category of the tissue samples (collagenase/HBSS-infused or not-
infused tissue samples) when delineating the islets. 
In human islets (consisting of alpha, beta, delta and PP cells), beta cells represent 
the majority of the endocrine content. Because porcine islets have comparable 
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cytoarchitecture as human islets, where the outermost cells are commonly beta cells 
(9-11), the area inside the surrounding line was considered to represent the endocrine 
content and colored black using Image J (Fig 1C,F). This black colored area was also 
quantified using the Zeiss KS400 image analysis system by calculating the percentage 
of black staining in each field. The ratio between the beta cell and endocrine content 
was calculated by dividing both percentages (of brown and black staining) in both 
the infused and not-infused tissue samples. Per tissue sample an average beta cell/
endocrine content ratio was calculated. 
To quantify alterations in islet morphology, the average beta cell/endocrine 
content ratio of not-infused and infused tissue samples of the same pancreas were 
compared. An in- or decline in beta cell/endocrine content ratio after infusion would 
implicate a change in islet morphology. For example, the greater the decline in beta 
cell/endocrine content ratio, the greater the morphologic change after collagenase/
HBSS infusion would be. 
Data analysis
Statistical analysis was performed using SPSS 16.0 (IBM Corporation, Somers, NY, 
USA) statistical software. After visual inspection of the data, these were found to 
be normally distributed so that parametric tests were used. Because the beta cell/
endocrine content ratio after infusion is related to the beta cell/endocrine content ratio 
before infusion, these ratios were compared for every individual pancreas using paired 
student t tests in both HBSS- and collagenase-infused pancreata. To assess the influence 
of the infused fluid, we calculated the difference between the beta cell/endocrine 
content before and after infusion for every individual pancreas and consequently 
compared the average difference between collagenase- and HBSS-infused pancreata 
using independent student t tests Results are presented as mean ± SD.
rEsuLts
In a pilot experiment, three observers (DEH, EB and a medical student) independently 
assessed infused and not-infused tissue samples of eight collagenase-distended 
pancreata. The tissue samples were blinded in such a way that the observers were 
unable to distinguish from the outside whether the samples were infused or not-
infused tissue samples. All observers could discriminate the infused and not-infused 
tissue samples with 100% accuracy, based on the substantial morphological differences 
observed in the histological structure of the islets and exocrine tissue.
No significant difference was found between the two observers in the 
quantification of the endocrine content (p = 0.90). The average of the two observers 
was therefore used in further assessments.
120 Chapter 8
In eight collagenase-infused pancreata, mean beta cell/endocrine content ratio 
(± SD) in the not-infused tissue samples was 0.44 ± 0.08. After infusion this ratio 
was significantly lower: 0.34 ± 0.07 (t = 2.545, p = 0.04) (Fig. 2). In 20 HBSS-infused 
pancreata, mean beta cell/endocrine content ratio in the not-infused tissue samples 
was 0.49 ± 0.09. After infusion this ratio was significantly lower: 0.38 ± 0.09 (t = 
figure 1: Calculation of the beta cell/endocrine content ratio
(A) Islet of a not-infused tissue sample. The brown stained (beta cell) area was quantified usinag an image 
analysis system. To quantify the endocrine content, every islet used in the assessment of the beta cell content, 
was surrounded by a manually drawn line (B). The area inside the surrounding line was considered to represent 
the endocrine content (C). The ratio between the beta cell and endocrine content was calculated: area A/area C 
= ratio not-infused.
(D) Islet of the same pancreas, infused with HBSS. The brown-stained (beta cell) area and endocrine content 
were determined in similar fashion as in the not-infused tissue sample (E, F). The ratio between the beta cell and 
endocrine content was calculated: area D/area F = ratio infused.
To quantify the morphological change after infusion, the ratios of the not-infused and infused tissue samples 
were compared.
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3.795, p = 0.001) (Fig. 2). No significant differences in beta cell/endocrine content 
ratios were found between different parts of the pancreas in both groups (data not 
shown). Furthermore, we found no significant differences between the beta cell mass 
or endocrine content before and after infusion of the pancreas with either collagenase 
or HBSS (data not shown).
To assess the influence of the infused fluid, the difference between the beta cell/
endocrine content ratio before and after infusion was compared between collagenase- 
and HBSS-infused pancreata. In collagenase-infused pancreata the mean decline of 
the beta cell/endocrine content ratio after infusion was 0.10 ± 0.11. In HBSS-infused 
pancreata, the mean decline of the beta cell/endocrine content ratio after infusion was 
0.11 ± 0.13 which is similar to the decline in collagenase-infused pancreata (t = 0.316, 
p = 0.76). This suggests that the beta cell/endocrine content ratio in the infused tissue 
samples is lower regardless of the infused fluid, so that it seems likely that this lower 
ratio is caused by volume expansion of the fluid entering in the islet. Because the lower 
figure 2: ratio beta cell/endocrine content before and after collagenase and Hbss infusion
The bars represent the mean and the error-bars the standard deviation. 
In the collagenase infused pancreata, mean beta cell/endocrine content ratio in the not-infused tissue samples 
was 0.44 ± 0.08. After infusion this ratio was significantly lower 0.34 ± 0.07, * p = 0.04 
In the HBSS infused pancreata, mean beta cell/endocrine content ratio in the not-infused tissue samples was 0.49 
± 0.09. After infusion this ratio was significantly lower: 0.38 ± 0.09, ** p = 0.001.
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ratio is not specific for collagenase, it seems that the digestive effect of collagenase 
plays no or only a minor role. After infusion, the weight of the pancreas was found to 
be 2.8 times higher than the weight before infusion, in both groups. This supports the 
hypothesis that there is an overall swelling of the organ, because the fraction endocrine 
content is too small to account for this increase. 
DIsCussIon
Ductal injection of collagenase has been shown the technique to produce the highest 
isolation yields. However, even when collagenase is delivered to the pancreas in this 
way, there is still a considerable loss of endocrine tissue. As a first step in finding 
explanations, this study showed that islets undergo a morphological change during 
an islet isolation procedure currently used in most porcine and human islet isolations. 
The observed decline in the beta cell/endocrine content ratio was not specific for 
collagenase, but also shown for HBSS, so the morphological changes seem most likely 
to be due to volume expansion. These results are supported by previous studies by 
Johnson et al. (6) and Cross et al. (5) which showed the presence of collagenase within 
the islets of porcine and human pancreata after collagenase distension. The present 
study adds that other fluids may have the same effect.
In the present study, the endocrine content was determined by manual 
delineation of the islets used in the assessment of the beta cell content. Because the 
assessment of the endocrine content could potentially have been influenced by the 
observer performing the delineation, this could have influenced our results. However, 
because the delineation was performed by two observers and no significant difference 
between these observers was found, our study results do not seem greatly affected by 
this. 
Peak activity of collagenase can be found at 37°C. In our study, we did not heat 
the enzyme to this temperature, as we would have performed when isolating the islets. 
This may have underestimated the potential effect of collagenase. However, because 
the biopsies after infusion were taken some time after infusion of the pancreas and 
the pancreas was not chilled during infusion, the temperature of the enzyme at that 
point would most likely lie close to room temperature. At this temperature collagenase 
already has considerable activity and could have influenced islet morphology. However, 
we cannot exclude that, when heated to 37°C, the digesting effect of collagenase does 
influence islet morphology. 
We have compared HBSS-infused pancreata with pancreata infused with 
collagenase dissolved in UW. This could potentially have influenced our results since 
the enzyme-free solution is different than the solution in which the enzyme is dissolved. 
However, since UW is commonly used in porcine islet isolation procedures and is not 
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known to have a negative influence on porcine isolation outcome, our results do not 
seem greatly affected by this.
Moreover, we only have assessed the change in morphology of the islets some 
time after infusion of the pancreas with collagenase and HBSS and did not assess the 
effect of the rest of the isolation procedure on islet morphology, further research is 
necessary to assess whether these effects remain over time or are resolved during 
further processing of the pancreas.
The results of this study may provide part of the explanation for the loss of 
endocrine tissue during isolation procedures. The volume expansion caused by 
collagenase entering into the islet could lead to disruption of cell-cell contacts, leading 
to islet fragmentation and eventually reduced islet yields. Also the pressure of the 
infusion of the fluid could lead to disruption of cell-cell contacts. Another explanation 
could be a change in islet density. After digestion of the pancreas, separation of exocrine 
and endocrine tissue by a gradient is based on a difference in density, with the exocrine 
having a higher density than the endocrine tissue. When collagenase enters the islet, 
this could change the density of the endocrine tissue and lead to a smaller difference 
in density between the endocrine and exocrine tissue. It would consequently be more 
difficult to separate these two fractions by a gradient leading to a reduction in isolation 
outcome. 
Besides lower yields, the volume expansion caused by collagenase could also 
play a role in impaired function after isolation, simply as a result of mechanical 
pressure from ductal infusion on the membranes of acinar cells leading to fluid 
entering vasculature and islets. This is supported by Dufrane et al. (11) who showed 
that large, well-structured porcine islets with central capillaries possessed a better 
potential for cellular engraftement than disrupted islets. In addition, other studies 
have shown that disruption of the microanatomy of the islets results in alteration of 
insulin secretory responses (12) and that glucose hemostasis not only depends on the 
number and integrity of beta cells, but also on their interaction with neighboring beta 
and non-beta cells (13). 
In conclusion, morphological changes of islets after collagenase infusion 
seem to depend on volume expansion caused by fluid entering the islets. This could 
potentially lead to islet fragmentation, resulting in reduced islet isolation outcome and 
impaired function. If future research finds a way to inject collagenase without the fluid 
entering the islets, this may result in a considerable improvement of isolation yields.
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Pancreas transplantation and islet of Langerhans transplantation are potential 
solutions to treat patients with type 1 diabetes. Both procedures have shown to abolish 
the need for exogenous insulin and to restore normoglycemia. However, pancreas 
grafts are scarce and there is a shortage of donor pancreata relative to the number of 
patients needing a transplant (1). Therefore, optimal use of the available donor organs 
is essential.
The aim of this thesis was to contribute to further optimization of pancreas graft 
survival in pancreas transplantation and optimization of islet isolation outcomes in 
islet of Langerhans transplantation, leading to better use of available organs. Over 
the last years, human islet transplantation has become routine clinical practice in 
approximately 30 centers worldwide. In the Leiden University Medical Center it is 
performed on a regular basis and currently making the transition to becoming routine 
clinical practice. Porcine islet transplantation is also, slowly but surely, making a 
transition from the laboratory to clinical practice worldwide. To achieve this aim, we 
first assessed the importance of several factors that may optimize the outcome of either 
pancreas or islet transplantation, using both registry-based comparative effectiveness 
research and systematic review techniques. This was combined with biomedical 
research to study the mechanisms through which some factors may influence the 
outcomes of transplantation or isolation outcome in more detail.
In the Netherlands, the Leiden University Medical Center is the largest center 
performing pancreas transplantations. In 2011, 86% of all pancreas transplantations in 
the Netherlands were performed in our center. In chapter 2 we have shown that both 
donor and recipient characteristics as well as donor-recipient matching influence graft 
survival. Pancreas graft survival was reduced in female patients who received a graft 
from a donor with a similar BMI with enteric drainage of the graft. Recipient factors 
remain most important and explain the largest proportion of the variance in both 
1-year and overall survival whereas donor factors were less important in both short-
term and long-term pancreas graft survival. 
Our method of quantifying the impact of donor versus recipient factors has not been 
shown before. The advantage of our method is that besides the assessment of which 
factors significantly influence pancreas graft survival, their importance in terms of 
their contribution to graft survival can also be established. Optimizing recipient 
factors thus seems more important for long-term survival than optimizing donor 
factors. This seems logical when considering that pancreas donors are highly selected 
prior to procurement and transplantation. Because of this selection, the variation in 
donor factors (e.g. variation in age) is much smaller than in recipient factors. This 
smaller variation in donor factors is likely to result in a smaller variation in survival, 
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thus explaining a smaller part of the differences in pancreas graft survival. Recipients 
on the other hand are selected to a smaller extent, in particular in more recent years 
in which pancreas transplantation is also offered to more high-risk patients (e.g. older 
patients with comorbidity) so that they differ far more in various characteristics that 
may influence survival. Further research may lead to an improvement of this model 
by including other factors, which may result in an even higher ability to explain 
differences in survival. 
Apart from donor or recipient factors, the procurement technique of a pancreas 
graft has also been shown to influence pancreas graft and patient survival. Surgical 
injuries that occur during pancreas procurement may lead to complications after 
transplantation, impaired function of the allograft, graft loss or even death of the patient. 
In chapter 3 we determined how often pancreata were refused for transplantation after 
procurement during back-table inspection, which type of problems were responsible 
for the decision not to transplant the pancreas and whether different problems were 
encountered in transplanted versus refused pancreata. Reasons to refuse pancreata 
for transplantation were for example: severe atherosclerosis, severe injuries of the 
pancreas parenchyma, superior mesenteric or splenic vein and of the splenic or dorsal 
pancreatic artery such that reconstruction and transplantation became impossible. 
We evaluated all procured pancreata transported to our center for transplantation in 
the period February 2002 until May 2008. Of these, 82.8% were transplanted while 
17.2% were refused for transplantation during back-table inspection, regardless of 
procurement region. Thirteen percent of the pancreata were refused solely due to 
surgical injuries. As one would expect, in refused pancreata a higher number of critical 
and non-critical problems per pancreas were found than in transplanted pancreata. 
Chances of refusal increased in pancreata from older donors procured by centers 
not performing pancreas transplantations. When pancreata were procured by these 
centers, chances of refusal were eight times higher compared with centers that did 
perform pancreas transplantations. These results have important implications for 
current practice in pancreas procurement. More extensive and recurrent training of 
pancreas procurement surgeons might lead to a better quality of the organs and thus 
to a reduction in refusal rates. Surgeons with experience in pancreas transplantation 
may be excellent teachers in such a training program. Another possibility to reduce 
pancreas refusal may be to leave pancreas procurement to those centers also performing 
pancreas transplantations, but this seems difficult (if not impossible) to implement in 
practice. It seems better to complement training with annual feedback to each center 
on the proportion of procured organs that could be transplanted compared to other 
centers, which may lead to further improvement if rates are lower than expected.
In selected patients, the alternative to pancreas transplantation is transplantation 
of isolated islets as a free graft. Sufficient islet numbers can be obtained from a 
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single-donor, but even in the most successful studies multiple transplantations were 
necessary to obtain (temporary) normalization of hyperglycemia in the recipients (2-
7). Furthermore, islet isolation outcome is highly variable. Given the relative shortage 
of donor pancreata, this emphasizes the need to optimize isolation yields so that 
sufficient islet numbers are routinely obtained from a single-donor. 
In chapter 4 we present a systematic review of donor, pancreas and isolation procedure 
related factors shown to influence islet isolation outcome. Higher pre-and post-
purification islets yields and a higher proportion of successful islet isolations were 
obtained when pancreata were preserved with the “two-layer method”, rather than 
with the University of Wisconsin solution in donors with shorter cold ischemia times 
(one hour longer cold ischemia time resulted in an average decline of pre-purification 
post-purification yields, and proportion of successful isolations of 59 IEQ/g, 54 IEQ/g 
and 21%, respectively). Higher pre-purification yields and a higher percentage of 
successful islet isolations were found in younger donors with higher BMI. Lower yields 
were found in donation after brain death (DBD donors) compared to donation after 
cardiac death (DCD donors). Higher post-purification yields were found in isolations 
with Serva collagenase.
However, these results were obtained by including only a selection of studies, as not 
all studies reported the same factors. To obtain more reliable evidence, standardized 
reporting of these factors would be necessary. In univariate analysis 66.3-87.5% of the 
available pancreata were analyzed on the effect on pre- and post-purfication yield or 
percentage of successful isolation. In multivariate analysis this percentage was only 
10.3-20.6%, due to missing data on at least 1 of the variables included. This indicates 
that the studies differ to such a great extent in the variables that are reported, even when 
only those variables reported in most studies were selected. Standardized reporting of a 
minimal set of variables in all future studies would also lead to a better fit of the model 
used in any meta-analysis. In the current analyses on post-purification yield 19% of 
the variance in islet isolation outcome could be explained by the variables included. In 
pre-purification islet yield and proportion of successful isolations, this percentage was 
better, but still only 50% of the variance could be explained. This suggests that besides 
the variables included in our systematic review, other factors also influence isolation 
outcome. 
Among these other factors influencing isolation outcome may be the occurrence of 
hyperemic islets (HIs), for which the mechanism describing its origin as well as their 
relevance for islet isolation outcome is unknown. In chapter 5 we studied histological 
characteristics of the human pancreas in relation to islet isolation. HIs were found 
in approximately half of the assessed pancreata. It is most likely that the HIs arose 
shortly before or during pancreas procurement and that a rise in blood pressure in 
combination with hemodynamic instability (associated with prolonged ICU stay), 
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are responsible for the formation of HIs. In addition, besides the pre-procurement 
hemodynamic status, the handling of the pancreas during surgery could also be a 
contributing factor in the development of HIs. 
With respect to the consequences of HI occurrence, we found substantially lower yields 
in pancreata with HI (HI+) than in pancreata without HI (HI-). It can be speculated 
that besides the reduced isolation outcome this phenomenon could also provide a 
possible explanation for the variable, unexplained loss of islets during culture and 
after transplantation. When islets are obtained from donor pancreata containing HIs, 
these islets would appear to be “normal” (since only a small proportion of the assessed 
islets was hyperemic) when in fact, the entire islet population of these pancreata may 
be affected to some extent. Therefore, these islets are more likely to fail in culture or 
have impaired function when transplanted. To establish the importance of HIs for islet 
transplantation, further research is needed focused on the impact on post-purification 
yield, purity and viability. Systematic reporting of the presence of hyperemic islets 
in future studies (by taking a biopsy prior to the isolation procedure for example) 
would make it possible to include this as a factor in a meta-analysis to determine their 
relevance on isolation outcome compared to other known factors.
A potential solution for the shortage of human donor pancreata is xenotransplantation 
of porcine islets. However, porcine islet isolation procedures have been shown to be 
notoriously difficult. Morphological characteristics of the porcine pancreata could also 
be responsible for the highly variable islet yields. Similar to our findings in human 
donor pancreata, a remarkably high number of HIs was encountered when studying 
histological characteristics of the porcine pancreas in relation to islet isolation, as 
described in chapter 6. HIs were found in 48% of the pancreata in purebred pigs 
and in 68% of the pancreata in crossbred pigs. Similar to our results in human 
pancreata, significantly lower yields in the HI+ pancreata were found compared to 
the HI- pancreata in both purebred and crossbred pigs. No evidence for an ongoing 
chronic process was found, so it can be speculated that the HIs arose shortly before the 
exsanguination and death of the animal and that for instance a sudden rise in blood 
pressure could be responsible for the formation of HIs. 
Since HIs were found in both human and porcine pancreata and have a similar effect 
on islet isolation outcome in both species, HIs are potentially an important factor in 
islet isolation outcome. 
Given that collagen is the major target in the enzymatic dissociation of the pancreas, 
the collagen substrate within the pancreas is another variable that could account for 
the unpredictable, highly variable islet yields. In chapter 7 we have described our 
findings in pancreata of 64 juvenile and 76 adult pigs. Islet isolation procedures in 
adult porcine pancreata are known to result in large islet yields (8, 9), whereas these 
procedures have been shown to be more difficult in juvenile porcine pancreata, 
130 Chapter 9
possibly as a result of the relative fragility of the islets of juvenile pigs (10, 11). Even 
though we found a difference in total amount of collagen between adult and juvenile 
pigs, this difference in collagen could not be explained by the age-difference, and 
should thus be explained by another (unknown) difference between adult and juvenile 
pigs. A collagen capsule surrounding the islet could potentially provide protection 
against enzymatic disintegration of islets and consequently their fragmentation. It 
has been suggested that a factor in the differing islet isolation outcomes is a more 
extensive capsule surrounding the islets of the adult pig pancreas as compared to the 
young pig pancreas (12, 13). However, in our study, we did not find a difference in islet 
encapsulation between adult and juvenile pigs. Both adult and juvenile pancreata had 
no or only a very limited collagen capsule. Furthermore, previous studies have shown 
that the amount of collagen in porcine pancreata was related to the isolation outcome 
(12). However, we did not observe a relation between islet isolation outcome and total 
amount of collagen, islet encapsulation or intra-islet collagen in 58 adult pigs. 
It can be speculated that the composition of the islet capsule, and the relative 
concentration of the components could influence islet isolation outcome and possibly 
confound the observed relation between islet isolation outcome and the complete islet 
capsule. However, since we found no or only a very limited collagen capsule in our 
study population when we stained tissue samples for all types of collagen, we expect 
that collagen subtypes play no or only a minor role. Other matrix elements on the 
other hand could play a role and should be further investigated.
Ductal injection of collagenase has been shown to be the technique to produce the 
highest isolation yields. However, even when collagenase is delivered to the pancreas 
in this way, there is still a considerable loss of endocrine tissue. We showed in chapter 
8 that islets undergo a morphological change during most porcine and human islet 
isolation procedures. To quantify the morphological change of the islets, the mean 
beta cell/endocrine content ratios of the infused and not-infused tissue samples 
were compared. In a second experiment, 20 pancreata were similarly assessed after 
intraductal injection with Hank’s Balanced Salt Solution (HBSS). The observed decline 
in the beta cell/endocrine content ratio was shown to be not specific for collagenase, 
but was also shown for HBSS, so that the morphological changes most likely seem 
to be due to volume expansion. This could potentially lead to islet fragmentation, 
resulting in reduced islet isolation outcome and impaired function. 
In conclusion, this thesis has added evidence that the focus in pancreas transplantation 
should be on optimizing recipients to improve graft survival and on improving quality 
of pancreata procured by centers not performing pancreas transplantation (for 
example, by training the procurement surgeons to optimize pancreas procurement 
thus resulting in more transplantable organs. 
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In islet transplantations, it is recommended that the reporting of donor, pancreas 
and isolation factors should become more standardized, which would enable us to 
determine more accurately which factors are important predictors for islet isolation 
outcome. Furthermore, if more biomedical factors (e.g. the presence of hyperemic 
islets) would be reported in addition to the other factors, we would be able to assess 
the independent effect of these biomedical factors on islet isolation outcome and 
eventually the effect on islet transplantation in the clinical setting. 
futurE PErsPECtIvEs
Pancreas transplantation
In December 2010, more than 36,000 pancreas transplantations have been reported 
to the International Pancreas Transplant Registry (IPTR): more than 24,000 
transplantations were performed in the US and more than 12,000 outside the US (14). 
Recipient age at transplantation increased over the course of 24 years of pancreas 
transplantation as well as transplantations in type 2 diabetes mellitus patients. Donor 
criteria have become more strict over time, with a concentration on younger donors, 
preferably trauma victims, with short preservation time. Surgical techniques for 
drainage of the pancreatic duct also changed over time. In the US, enteric drainage 
is the predominantly used technique in combination with systemic drainage of the 
venous effluent of the pancreas graft. In the Leiden University Medical Center, a 
two-step approach is routinely performed in most patients. Pancreas transplants 
are bladder drained initially, with patients undergoing elective pancreas conversion 
to enteric drainage 6 – 12 months after transplantation (15). Immunosuppressive 
protocols developed towards antibody induction therapy with Tacrolimus and 
Mycophenolate Mofetil (MMF) as maintenance therapy. The rate of transplantations 
with steroid avoidance increased over time. All of these changes together have resulted 
in improved patient and graft survival. Patient survival is now 95% at one year and over 
83% 5 years after transplantation. Because donors are already highly selected prior to 
pancreas transplantation, future improvements in patient and pancreas graft survival 
may be realized primarily by optimizing recipient factors (e.g. BMI). Alternatively, 
living donor segmental pancreatectomy has been reported as a therapy in selected 
patients (16). An initial technical failure rate of more than 33% has been reported; 
nearly twice the rate in deceased donors, but this has declined to less than 1% since the 
start of this therapy. Living donor and deceased donor graft survival rates are more or 
less equivalent. If the use of living donors would increase, it is likely that eventually not 
only highly selected donors will be considered to be suitable, but criteria will become 
less strict over time, leading to more variation in donor characteristics that may 
influence survival. In this way, the use of living donors could potentially increase the 
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importance of donor factors in explaining survival differences. The potential downside 
of this therapy is that the donor must face a major surgical intervention, and even if 
a minimally invasive technique is used, the donor faces risks of surgical diabetes and 
potential risks for complications such as pancreatic fistula or infection. 
Human islet transplantation
Clinical islet transplantation is currently being offered to a subset of approximately 
15% of patients with type 1 diabetes with refractory hypoglycemia or marked 
hypoglycemic episodes. With over 750 islets transplants performed in over 30 
international centers yearly, this therapy has been transferred from research to 
becoming a standard recognized clinical therapy (5). In the Leiden University Medical 
Center, 19 transplantations have been performed in 13 patients since the start in 2007. 
Currently, islet transplantation offers a means of endogenous, regulated insulin 
secretion, thereby stabilizing glycemic control, preventing hypoglycemia, and 
correcting glycosylated hemoglobin (HbA1C) to a level predicted to prevent and reverse 
secondary complications of diabetes. However, patients require immunosuppressive 
therapy for the rest of their lives. Islet transplantation is also being offered after kidney 
transplantation, where the choice is simpler as these patients already require lifelong 
immunosuppressive therapy, and the intraportal islets implantation procedure is a 
simple nonsurgical intervention with a relatively low risk. 
Islet transplantation is thus likely to become a standard therapy once islet transplantation 
becomes more readily available. This means that the islet supply should be expanded (e.g. 
through expansion of existing islets, stem cell approaches or when xenotransplantation 
sources become available). The remaining challenges of inducing immunological 
tolerance, preventing islet destruction due to autoimmunity or alloimmune rejection 
and avoiding all potential side-effects due to immunosuppressive therapies, will all 
need to be addressed to facilitate this transition towards becoming a standard therapy. 
Furthermore, routine attainment of single-donor islet transplants success remains an 
important goal in islet transplantation. This would allow for many more subjects to 
be treated with islets, and would reduce the potential risk of donor HLA-sensitization 
by avoiding exposure to multiple donors. Islet allograft transplantation has also been 
performed with islets from three living donors, the last one successfully, showing the 
potential for further application (17-19).
Moving from multiple-donor to single-donor success will require a multimodal 
approach, including optimization of the pre-procurement condition of donor pancreas 
organs, protection of islets from cold and warm ischemic injury and the process of 
islet isolation, access to effective, stable and consistent human compatible collagenase 
enzyme blends for digestion, and several multimodal strategies for treatment of the 
recipient to suppress immunological, inflammatory and thrombosis pathways, while at 
the same time stimulating neovascularization and metabolic function of the islet graft. 
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Such a multimodal approach will transform short- and long-term islet transplantation 
success and will continue to facilitate the rapid transition from research to routine 
clinical care. This emphasizes the importance of optimizing islet isolation outcome.
In contribution to optimization of islet transplantation outcome, research in the Leiden 
University Medical Center is focused on the development of devices (in collaboration 
with the Technical University Twente) to create an optimal microenvironment for 
transplanted islets and alternative cell sources (e.g. precursor cells).
Porcine islet transplantation
Porcine islets could be an alternative to human islet transplantation, particularly if 
delivered in a way that evades the host immune system rejection (20). This can be 
achieved by protecting xenogeneic islets from immune rejection by selective semi-
permeable barriers. Designated pathogen-free herds (21, 22) could provide a supply 
of wild-type porcine islets that are well tolerated when administered in a suitable 
protective delivery vehicle. Such barrier systems have enabled amelioration of diabetes 
in a variety of animal models and preliminary evidence suggests that similar results 
could be obtained in humans. Ongoing trials using encapsulated islets, without 
immunosuppressive therapy, are sponsored by Living Cell Technologies (LCT), either 
in Russia or New Zealand, as well as trials that are still in the planning phase in the 
US. The trial in New Zealand started in 1995 with six type 1 diabetes patients receiving 
either encapsulated or non-encapsulated neonatal porcine islets. One individual, 
receiving encapsulated islets, showed a reduction in average monthly insulin dose, a 
reduction in glycosylated hemoglobin and the detection of porcine C-peptide in urine. 
A biopsy from this patient 9,5 years after transplantation showed encapsulated islets 
expressing insulin (23). These improvements in diabetic state, although temporary, 
were encouraging and prompted further expansion. However, trials were temporarily 
put on hold because of concerns raised by the documentation of in vitro pig-to-human 
transmission of porcine endogenous retroviruses. This resulted in a long process of 
communication with the New Zealand regulatory authorities to fulfill requirements 
associated with the health status of the source pigs, pancreas processing and islet 
encapsulation, nationwide public consultation and implementation of a safety strategy. 
In the Russian trial, commenced in 2007, eight patients were transplanted with 5000-
10000 IEQ/kg. Presenting the three- and six-month post-transplant data, evidence for 
efficacy was demonstrated in some, but not in all, patients. Five patients manifested 
a reduced insulin need and two patients (one at three months and one at six months 
after transplantation) temporarily did not need any insulin. Six patients showed a 
reduction in circulating glycosylated hemoglobin, average levels being 8.9% before 
transplantation, 6.9% at three months after transplantation and 7.3% at six months 
after transplantation. The procedure was found to be safe and could be repeated safely.
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The trial in New Zealand continued in October 2009. It is an open-label dose-range 
study for one implant with 10000-15000 IEQ/kg in eight patients with unstable 
diabetes and severe hypoglycemic episodes. All patients, with a follow-up of 20-36 
weeks, showed a clear reduction in hypoglycemia score. At the XXIII international 
congress of the Transplantation Society (24) one patient was presented in more detail, 
showing a 20% insulin dose reduction at 4 weeks after transplantation
These data show that clinical porcine islet transplantation is a safe procedure that might 
benefit patients with hypoglycemia unawareness and gives a modest improvement in 
diabetes control. In upcoming studies, the dose and timing of possible repeat doses 
will be addressed. Optimization of porcine islet isolation outcome would become of 
even greater importance once porcine islet transplantation becomes a more standard 
recognized clinical therapy.
This thesis is a first step in the direction of these future developments. By combining 
several research methods (registry-based comparative effectiveness research, systematic 
review techniques and biomedical research) we have accomplished a profitable 
interaction. On one hand we have assessed the general overview (by determining 
the relative importance of factors on outcomes of transplantation) and on the other 
hand we have unraveled some of the mechanisms through which potential factors 
may influence the outcomes of transplantation. The advantage of such a combination 
is that we do not only investigate how certain factors may influence transplantation 
outcomes, but at the same time try to quantify which part of the variation in outcomes 
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Pancreastransplantatie en eilandjes van Langerhans transplantatie zijn potentiële 
oplossingen voor de behandeling van patiënten met Diabetes Mellitus type 1. Beide 
procedures hebben bewezen dat zij het gebruik van exogeen insuline overbodig maken 
en kunnen leiden tot normoglycemie. Pancreasdonororganen zijn echter schaars en er 
is een relatief tekort aan donorpancreata in vergelijking met het aantal patiënten dat op 
de wachtlijst staat voor een transplantatie (1). Het is daarom essentieel dat beschikbare 
organen optimaal benut worden. 
Het doel van dit proefschrift is om een bijdrage te leveren aan de voortschrijdende 
verbetering van pancreastransplantaatoverleving en de eilandjesisolatieopbrengst, 
zodat optimaal gebruik kan worden gemaakt van beschikbare organen. Hiervoor richten 
wij ons in deel I op pancreastransplantatie en in deel II en III op eilandjestransplantatie. 
Humane eilandjestransplantatie heeft zich in de afgelopen jaren ontwikkeld tot een 
routinebehandeling in ongeveer 30 centra in de wereld. In het Leids Universitair 
Medisch Centrum vindt momenteel de transitie van experimentele naar routinematige 
behandeling plaats. De transplantatie van varkenseilandjes maakt ook langzaam maar 
zeker de overgang van het laboratorium naar klinische toepassing. 
Om dit doel te bereiken hebben wij, middels vergelijkend onderzoek naar de 
effectiviteit in registraties en via systematische reviewtechnieken, eerst verschillende 
factoren bekeken die in potentie de uitkomsten van pancreas- of eilandjestransplantatie 
kunnen verbeteren. Dit werd gecombineerd met biomedisch onderzoek om het 
mechanisme, waardoor verschillende factoren de uitkomst van transplantatie of 
isolatieopbrengst kunnen beïnvloeden, in meer detail te bestuderen.
Het Leids Universitair Medisch Centrum is het grootste centrum in Nederland dat 
pancreastransplantaties verricht. In 2011 werd 86% van alle pancreastransplantaties 
hier verricht. Hoofdstuk 2 laat zien dat zowel donor- als ontvangerfactoren als 
ook matching van donor met ontvanger de transplantaatoverleving beïnvloeden. 
Pancreastransplantaatoverleving is korter bij vrouwen die een orgaan ontvingen 
van een donor met eenzelfde BMI met enterale drainage van het transplantaat. 
Ontvangerfactoren zijn het meest belangrijk en verklaren het grootste deel van de 
variatie in overleving zowel na 1 jaar als op de lange termijn. Donorfactoren zijn 
minder belangrijk dan ontvangerfactoren. Dit geldt in ongeveer gelijke mate voor  de 
korte en de lange termijn.
Onze methode, waarbij het effect van donorfactoren wordt gekwantificeerd 
ten opzichte van ontvangerfactoren, is niet eerder beschreven. Het voordeel van deze 
methode is dat niet alleen onderzocht wordt welke factoren een significante invloed 
hebben op pancreastransplantaatoverleving, maar dat ook de relatieve bijdrage aan 
de transplantaatoverleving bepaald kan worden. Voor transplantaatoverleving op 
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lange termijn lijkt het optimaliseren van ontvangerfactoren dus belangrijker dan het 
optimaliseren van donorfactoren. Dit is waarschijnlijk een logisch gevolg van het feit 
dat pancreasdonoren voor de uitname en transplantatie al uitgebreid geselecteerd 
worden. Door deze selectie is er een kleinere variatie in donorfactoren (bijv. variatie 
in leeftijd) dan het geval is bij ontvangerfactoren. Deze kleinere variatie resulteert 
zeer waarschijnlijk in een kleinere variatie in overleving en zal daarom een geringer 
deel van de verschillen in pancreastransplantaatoverleving verklaren. Ontvangers 
worden in veel mindere mate geselecteerd, zeker in de afgelopen jaren waarbij 
pancreastransplantatie ook wordt aangeboden aan meer hoog-risico patiënten (bijv. 
oudere patiënten met comorbiditeit). Hierdoor verschillen de karakteristieken die 
van invloed kunnen zijn op de overleving bij ontvanger veel meer. Verder onderzoek 
zal leiden tot een verbetering van dit model als er bijvoorbeeld ook andere factoren 
meegenomen worden, zodat we nog beter in staat zijn om verschillen in overleving te 
verklaren. 
Naast donor- en ontvangerfactoren beïnvloedt ook de uitnametechniek van een pancreas 
de overleving van het transplantaat en van de patiënt. Chirurgische schade die ontstaat 
bij de uitnameprocedure kan leiden tot complicaties nadat het orgaan getransplanteerd 
is, een verminderd functioneren van het transplantaat, transplantaatverlies en 
zelfs overlijden van de patiënt. In hoofdstuk 3 hebben wij bekeken hoe vaak 
pancreata werden afgewezen voor transplantatie nadat zij zijn uitgenomen, tijdens 
de zogenaamde “back-table” inspectie. Daarnaast hebben wij bekeken welk type 
problemen hier verantwoordelijk voor waren en of in getransplanteerde pancreata 
andere problemen werden gezien dan in afgewezen pancreata. Redenen om pancreata 
af te wijzen voor transplantatie waren: ernstige atherosclerose, ernstige schade aan het 
pancreasparenchym en dusdanige beschadiging van de normale anatomie van de v. 
mesenterica superior,  de v. lienalis en de a. lienalis of van de a. pancreatica dorsalis dat 
reconstructie en daardoor transplantatie niet mogelijk waren.
Alle uitgenomen pancreata die getransporteerd werden naar ons centrum in 
de periode februari 2002 – mei 2008 zijn onderzocht (n = 134). Van deze pancreata 
werd 82,8% getransplanteerd en 17,2% werd afgewezen voor transplantatie tijdens de 
“back-table” inspectie. Dertien procent van de pancreata werd afgewezen op basis van 
chirurgische schade. Zoals te verwachten viel, werden in afgewezen pancreata meer 
kritieke en niet-kritieke problemen gevonden dan in getransplanteerde pancreata. 
De kans dat een pancreas werd afgewezen voor transplantatie was hoger in pancreata 
van oudere donoren, uitgenomen door centra waar geen pancreastransplantaties 
worden verricht. Pancreata hadden een 8 keer hogere kans om afgewezen te worden 
wanneer zij werden uitgenomen door deze centra in vergelijking met centra die wel 
pancreastransplanties verrichten. Deze bevindingen hebben belangrijke implicaties 
voor het huidige pancreasuitnamebeleid. Uitgebreidere en frequentere training van 
pancreasuitnamechirurgen kan leiden tot betere kwaliteit van de uitgenomen organen 
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en dus voor een afname van het percentage afgewezen organen. Chirurgen met 
ervaring met pancreastransplantaties zouden goede instructeurs zijn in een dergelijk 
trainingsprogramma. Een andere manier om het percentage afgewezen organen te 
verlagen zou bereikt kunnen worden door pancreasuitnames alleen te laten verrichten 
door centra die ook pancreastransplanties uitvoeren. Dit is in de praktijk echter 
moeilijk (zo niet onmogelijk) te bewerkstelligen. Een betere oplossing lijkt te zijn 
om naast het geven van training ook jaarlijks het percentage niet-transplanteerbare 
pancreata terug te koppelen aan uitnamecentra. 
Bij een geselecteerde groep patiënten is de transplantatie van eilandjes van Langerhans 
een goed alternatief voor pancreastransplantatie. Voldoende eilandjesopbrengst kan 
worden verkregen van een enkele donor, maar zelfs in de meest succesvolle studies zijn 
vaak multipele transplantaties nodig om (tijdelijke) normalisatie van hyperglycemie 
in de ontvangers te bewerkstelligen (2-7). Daarnaast is de opbrengst van eilandjes uit 
een pancreas erg variabel. Omdat er een relatief tekort aan donorpancreata is, is het 
noodzakelijk om dit proces te optimaliseren zodat er routinematig voldoende eilandjes 
van een enkele donor worden verkregen.
Hoofdstuk 4 is een systematische review van donor-, pancreas- en isolatieprocedure 
gerelateerde factoren die van invloed zijn op de eilandjesisolatieopbrengst. Hogere 
pre- en post-purificatie opbrengst en een hoger percentage succesvolle isolaties 
werden bereikt wanneer pancreata werden gepreserveerd met de “two-layer method” 
in plaats van University of Wisconsin oplossing en wanneer ze afkomstig waren 
van donoren met een korte koude ischemietijd. Een uur langere koude ischemietijd 
resulteerde in een gemiddelde daling van pre-purificatie, post-purificatie opbrengst 
en percentage succesvolle isolaties van respectievelijk 59 IEQ/g,  54 IEQ/g en 21%. 
Hogere pre-purificatie opbrengst en een hoger percentage succesvolle isolaties werden 
bereikt in jongere donoren met een hoger BMI. Lagere opbrengst werd gevonden in 
heartbeating donoren in vergelijking met non-heartbeating donoren. Hogere post-
purificatie opbrengst werd gevonden wanneer de isolatieprocedure werd verricht 
met Serva collagenase. Omdat niet alle studies dezelfde factoren rapporteerden, 
werden bovenstaande resultaten gevonden op basis van slechts een deel van de 
studies. Om deze bevindingen met grotere betrouwbaarheid vast te stellen is het 
noodzakelijk dat er een gestandaardiseerde rapportage van deze factoren komt. Bij 
de univariate analyse werd 66,3-87,5% van alle beschikbare pancreata geanalyseerd 
terwijl bij de multivariate analyse slechts 10,3-20,6% van alle beschikbare pancreata 
werd geanalyseerd als gevolg van missende data. Dit laat zien dat er grote variatie 
is tussen de gerapporteerde variabelen in de verschillende studies, zelfs als alleen 
die variabelen geselecteerd worden die in de meeste studies worden gerapporteerd. 
Gestandaardiseerde rapportage van een minimale set van variabelen zal ook leiden 
tot een betere “fit” van het model dat gebruikt werd in de multivariate analyse. In 
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onze huidige analyse van post-purificatie opbrengst werd 19% van de variatie in 
isolatieopbrengst verklaard door de geïncludeerde variabelen. In de analyses van pre-
purificatie opbrengst en percentage succesvolle transplantaties was dit percentage 
hoger, maar werd ook slechts 50% van de variatie verklaard. Dit suggereert dat naast 
de factoren die in onze systematische review werden geïncludeerd, ook andere (nog 
onbekende) factoren de isolatieopbrengst beïnvloeden.
Het voorkomen van hyperemische eilandjes (HE’s) zou een van de andere 
factoren kunnen zijn die de isolatieopbrengst beïnvloeden. Het ontstaansmechanisme 
van deze eilandjes en hun relevantie voor isolatieopbrengst is onbekend. In hoofdstuk 
5 hebben wij histologische karakteristieken van het humane pancreas in relatie tot 
eilandjesisolatie bestudeerd. HE’s werden in ongeveer de helft van de onderzochte 
pancreata gevonden. De meest waarschijnlijke verklaring is dat de HE’s kort voor 
of tijdens de uitname van het pancreas ontstaan als gevolg van een stijging in de 
bloeddruk gecombineerd met hemodynamische instabiliteit (geassocieerd met een 
langere IC opname). Daarnaast kan ook de manipulatie van het pancreas tijdens de 
uitnameprocedure bijdragen aan het ontstaan van HE’s. 
Wij vonden een substantieel lagere isolatieopbrengst in pancreata met HE’s 
(HE+) dan in pancreata zonder HE’s (HE-). Speculatief kan gesteld worden dat 
naast de lagere isolatieopbrengst de aanwezigheid van HE’s ook een verklaring 
is voor het variabele, onverklaarde verlies van eilandjes tijdens het kweken en na 
transplantatie. Wanneer eilandjes worden geïsoleerd uit pancreata die HE’s bevatten, 
lijken deze eilandjes “normaal” (omdat slechts een klein percentage van de eilandjes 
in een pancreas hyperemisch was), terwijl eigenlijk de hele populatie aan eilandjes 
in dergelijke pancreata in meer of mindere mate is aangedaan. Deze eilandjes 
overleven waarschijnlijk eerder het kweken niet of hebben een verminderde functie 
wanneer zij getransplanteerd worden. Om het belang van HE’s te bepalen in het licht 
van eilandjestransplantatie zal verder onderzoek moeten worden gedaan waarbij 
de focus moet liggen op de invloed op post-purificatie opbrengst, zuiverheid en 
levensvatbaarheid van de eilandjes. Systematische rapportage van het voorkomen van 
hyperemische eilandjes in toekomstige studies (door bijvoorbeeld het nemen van een 
biopt voor de isolatieprocedure) zal het mogelijk maken deze factor te includeren in 
een meta-analyse, zodat de relevatie hiervan voor eilandjesisolatieopbrengst bepaald 
kan worden bepaald in vergelijking met andere bekende factoren.
Een mogelijke oplossing voor het tekort aan humane donorpancreata is 
xenotransplantatie van varkenseilandjes. De isolatie van varkenseilandjes is 
echter moeizaam en sterk variabel gebleken. Morfologische karakteristieken van 
varkenspancreata zijn waarschijnlijk verantwoordelijk voor de variabele opbrengst. 
Wanneer histologische kenmerken van varkenspancreata werden bestudeerd in 
relatie tot isolatieopbrengst, werd evenals bij onze studie in humane donorpancreata, 
142 Chapter 10
een verrassend hoog aantal hyperemische eilandjes gevonden, zoals beschreven in 
hoofdstuk 6. HE’s werden gevonden in 48% van de pancreata van raszuivere en in 
65% van de pancreata van hybride varkens. Net als in onze humane studie werden 
significant lagere isolatieopbrengsten gevonden in HE+ pancreata in vergelijking met 
HE- pancreata in zowel raszuivere als hybride varkens. Er werden geen aanwijzingen 
gevonden voor een chronisch ontstaansproces, zodat kan worden gespeculeerd dat 
HE’s kort voor de dood van het varken ontstaan door bijvoorbeeld een plotselinge 
stijging van de bloeddruk.
Omdat HE’s in zowel humane als varkenspancreata gevonden worden en in 
beiden eenzelfde effect lijken te hebben op de isolatieopbrengst, zou het voorkomen 
van HE’s mogelijk een belangrijke factor kunnen zijn in eilandjes isolatieopbrengst.
Bij de enzymatische vertering van de pancreas (om eilandjes te isoleren) is collageen 
het belangrijkste doelwit. De hoeveelheid collageen in het pancreas is daarom een 
andere factor die de onvoorspelbare, variabele isolatieopbrengst kan verklaren. In 
hoofdstuk 7 beschrijven wij de resultaten van onze studie in 64 jonge en 76 volwassen 
varkens. Hierbij hebben wij eerst gekeken naar het verschil tussen jonge en volwassen 
varkens. Van isolatieprocedures in volwassen varkens is beschreven dat zij over het 
algemeen resulteren in hoge eilandjesopbrengst (8, 9). In jonge varkens blijkt deze 
procedure echter moeilijker te zijn, mogelijk als gevolg van de relatief fragiele eilandjes 
(10, 11). Hoewel wij een verschil in hoeveelheid collagen vonden tussen volwassen en 
jonge varkens, bleef dit verschil bestaan ook als wij rekening hielden met het verschil in 
gemiddelde leeftijd tussen de groepen. Dit verschil moet daarom worden veroorzaakt 
door een ander verschil tussen jonge en volwassen varkens.
Een collageen kapsel rondom het eilandje zou in potentie het eilandje kunnen 
beschermen tegen de enzymatische desintegratie en zodoende tegen de fragmentatie 
van het eilandje. Er is beschreven dat een uitgebreider collageen kapsel rond 
eilandjes van volwassen varkens in vergelijking met jonge varkens het verschil in 
isolatieopbrengst tussen jonge en volwassen varkens zou kunnen verklaren (12, 13).  In 
onze studie vonden wij echter geen verschil in de collageenomkapseling van eilandjes 
tussen volwassen en jonge varkens. Zowel in volwassen als in jonge varkens waren de 
eilandjes niet of slechts zeer beperkt omkapseld met collageen. 
Naast het verschil tussen volwassen en jonge varkens hebben wij ook gekeken 
naar de invloed van collageen op de isolatieopbrengst in een studie van 58 volwassen 
varkens. Eerdere studies lieten zien dat de totale hoeveelheid collageen invloed had 
op de isolatieopbrengst (13). Wij vonden echter geen relatie tussen totale hoeveelheid 
collageen, collageenomkapseling van eilandjes en collageen binnenin de eilandjes en 
de uiteindelijke isolatieopbrengst. 
De samenstelling van het kapsel van het eilandje en de relatieve concentratie van 
de afzonderlijke componenten zouden van invloed kunnen zijn op de isolatieopbrengst 
en een mogelijke bias kunnen veroorzaken in de geobserveerde relatie tussen 
143Nederlandse samenvatting
isolatieopbrengst en het gehele kapsel rondom het eilandje. Omdat wij geen of slechts 
een zeer beperkte collageenomkapseling van de eilandjes vonden in onze studie 
(wanneer wij weefselbiopten kleurden voor alle typen collageen), verwachten wij dat 
collageen subtypes slechts een beperkte rol spelen. Andere matrixelementen zouden 
echter wel een rol kunnen spelen en dienen nader onderzocht te worden.
Ductale injectie van collagenase is de techniek gebleken waarbij de hoogste 
isolatieopbrengst wordt verkregen. Er is echter nog steeds een aanmerkelijk verlies 
van endocrien weefsel bij gebruik van deze techniek. In hoofdstuk 8 laten wij zien 
dat eilandjes een morfologische verandering ondergaan tijdens isolatieprocedures 
bij varkens en bij humane procedures. Om deze morfologische verandering te 
kwantificeren hebben wij de gemiddelde beta cel/endocrien weefsel ratio bepaald 
van opgespoten en niet-opgespoten weefselbiopten. In een 2e experiment werden 
20 pancreata op eenzelfde manier beoordeeld na intra-ductale injectie van Hank’s 
Balanced Salt Solution (HBSS). De geobserveerde daling in beta cel/endocrien 
weefsel ratio bleek niet specifiek te zijn voor collagenase, maar werd ook gezien in 
het experiment met HBSS. De morfologische verandering van eilandjes lijkt daarom 
meest waarschijnlijk het gevolg te zijn van volume-expansie door de ingespoten 
vloeistof. Dit zou kunnen leiden tot fragmentatie van de eilandjes met verminderde 
isolatieopbrengst en een verminderde functie tot gevolg. 
Concluderend stellen we dat dit proefschrift bijdraagt aan de bewijslast dat de focus zou 
moeten liggen op de optimalisatie van ontvangers om pancreastransplantaatoverleving 
te verbeteren en op de verbetering van de kwaliteit van de uitgenomen pancreata 
door centra die geen pancreastransplantaties verrichten (bijv. door uitnamechirurgen 
te trainen waardoor pancreasuitname wordt verbeterd, hetgeen resulteert in meer 
transplanteerbare pancreata). 
Bij eilandjestransplantatie zou de rapportage van donor-, pancreas- en 
isolatiefactoren meer gestandaardiseerd moeten worden waardoor er nauwkeuriger 
bepaald kan worden welke factoren belangrijke voorspellers zijn voor isolatieopbrengst. 
Als daarnaast meer biomedische karakteristieken (bijv. de aanwezigheid van 
hyperemische eilandjes) worden gerapporteerd, dan zouden we in staat zijn om het 
onafhankelijke effect van de biomedische factoren te bepalen en uiteindelijk de invloed 




In december 2010 zijn meer dan 36.000 pancreastransplantaties geregistreerd bij de 
International Pancreas Transplant Registry (IPTR). Meer dan 24.000 transplantaties 
zijn uitgevoerd binnen de VS en 12.000 daarbuiten (14). Gedurende de afgelopen 24 jaar 
is de leeftijd van de ontvangers toegenomen evenals het aantal patiënten met Diabetes 
Mellitus type 2. De criteria voor donoren zijn in deze periode strikter geworden 
waarbij de nadruk ligt op jongere donoren, bij voorkeur traumaslachtoffers met korte 
preservatietijd. Ook chirurgische technieken voor drainage van de ductus pancreaticus 
zijn veranderd in de loop van de tijd. In de VS is enterale drainage in combinatie 
met systemische veneuze afvloed van het pancreastransplantaat de meest gebruikte 
techniek. In het Leids Universitair Medisch Centrum wordt een 2-staps benadering 
routinematig toegepast bij de meeste patiënten. Hierbij wordt het pancreastransplantaat 
in eerste instantie gedraineerd via de blaas en vindt na 6-12 maanden een electieve 
conversie naar enterale drainage plaats (15). Protocollen voor immunosuppresieve 
therapie hebben zich ontwikkeld in de richting van inductietherapie met antilichaam, 
gevolgd door Tacrolimus en Mycophenolaat Mofetil (MMF) als onderhoudstherapie. 
Het aantal transplantaties zonder behandeling met steroïden is ook toegenomen in 
de afgelopen jaren. Deze ontwikkelingen hebben geresulteerd in een toegenomen 
patiënt- en transplantaatoverleving. Patiëntoverleving is nu 95% na 1 jaar en 83% 
5 jaar na transplantatie. Omdat donoren al uitgebreid geselecteerd worden voor 
de transplantatie, zal verdere verbetering van patiënt- en transplantaatoverleving 
gerealiseerd moeten worden door de optimalisatie van ontvangers (bijv. optimalisatie 
van het BMI). Als alternatief wordt ook segmentele pancreastransplantatie van levende 
donoren beschreven (16).  Initieel was er een technisch falenpercentage van 33% (bijna 
2 keer zo hoog als in overleden donoren), maar dit is inmiddels gedaald tot minder dan 
1%. Percentages transplantaatoverleving zijn in beide groepen ongeveer even hoog. Bij 
toename van het gebruik van levende donoren zullen in de toekomst waarschijnlijk 
niet alleen streng geselecteerde donoren worden gebruikt, maar zullen de selectie 
criteria voor donoren in de loop van de tijd minder stringent worden. Uiteindelijk zal 
dit leiden tot meer variatie in donorkarakteristieken die de overleving beïnvloeden. 
Op deze manier zal het gebruik van levende donoren de invloed van donorfactoren - 
bij het verklaren van verschillen in overleving - vergroten. Nadelen van deze therapie 
zijn de grote operatie die de donor moet ondergaan (zelfs als minimaal-invasieve 
technieken worden toegepast), en het risico van de donor om diabetes, pancreasfistels 
of infecties te ontwikkelen.
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Humane eilandjestransplantatie
Klinische eilandjestransplantatie wordt momenteel uitgevoerd bij ongeveer 15% 
van de patiënten met Diabetes Mellitus type 1 met refractaire hypoglycemie 
of hypoglycemische episodes en is inmiddels een gestandaardiseerde klinische 
behandeling. Jaarlijks worden 750 transplantaties verricht wereldwijd in ongeveer 30 
centra (5).  In het Leids Universitair Medisch Centrum zijn, sinds de start in 2007, 
19 transplantaties uitgevoerd bij 13 patiënten. Eilandjestransplantatie zorgt voor 
een endogene regulatie van insulinesecretie en daardoor voor een stabilisatie van de 
glucoseregulatie waardoor hypoglycemieën worden voorkomen en het geglycosyleerde 
Hb (HbA1c) wordt gecorrigeerd tot een dusdanig niveau dat secundaire complicaties 
van Diabetes Mellitus worden voorkomen en gecorrigeerd. Patiënten moeten echter 
de rest van hun leven behandeld worden met immunosuppresiva. Transplantatie 
van eilandjes wordt ook uitgevoerd na een eerdere niertransplantatie.  Hier is de 
overweging gemakkelijker, omdat deze patiënten vanwege de niertransplantatie al 
behandeld moeten worden met immunosuppresiva. Verder is de procedure voor 
eilandjestransplantatie een simpele, niet chirurgische interventie met een relatief laag 
risico op complicaties. 
Transplantatie van eilandjes zal zich, om bovenstaande redenen, waarschijnlijk 
ontwikkelen tot een standaardtherapie, wanneer het meer voorhanden zou zijn. 
Dit betekent dat de voorraad eilandjes moet toenemen (bijv. door toename van de 
voorraad bestaande eilandjes, door stamcellen of wanneer xenotransplantatie bronnen 
meer beschikbaar zouden komen). Daarnaast moeten problemen van immunologische 
tolerantie (waarbij destructie van eilandjes door auto- of alloimmuun reacties wordt 
voorkomen) en potentiële bijwerkingen van immunosuppressieve therapie worden 
aangepakt om de transitie naar een standaardtherapie te bewerkstelligen. Verder 
blijft het routinematig verkrijgen van voldoende eilandjes van een enkele donor 
een belangrijk doel. Dit zorgt ervoor dat meer patiënten kunnen worden behandeld 
met eilandjes en zorgt eveneens voor een verlaging van het potentiële risico op 
HLA-sensitisatie doordat de blootstelling aan multipele donoren wordt voorkomen. 
Allotransplantatie van eilandjes is ook uitgevoerd met eilandjes van drie levende 
donoren. De laatste hiervan was succesvol en biedt dus perspectief voor toekomstige 
behandelingen (17-19).
De overstap van multipele-donoren naar enkelvoudige-donor succes vraagt 
om een multimodale aanpak. Dit vereist optimalisatie van de conditie van het 
donorpancreas voor de uitname, bescherming van eilandjes tegen schade als gevolg 
van koude en warme ischemie, optimalisatie van het eilandjesisolatieproces, toegang 
tot een effectief, stabiel, humaan collagenase-enzymmengsel en verschillende 
strategieën voor de behandeling van de ontvanger om immunologische, ontstekings- 
en trombosereacties te onderdrukken, waarbij tegelijkertijd de neovascularisatie en de 
metabole functie van het transplantaat moeten worden gestimuleerd. Een dergelijke 
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multimodale aanpak zal van invloed zijn op het succes van eilandjestransplantatie 
op korte en lange termijn en zal de snelle overschakeling van onderzoek naar 
routinematige klinische behandeling ondersteunen. Dit benadrukt de noodzaak om 
de isolatieopbrengst van eilandjes te optimaliseren. 
Om deze optimalisatie van de eilandjesisolatieopbrengst te bewerkstelligen 
ligt de focus van het onderzoek in het Leids Universitair Medisch Centrum op de 
ontwikkeling van ‘devices’ (in samenwerking met de Technische Universiteit Twente) 
die een optimale micro-omgeving van getransplanteerde eilandjes creëren en op 
alternatieve celbronnen (bijv. precursorcellen).
Xenotransplantatie
Varkenseilandjes kunnen een alternatief zijn voor humane eilandjestransplantatie, 
met name als zij op een dusdanige manier worden getransplanteerd dat het 
immuunsysteem van de ontvanger omzeild wordt (20). Dit kan worden bereikt 
door de xenogene eilandjes te beschermen tegen immuunreacties van de ontvanger 
door ze te omkapselen met selectieve semipermeabele barrières. Speciaal gefokte 
pathogeen-vrije kuddes (21, 22) kunnen voor een voorraad varkenseilandjes zorgen 
die goed getolereerd worden wanneer zij in zo’n beschermend transportvehikel 
toegepast worden. Deze barrièresystemen zijn succesvol gebleken in de behandeling 
van diabetes in verschillende diermodellen en eerste studies laten zien dat dergelijke 
resultaten ook kunnen worden bereikt in mensen. Lopende studies waarin omkapselde 
varkenseilandjes worden gebruikt zonder immunosuppressieve therapie, worden 
gesponsord door Living Cell Technologies (LCT) in Rusland en Nieuw-Zeeland,  evenals 
studies die in de planningsfase zijn in de VS. De studie in Nieuw-Zeeland startte in 1995 
met zes patiënten met DM type 1 die een transplantatie met omkapselde, dan wel niet-
omkapselde eilandjes ontvingen. Eén individu, dat een transplantatie met omkapselde 
eilandjes kreeg, liet een daling van de gemiddelde maandelijkse insulinedosis zien, 
een afname van het HbA1C en er werd in het bloed varkens C-peptide gedetecteerd. 
Een biopt bij deze patiënt, 9,5 jaar na de transplantatie, liet omkapselde eilandjes zien 
met expressie van insuline (23). Deze, alhoewel tijdelijke, vooruitgang in diabetische 
status was veelbelovend en gaf aanleiding tot verder onderzoek. Helaas werd de studie 
tijdelijk stopgezet vanwege bezorgdheid over in vitro varken-naar-humane transmissie 
van endogene retrovirussen. Dit resulteerde in een lang proces van overleg met de 
Nieuw-Zeelandse autoriteiten om te voldoen aan kwaliteitseisen met betrekking tot 
de gezondheidsstatus van de varkens, pancreasverwerking en eilandomkapseling, 
voorlichting aan het publiek en implementatie van een veiligheidsstrategie.
In de Russische studie, gestart in 2007, werden bij acht patiënten 5000-10000 
IEQ/kg eilandjes getransplanteerd. Na 3 en 6 maanden was er effect merkbaar in een 
aantal, maar niet in alle, patiënten.
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Vijf patiënten lieten een gereduceerde insulinebehoefte  zien en twee patiënten 
(één na 3 en één na 6 maanden), waren tijdelijk insulineonafhankelijk. Zes patiënten 
hadden een lager HbA1C (gemiddeld 8,9% voor transplantatie, 6,9% 3 maanden na 
transplantatie en 7,3% na 6 maanden). De procedure werd veilig bevonden en ook het 
herhaald geven van eilandjestransplantaties werd veilig bevonden.
De studie in Nieuw-Zeeland werd hervat in oktober 2009. Het is een open-
label dose-range studie met een transplantatie van 10000-15000 IEQ/kg in acht 
patiënten met instabiele DM en ernstige hypoglycemische periodes. Op het XXIIIe 
internationale congres van de Transplantation Society (24) werd één patiënt meer 
gedetailleerd gepresenteerd. Hierbij werd een insuline reductie van 20% bereikt, 4 
weken na transplantatie. 
Deze data laat zien dat klinische varkenseilandjestransplantatie een veilige 
procedure is die voordelen kan hebben voor patiënten die zich niet bewust zijn van 
hypoglycemische episodes en die een bescheiden verbetering van de diabetescontrole 
geeft. In komende studies zal de dosis en de timing van de toegediende eilandjes 
onderzocht worden. Optimalisatie van isolatieopbrengst van varkenseilandjes zal nog 
belangrijker worden als de transplantatie van varkenseilandjes een standaardtherapie 
wordt.
Dit proefschrift is een eerste stap in de richting van deze toekomstige ontwikkelingen. 
Door het combineren van diverse onderzoeksmethodes, namelijk vergelijkend 
onderzoek naar de effectiviteit in registraties, systematische review technieken en 
biomedisch onderzoek hebben wij een vruchtbare interactie bewerkstelligd. Aan de 
ene kant hebben wij het effect van factoren op uitkomsten voor de patiënt onderzocht 
(door het bepalen van de relatieve invloed van factoren op transplantatie uitkomsten) 
en aan de andere kant hebben wij enkele mechanismen proberen te ontrafelen waardoor 
deze potentiële factoren de transplantatieuitkomst beïnvloeden. Het voordeel van een 
dergelijke combinatie is dat wij niet alleen onderzocht hebben hoe sommige factoren 
de transplantatieuitkomst beïnvloeden, maar tegelijkertijd geprobeerd hebben te 
kwantificeren welk deel van de variatie in uitkomst wordt verklaard door deze factor. 
Hierdoor kan bepaald worden waar de ruimte voor verbetering ligt in deze uitkomsten.
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